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ABSTRACT 
 In response to persistent shortages of primary care physicians, researchers have 
suggested increased use of non-physician providers to mitigate the consequences of the 
strained supply of physicians. As more health care systems implement a team-based 
approach in treating patients, better understanding the pattern of team care and its effects 
on outcomes and cost is critical in transitioning away from physician-centric care. This 
dissertation focuses on the prescribing component of care to explore the effects of team 
medication management on prescribing patterns, clinical outcomes, and care costs in 
Veterans with diabetes.  
In Chapter 2 I examine the outpatient prescribing patterns of oral antidiabetic 
drugs (OADs) over a 2-year period among patients who receive sole-provider prescribing 
or team-based prescribing. I find that team-prescribing patients receive significantly more 
sulfonylureas and metformin/sulfonyl urea combinations, suggesting that team 
prescribing may respond to patients’ needs quicker and intensify treatment earlier by 
switching or augmenting the initial medication.  
To determine the effect of prescribing modality on health outcomes, I compare 
		 vii 
mean changes in diabetes-related lab measures between the sole-provider models and 
team-prescribing models in Study 2. I perform 2-stage least squares regression to 
estimate the change in outcome measures from baseline to follow-up and find that while 
patients receiving NP prescribing achieve significantly greater reductions in glucose level 
compared to those receiving physician prescribing, the differences in HbA1c, glucose, 
and LDL reductions between team prescribing patients and sole-provider patients are 
insignificant.  
In Study 3 I explore the effect of prescribing model on health care costs. I use 
generalized linear modeling to estimate mean total outpatient cost among patients 
managed under different prescribing models. In addition, I perform logistic regression to 
estimate the likelihood of incurring any inpatient cost. I find no significant differences in 
mean outpatient cost or the likelihood of incurring any inpatient cost between sole-
provider prescribing and team prescribing, suggesting that prescribing modality may not 
be associated with care costs. 
Evidence from this dissertation suggests that while team prescribing appears to 
provide more responsive medication management, it does not result in significant 
improvements in health outcomes or affect overall care costs.  
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CHAPTER ONE: INTRODUCTION 
The use of non-physician providers (NPPs) including nurse practitioners (NPs) 
and physician assistants (PAs) has increased substantially since the late 1990s in response 
to a persistent shortage of primary care physicians (Huang, Yano, Lee, Chang, & 
Rubenstein, 2004; Woodmansee & Hooker, 2010). In light of numerous projections 
indicating physician shortage (IHS, 2015; HRSA, 2013), researchers have suggested 
expanding NPPs' scope of practice to increase primary care workforce, thereby boosting 
the health care system's capacity (Bodenheimer & Smith, 2013; Green, Savin, & Lu, 
2013). Despite much resistance from physicians out of concern that NPPs do not have 
adequate training and competency, the clinical roles of NPPs are expanding to meet the 
growing demand for health care (Kartha, et al., 2014). One component of NPP practice 
that would benefit from an expanded scope of practice is prescribing authority.  An 
expansion of NPPs' prescribing authority that allows for a greater autonomy in their 
ability to initiate or terminate medications would enable NPPs to manage medication 
therapy more effectively. This is especially true for NPPs caring for the chronically ill 
because patients with chronic conditions take several different medications due to the 
complexity of their illness. Greater prescribing autonomy would enable NPPs to respond 
to side effects and/or ineffective treatment and make medication changes promptly 
without having to wait for physician approval or consultation.   
While the literature to date documents the efficacy and effectiveness of NPPs as 
independent prescribers in comparison to their physician (MD) counterparts, minimal 
attention has been given to NPPs' impact on medication management in a team-care 
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setting. This dissertation attempts to shed light on NPP/MD team prescribing by 
examining the effects of team medication management of oral antidiabetic drugs on 
diabetes-related outcome measures and costs. Defining NP/MD team, PA/MD team, and 
sole-provider type prescribing as distinct prescribing models, Chapter 2 describes the 
prescribing pattern of oral antidiabetic drugs by volume and agent across different 
provider types and prescribing models. Chapter 3 investigates the effect of prescribing 
model on clinical outcomes related to diabetes by comparing the adjusted differences in 
the change in HbA1c, glucose, LDL, and creatinine levels among patients managed under 
different prescribing models. Chapter 4 estimates the differences in mean outpatient cost 
and the likelihood of incurring inpatient cost between team prescribing and sole-provider 
type prescribing. To adjust for treatment selection bias and unmeasured confounding, I 
implement the instrumental variables method in Chapters 3 and 4 by constructing an 
instrumental variable that predicts prescribing model. Chapter 5 concludes. 
 
Trend in NPP use 
 As a part of its vast effort to improve access and quality of health care, Veterans 
Health Administration (VHA) has substantially increased the use of NPs and other NPPs 
since the late 1990s in order to serve more veterans in ambulatory and primary care 
settings. In VHA a rapid growth of the NPP workforce started in the 1990s; the number 
of NPs per VHA primary care practice increased by 60% between 1996 and 1999 
(Huang, Yano, Lee, Chang, & Rubenstein, 2004) and the total number of PAs nationally 
grew by 55% from 1992 to 2009 (Woodmansee & Hooker, 2010). The staffing of NPPs 
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varies by region, state, and VISN—Veterans Integrated Service Networks—and several 
factors including the state's HMO penetration rate and NP supply predict NP use (Huang, 
Yano, Lee, Chang, & Rubenstein, 2004; Woodmansee & Hooker, 2010). Employment of 
NPPs is similarly widespread in non-VHA facilities. Of the 26 academic medical centers 
included in the study, which cover most of the regions in the U.S. except the Northwest, 
Moote et al. (2011) report virtually 100% of the academic medical centers using NPPs 
across most services and 81% using NPPs as resident substitutes. Besides direct patient 
care, NPPs also serve as care coordinator, case manager, and research coordinator in 62% 
of the academic medical centers (Moote, Krsek, Kleinpell, & Todd, 2011).  
 
NPPs as physician substitutes 
In interviews and questionnaires regarding perceptions/attitudes toward NPPs 
physicians have expressed much concern regarding the adequacy of training and clinical 
competence of NPPs as independent providers. While most physicians agree that nurse 
practitioners are effective patient educators, communicators, and genuine care givers, 
they seldom consider NPs as qualified to practice independently in primary care 
(Fletcher, Baker, Copeland, Reeves, & Lowery, 2007). Physicians' view NPs as better 
suited to manage patients with chronic and less complex illnesses rather than acute 
conditions. Fletcher et al. (2011) find that patients seen by physicians have significantly 
higher comorbidities and are more likely to have both hypertension and diabetes 
compared to patients under NP care, suggesting that patients with more complex illnesses 
are referred away from NPs. However, a more recent study by Morgan et al. (2017) notes 
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that the proportion of the most medically complex patients, measured by the Diagnostic 
Costing Group score, assigned to MDs, NPs, and PAs appears to be similar in the VHA. 
In an inpatient setting, NPPs' strengths in communication and care coordination play a 
significant role in increasing continuity of care, improving care quality, and reducing 
costs (Ford & Britting, 2010). Nurse practitioners and physician assistants serve primarily 
as support staff coordinating discharges, taking patient history and progress notes, and 
communicating with primary care providers, although some NPPs do perform procedures 
(Kartha, et al., 2014). Despite physicians' skepticism regarding NPPs' clinical 
competence much evidence suggests that NPPs are capable of providing quality patient 
care comparable to that of physicians. 
Several studies dating back as early as 1974 have shown that NPPs are competent 
clinicians who can provide primary care services at the quality equivalent to or better 
than that of physicians. A small study comparing two groups of diabetic female patients, 
one group treated by an NP and the other by a physician, finds no significant differences 
within or between the two groups in the changes in the mean blood sugar level and body 
weight during a 6-month follow-up period (Stein, 1974). The study also finds a 
significant difference in the changes in diabetes knowledge questionnaire scores, 
suggesting that an NP can be a more effective patient educator than a physician. Several 
subsequent studies have documented the effectiveness of NPPs in diabetes care. Vrijhoef 
et al. (2001) examine the effects of the nurse substitution model, in which nurse 
specialists are the primary provider, on diabetes-related health measures including 
glycated hemoglobin concentration (HbA1c), body mass index, systolic and diastolic 
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blood pressures, total and HDL-cholesterol, as well as various instruments that measure 
health status, self-care behavior, and patient satisfaction. They report no significant 
differences between the intervention group and the control group in all outcomes but 
glycemic control, for which the intervention group achieved slightly better results. 
During a 12-week follow-up, Chan et al. (2006) also find that the nurse-led group 
achieved greater improvement in HbA1c. Houweling et al. (2009) find similar results 
using a randomized controlled trial. They compare various clinical and utilization 
outcomes of diabetic patients assigned to diabetes specialist nurses to those of patients 
who received standard of care and show that both patient groups achieved similar health 
improvements over a one-year follow-up. In all three studies, the authors highlight the 
fact that a standardized treatment and management protocol developed by all providers 
involved was followed. 
The literature on physician substitution by NPPs—although mostly on nurse 
practitioners and nurse specialists—extends beyond diabetes care. Studies have 
investigated whether NPPs can be effective and appropriate substitutes for physicians in 
primary care settings. Even after adjusting for demographics and baseline health status, 
Mundinger et al. (2000) find no differences in self-reported health status or patient 
satisfaction between the NP and physician patients. A systematic review of 21 studies 
comparing NPP care to physician care concludes that NPPs perform similarly to 
physicians in process (e.g., data gathering, triage decisions, and diagnoses), outcome, and 
quality (e.g., patient satisfaction) of care (Sox, 1979). A more recent review of NPs, 
while mostly consistent with Sox et al. (1979), does find that patients are more satisfied 
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with nurse practitioners than physicians (Horrocks, Anderson, & Salisbury, 2002).  
 A Cochrane review of 16 studies, some of which were included in the previous 
reviews, provides further insight into the substitution effect of NPs by reviewing studies 
that assess resource utilization and costs (Laurant, et al., 2005). It reports that regardless 
of the type of service provided—primary, ambulatory, or chronic condition 
management—no significant differences exist between nurse practitioners and physicians 
in resource utilization or direct costs. The most recent review of the impact of non-
physician clinicians, published by the same lead author, however, suggests a more 
ambiguous effect. While NPPs often decrease resource utilization via reduced number of 
prescriptions and hospital readmissions, they may also increase it by ordering more tests 
(Laurant, et al., 2009). Other studies also generally find higher test rates and 
investigations by NPs compared to physicians, but the types of tests and/or investigations 
may differ. Venning et al. (2000) report that nurses tend to order more screening tests 
such as urine testing and cervical screening, whereas Hemani et al. (1999) observe 
significantly higher imaging tests among nurses while finding no significant difference in 
the total number of laboratory tests. 
 
NPPs as physician supplements 
 A team-based approach to primary care has become increasingly common in 
practice. To alleviate physician shortage, Bodenheimer et al. (2013) suggest 
redistributing clinical responsibilities to NPPs, effectively increasing capacity to provide 
care. They identify several components that may facilitate such change including 
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payment reform, changes in scope of practice, additional NPP training, and change in 
culture. A payment system that incentivizes physicians to hire NPPs, an expanded scope 
of practice that allows NPPs to perform more clinical duties, training that ensures 
competency and safety of NPP practice, and a change in physician culture that recognizes 
NPPs as peers and not subordinates are all critical in promoting an effective team care. A 
simulation study estimates that sharing patients among 2 or 3 physicians and diverting 
20% of patient load to NPPs could eliminate most of the projected primary care physician 
shortage (Green, Savin, & Lu, 2013).  
 Having NPPs take on more clinical responsibilities can save a substantial amount 
of physician time. In addition to the traditional duties such as history taking, post-visit 
follow up, and helping patients navigate the system, NPPs with proper training may also 
manage medications or even provide direct care within their scope of practice 
(Bodenheimer & Laing, 2007). When compared to standard care in which the physician 
is the sole provider, team care led by NPPs appears to be especially effective for patients 
with chronic conditions. Team-based care led by appropriately-trained nurses has been 
shown to improve patient outcomes and provider adherence to guidelines (Wagner E. H., 
2000). For diabetic patients, significant improvements in HbA1c, blood pressure, and 
LDL measures have been reported (Chen, et al., 2010). Treating chronic conditions such 
as diabetes not only requires accurate initial assessment and treatment, but also consistent 
adherence and management of medications and behavior modification—namely, life style 
changes such as diet and exercise—through patient education. Using effective 
communication skills and patient-oriented training, NPPs can improve patients' ability to 
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self-manage their conditions through patient education and close monitoring of health 
status (Renders, et al., 2001). 
 
NPP prescribing 
In general there are two forms of NPP prescribing: supplementary and 
independent. The U.K.'s Department of Health defines supplementary prescribing as “a 
voluntary prescribing partnership between an independent prescriber (a doctor or dentist) 
and a supplementary prescriber to implement an agreed patient specific clinical 
management plan with the patients' agreement” (Baird, 2005). The “voluntary 
partnership” often requires supplementary prescribers to write prescriptions under the 
oversight of an independent prescriber. Independent prescribing, on the other hand, is the 
form of prescribing in which the prescriber is able to prescribe without any restriction 
other than his license. The key difference between supplementary prescribing and 
independent prescribing is the provider responsible for diagnosis; in supplementary 
prescribing the physician is responsible for the patient's diagnosis, whereas the 
prescribing NPP is responsible for the patient’s diagnosis in independent prescribing 
(Baird, 2005). However, the extent to which supplementary NPP prescribers are able to 
adjust and prescribe medications after the initial diagnosis has been made by the 
supervising physician is still unclear. Moreover, if the clinical management plan places 
excessive restrictions on the NPPs' scope of prescribing, it can potentially underutilize the 
supplementary NPP prescribers' capabilities and limit their professional autonomy.  
Several factors have been reported to hamper prescribing by both independent and 
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supplementary prescribers. The greatest impediments to prescribing among independent 
prescribers include local restrictions such as the availability of prescription pads/budgets, 
while difficulties in implementing clinical management plans are the biggest obstacle 
among supplementary prescribers (Courtenay & Carey, 2008). Of note, lack of peer 
support and objections by medical staff or pharmacists rank equally high in both 
prescribing groups—ranging from 13% to 17% of respondents for each factor in both 
groups. This is consistent with the qualitative findings on physicians' skeptical views 
regarding NPPs as independent care providers. Even among those who have qualified as 
independent prescribers lack of peer support appears to be a persistent barrier for NPPs. 
A more recent study finds that physicians view prescribing as a “shared territory” with 
NPPs in managing diabetes patients, implying physicians' willingness to accept NPPs as 
peers when it comes to chronic care (Carey, Stenner, & Courtenay, 2010). 
 Patient attitudes toward NP prescribing are mixed. While patients, too, report 
perceived limitations on NPs' prescribing knowledge and competence, they feel in 
general confident about receiving prescriptions from their NPs (Courtenay, Stenner, & 
Carey, 2010). Some patients indicate a higher level of confidence in specialist NPs (e.g., 
diabetes specialist nurses), whereas others are just as comfortable with regular NPs as 
long as they practice within their scope of practice and training. Such mixed attitudes are 
demonstrated in another study, in which patients were asked to rate their attitudes toward 
nurse prescribing. BenNatan et al. (2013) find only 31% of survey respondents favor 
expanding nurses' prescribing authority, in contrast to 90% of respondents who support 
expansion of nurse authority in general. While the respondents agree that expanding 
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nurse prescribing would shorten wait times and improve adherence, they are less 
confident that nurses have the necessary training to initiate or change medications 
without physician approval. A two-part systematic review of 44 studies—published 
separately—reaffirms patients' concern regarding the adequacy of NPs' training and 
education in prescribing. Patients are generally in favor of nurse prescribing, but those 
with psychiatric conditions tend to be less supportive of independent nurse prescribing 
(O'Connell, Creedon, McCarthy, & Lehane, 2009). Moreover, a significant number of 
nurses in numerous studies report that they required additional prescribing education; 
specialist training and continuing education have been reported to significantly increase 
nurses' confidence in prescribing (Creedon, O'Connell, McCarthy, & Lehane, 2009).  
 The Nursing and Midwifery Council in the U.K. advises that a nurse prescriber 
should possess sufficient knowledge and competence to assess a patient's clinical 
condition, determine whether medication treatment is appropriate, and consult with a 
patient regarding side effects and risks associated with any prescribed medication (Latter 
S. , 2008). A review of the observational studies that examine nurse consultations 
suggests that nurse prescribers not only use a wide range of competencies to assess and 
diagnose patients' condition, but also make clinically appropriate prescribing decisions 
(Latter S. , 2008). One study uses the Medication Appropriate Index (MAI) to assess 
clinical appropriateness of nurse prescribing decisions (Latter, Maben, Myall, & Young, 
2007). The MAI is a validated, 10-item instrument that rates clinical appropriateness of a 
prescribed drug. Some of the items include medication indication, dosage, potential 
medication interactions, unnecessary duplication, and duration. An expert panel of 
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physicians uses the MAI to review 118 nurse consultations and reports the majority of 
nurse prescribing were clinically appropriate (Latter, Maben, Myall, & Young, 2007).  
 NPPs have been shown to exhibit similar prescribing patterns to those of 
physicians. Both NPPs and physicians prescribe at least one medication in approximately 
60 to 67% of visits, with an average of 1.5 medications per visit (Hooker & Cipher, 
2005). NPs tend to prescribe more medications per visit in nonmetropolitan areas than 
PAs or physicians—likely due to NPs’ role as the only primary care provider for patients 
living in rural areas. Types of medications prescribed are also similar, although PAs 
prescribe slightly more controlled substances than NPs and physicians. Hooker et al. 
(2005) suggest PAs' availability for urgent and same-day appointments as a possible 
explanation for the finding. In addition, NPs were allowed to prescribe controlled 
substances in only 11 states at the time of the study, compared to 40 and 50 states for PAs 
and physicians, respectively (Cipher, Hooker, & Guerra, 2006). Today, NPs have a 
broader prescriptive authority across the states than PAs, allowing them to prescribe the 
same or more schedules of controlled substances than PAs (DEA, 2015).  
 In diabetes management, prescribing by diabetes nurse specialists (DNS) has been 
shown to have positive effects on patient outcomes. In a quasi-experimental study, Carey 
et al. (2008) compare the number of medication errors and length of stay before and after 
the DNS intervention and find that DNS's significantly reduce medication errors and 
improved the accuracy of dose adjustment. While they do not find any significant 
differences in length of stay before and after the intervention, they find a significant 
positive correlation between medication errors and length of stay, suggesting that higher 
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medication errors might contribute to longer length of stay (Carey, Courtenay, James, 
Hills, & Roland, 2008). An audit of patient notes and prescriptions by diabetes physicians 
in New Zealand has shown similar findings that DNS prescribing leads to safe, high 
quality, and effective management of diabetes patients (Wilkinson, Carryer, & Adams, 
2014). The study finds no adverse events or hospitalization associated with DNS 
prescribing and stable or improved measures of diabetes outcomes such as blood 
pressure, HbA1c, cholesterol, and creatinine. Furthermore, it reports qualitative findings 
that indicate high confidence and satisfaction among patients regarding DNS prescribing, 
increased job satisfaction among DNS's for having the extended role, and reduced 
physician workload as well as patient wait times. 
 Mounting evidence for safety and effectiveness of NPP prescribing—
supplementary or independent—appears to support a greater prescribing role of NPPs. A 
review of 35 studies—22 of which involve independent nurse prescribing—finds that 
NPPs exhibit similar prescribing patterns compared to those of physicians (Gielen, 
Dekker, Francke, Mistiaen, & Kroezen, 2014). The majority of the reviewed studies 
report no significant difference in the total volume of prescriptions, the total number of 
visits resulting in a prescription, the mean number of prescriptions per visit, and the type 
and dosage of medications. Moreover, patients experience no significant difference in 
health measures such as laboratory measures, physical status, emotional and social 
functioning, patient satisfaction and quality of care. Only a few studies report mixed 
results for each outcome. Another literature review, in addition to 35 selected studies, 
also examine 30 anecdotal publications and 20 policy documents (so-called “gray 
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literature”) that focus on perspectives of different stakeholders, professional 
relationships, and barriers to the implementation of NPP prescribing (Cooper, et al., 
2008). The review provides additional insight into NPP supplementary prescribing as it 
includes 20 peer-reviewed publications relating to pharmacists. Both nurses and 
pharmacists report high confidence in their ability to prescribe and increased job 
satisfaction from supplementary prescribing.  
Physicians, on the other hand, while generally supportive of NPP prescribing, 
have raised concerns over safety and adequacy of training as well as potential erosion of 
professional hierarchies. Several reviewed studies also report physicians' unawareness of 
NPP prescribing in general. In fact, Cooper et al. (2008) identify physician unawareness 
as the most frequently cited barrier in implementation of supplementary prescribing by 
NPPs. Training, communication, accountability, and lack of IT and administrative 
support are also found to impeded NPP prescribing. 
 
A team-based approach in health care 
Several studies have suggested that an effective interdisciplinary team takes more 
than just having a group of health care providers. Building a team is a time and resource-
intensive process that progresses through multiple phases from uncertainty and 
disagreement to consensus, ultimately achieving cooperation (Belanger & Rodriguez, 
2008). An interdisciplinary care team consisting of different types of providers with 
different professional training and culture needs to overcome physician-dominated 
hierarchies, resolve role confusion, and establish clear team objectives (Sibbald, Wathen, 
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Kothari, & Day, 2013). Through a focus group study of volunteers with a diverse range 
of professions in primary health care teams Sargeant et al. (2008) have identified five 
elements of an effective care team: communication, understanding and respecting team 
members' roles, recognizing that teamwork requires work, having the practical “know-
how” for sharing patient care, and understanding primary health care. Communication 
and respect among team members are particularly common themes cited by other studies 
(Belanger & Rodriguez, 2008; Al Sayah, Szafran, Robertson, Bell, & Williams, 2014). 
Lack of trust and respect between team members can hamper cooperation and efficient 
coordination of patient care (Belanger & Rodriguez, 2008). Nurses in a qualitative study 
report that the lack of trust between nurses and physicians is likely due to the lack of 
clear role definition and division of labor in the context of team-based care (Al Sayah, 
Szafran, Robertson, Bell, & Williams, 2014). Another study suggests that mistrust and 
poor communication between physicians and non-physician providers occur because each 
group perceives teamwork differently. Physicians tend to associate teamwork with 
achieving coordination and efficiency with their technical skills and NPPs who serve 
their needs, whereas NPPs are more likely to consider having courtesy, respect, and 
appreciation for other members as critical elements of teamwork (Finn, Learmonth, & 
Reedy, 2010). 
 
Significance 
In light of the projected shortage of primary care physicians, the role of PAs and 
NPs serving as independent primary care providers in interdisciplinary teams is likely to 
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grow. As such, understanding the patterns of care provided by non-physician providers 
and evaluating the health outcomes of the patients receiving care from NPPs are critical 
in evaluating the efficacy and effectiveness of the expanded roles of NPPs. While the 
extensive body of evidence reviewed in this chapter suggests NPPs are effective 
substitutes for physicians in primary care, limited research has been done in examining 
their impact on patient outcomes and costs when they work collaboratively with their 
physician counterparts in a team setting. Previous studies have found that that expansion 
of NPPs’ scope of practice alone may not result in full autonomy of NPP practice. Peer 
and patient perceptions, attitudes, and trust as well as administrative barriers have been 
found to hamper NPPs’ ability to exercise practice autonomy. 
Granting greater prescribing autonomy for NPPs is of particular interest in 
managing chronic conditions. Patients with chronic conditions such as diabetes require 
close monitoring of pharmacotherapy due to the complexity of illness. They typically 
have comorbidities and take several different medications, which require frequent 
adjustments to their regimen to mitigate side effects and optimize medication therapy. 
Other benefits of medication management by NPPs include reduced medication errors, 
improved patient education, and increased adherence (O'Connell, Creedon, McCarthy, & 
Lehane, 2009). While much research supports independent prescribing by NPPs (Gielen, 
Dekker, Francke, Mistiaen, & Kroezen, 2014; Latter S. , 2008; Latter, Maben, Myall, & 
Young, 2007; O'Connell, Creedon, McCarthy, & Lehane, 2009), prescribing autonomy of 
NPs and PAs in the U.S. still varies from state to state and/or from facility to facility. 
Many physicians have expressed concerns in granting greater prescribing autonomy to 
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NPs and PAs; negative perceptions regarding NPPs' adequacy of training and 
competency persist in many large health care settings (Fletcher, Baker, Copeland, 
Reeves, & Lowery, 2007). NPPs are integral members of interdisciplinary teams of 
health care providers capable of safe and effective prescribing. Cowan et al. (2006) show 
that the collaboration between physicians and NPs “can reduce LOS and hospital costs 
without affecting readmissions or mortality.”  
Given much evidence that NPP prescribing may significantly reduce medication 
errors, improve adherence, and enhance patients’ self-management of their medication 
treatment, this dissertation aims to contribute to the existing literature by investigating 
whether NPP/MD team medication management significantly improves clinical outcomes 
compared to sole-provider medication management. Moreover, it explores the effect of 
team medication management on costs by comparing the cost differences among patients 
assigned to different prescribing models. 
 
Conceptual model 
I use the Chronic Care Model (Wagner E. H., 1999) as the overarching framework 
to conceptualize the role of NPPs in a care team (Figure 1). The original model posits that 
patient outcomes improve through productive interactions between a prepared practice 
team and an activated patient given the necessary resources and decision support systems 
in place. Productive interactions entail “systematic assessment of functional and clinical 
status, collaborative treatment planning, the implementation of effective treatments, 
support of the patient's self-management tasks, and organized follow-up (Wagner E. H., 
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1999).” In my adapted model of chronic care, I highlight NPPs' emergence as the main 
facilitator of such productive interactions driven by greater professional autonomy. In 
addition, I introduce some elements of Andersen's Behavioral Model of Health Services 
Use (Andersen, 1995)—predisposing and enabling factors—to suggest that the degree of 
activation and awareness may vary across patients. 
Grumbach et al. (2004) summarize the five key elements of team building as 
suggested by the literature: clearly defined goals, clinical and administrative systems, 
division of labor, training, and communication. NPPs are well-positioned to facilitate a 
functional care team due to their patient-centered training and professionally developed 
communication skills. Given greater autonomy, they have the potential to improve all 
aspects of team-based care. 
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Figure 1. Non-physician provider-facilitated chronic care model 
 
Expansion of NPPs' scope of practice and responsibility—a form of role 
revision—occurs if the practice environment becomes more favorable to such a change. 
Practice environment is determined by several factors. First, regulations and policies 
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define the legal scope of practice. Second, reimbursement structure provides the 
mechanism by which NPPs are compensated. Third, training infrastructure must be in 
place to graduate new NPPs and provide continuing education. Lastly, inter-professional 
and patient perception and attitude toward NPP practice can also influence practice 
environment. Even if NPPs have the required training and legal authority to practice, 
their “practical” professional autonomy might vary depending on the perceptions and 
attitudes of their peers—physicians in particular—and on patients’ perception of their 
competence. 
Expansion of scope of practice via role revision in turn increases NPPs' 
professional autonomy. Physicians may delegate more patient care responsibilities to 
NPPs and trust NPPs to make treatment decisions on their own. Increased professional 
autonomy has to be supported by clinical and administrative systems to fully enable 
NPPs to do their job. For example, the clinical system should reflect NPPs' greater 
authority in prescribing medications or treatments. Communication between physicians 
and NPPs becomes more important as NPPs take on greater patient care responsibilities. 
Goals and protocols should be clearly defined to provide the most efficient team care. 
Patients with different demographic and socioeconomic backgrounds may exhibit 
varying degrees of activation. Being more proactive and asking questions might not be 
viewed favorably in some cultures. Patients might be afraid to ask more questions out of 
fear that it may lead to greater expenses. Low income individuals with limited or no 
access to the Internet or a mobile phone are more likely to be less informed about their 
illness and self-management skills. As many obtain information through their social 
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network, racial or cultural background may determine the extent of social network use as 
a source of information. Heterogeneity in patient activation and awareness due to 
predisposing and enabling factors in turn affect interactions between patients and care 
team, and ultimately, patient outcomes. 
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CHAPTER TWO: TEAM PRESCRIBING VERSUS SOLE-PROVIDER 
PRESCRIBING: PRESCRIBING PATTERNS OF ORAL ANTIDIABETIC 
DRUGS IN THE VETERANS HEALTH ADMINISTRATION 
 
Introduction  
Historically, non-physician providers (NPPs) including nurse practitioners (NPs) 
and physician assistants (PAs) in the health care system have served primarily as a 
support staff coordinating care and assisting physicians (Kartha, et al., 2014). However, 
their role has been evolving rapidly to provide more direct care in response to their 
increased use. Faced with a persistent shortage of primary care physicians, use of NPPs 
has risen substantially since the late 1990s; virtually 100% of academic medical centers 
across the U.S. employ NPPs today—81% use them as resident substitutes (Huang, Yano, 
Lee, Chang, & Rubenstein, 2004; Woodmansee & Hooker, 2010; Moote, Krsek, 
Kleinpell, & Todd, 2011). To enable NPPs to effectively fulfill their increased patient 
care responsibilities, researchers have advocated for an expansion of NPPs’ scope of 
practice (Bodenheimer & Smith, 2013; Green, Savin, & Lu, 2013).  
 NPP prescribing is one component of care that could benefit from an expanded 
scope of practice. An effective management of medications requires the prescriber to be 
able to freely adjust medication treatment by initiating, switching, augmenting, or 
terminating drug therapy. NPPs as prescribers are often limited in their ability to perform 
such activities due to their prescribing authority, which varies greatly by state. NPPs 
practicing in states that allow a greater prescribing authority, given the proper training 
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and certification, are able to initiate and make changes to medication treatment 
independently. On the other hand, NPPs practicing in more restrictive states require 
physician oversight before carrying out medication management activities. Prescribing 
authority also varies by type of NPP. For example, NPs generally have a broader 
prescribing authority than PAs, differentiated by the number of controlled substance 
classes they are allowed to prescribe (DEA, 2015).  
Restrictions to NPP prescribing such as requiring physician consultation or 
approval, while sometimes necessary for clinical safety, can have several consequences 
for the patient, the NPP prescriber, and the system. Waiting for physician consultation or 
approval creates a delay in making the necessary therapy adjustment, which in turn raises 
the patient risk for adverse effects and complications. To fully optimize medication 
management and achieve the best patient outcomes possible, NPPs should be able to 
adjust treatment as they deem clinically necessary without delay. Limiting NPPs in their 
ability to provide a service for which they obtained qualification through training and 
certification also limits NPPs’ professional autonomy. Furthermore, it results in a waste 
of resources due to the underutilization of NPPs’ capabilities as independent providers. 
Limited scope of prescribing is not the only impediment to NPP prescribing. Even 
with the legal and clinical policies allowing them to prescribe, NPPs experience several 
other obstacles in fully exercising their prescribing authority. Local restrictions including 
the unavailability of prescription pads and limited budgets as well as difficulties in 
implementing clinical management plans have been cited (Courtenay & Carey, 2008). In 
addition, Courtenay and Carey (2008) report low peer support and objections by medical 
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staff or pharmacists stemming from skeptical views regarding NPPs as independent care 
providers as other sources of barriers for NPP prescribing. Patients’ views on NPP 
prescribing are mixed and vary by specialty. While patients are generally confident of 
NPP prescribing, they are less likely to be in favor of expanding nurses’ prescribing 
authority (Courtenay, Stenner, & Carey, 2010; Ben Natan, Kabaha, Jackob, Atallah, & 
Sharon, 2013). The level of confidence in NPP prescribing is higher in diabetes patients 
compared to those with psychiatric conditions (Courtenay, Stenner, & Carey, 2010; 
O'Connell, Creedon, McCarthy, & Lehane, 2009). 
 Despite the legal, logistical, and perceptive challenges, previous studies have 
shown that NPPs prescribe similarly to their physician (MD) counterparts and achieve 
comparable patient outcomes. Both NPPs and MDs prescribe at least one medication in 
approximately two-thirds of the visits, averaging 1.5 medications per visit (Hooker & 
Cipher, 2005). More broadly, a systematic review finds that no significant differences 
exist between NPPs and MDs in the total number of prescriptions, the total number of 
visits resulting in prescription, the mean number of prescriptions per visit, and the type 
and dosage of medications (Gielen, Dekker, Francke, Mistiaen, & Kroezen, 2014). 
Several studies have shown that NPP prescribing is clinically appropriate and safe and 
achieves comparable results in managing blood pressure, HbA1c, cholesterol, and 
creatinine (Latter, Maben, Myall, & Young, 2007; Latter S. , 2008; Carey, Courtenay, 
James, Hills, & Roland, 2008; Wilkinson, Carryer, & Adams, 2014). However, no study 
to date has explicitly examined the impact of NPPs in prescribing medications when 
NPPs co-prescribe with MDs in a team setting.   
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 To understand better how NPP/MD team prescribing compares to sole-provider 
prescribing this study provides a descriptive analysis of the prescribing patterns of oral 
antidiabetic drugs (OADs) in veterans with diabetes. In the first half of the analysis I 
examine the distributions of the initial OAD prescriptions and the overall OAD 
prescriptions over a two-year follow-up by prescriber type, class, and agent. In the latter 
half of the analysis I compare team-based prescribing to sole-provider prescribing in NP 
and PA samples separately. While I do not perform any multivariable regression analysis, 
the unadjusted figures from this study provide a useful insight into not only how team-
based prescribing compares to sole-provider prescribing, but also the composition of 
patients managed under different prescribing models in terms of their baseline 
demographics, socioeconomics, and health.  
 
Methods 
Data 
The study draws from the pharmacy extract (PHA) of the Managerial Cost 
Accounting System (MCA, formerly Decision Support System or DSS) in the Veterans 
Health Administration (VHA). MCA PHA contains prescription information such as 
medication description, dose, quantity, and days-supply, as well as limited information on 
patient, provider, and cost. I supplement the pharmacy data with patient demographic and 
socioeconomic data constructed from various VHA data sources including MedSAS 
Inpatient and MedSAS Outpatient datasets. Since demographic information—date of 
birth, sex, and race—does not change over time, multiple data sources from fiscal years 
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(FY) 1991 to 2012 are used to obtain the most consistent and accurate data.   
 Diabetes Epidemiology Cohort (DEpiC) is a registry of diabetic veterans 
constructed from multiple VHA and Medicare data sources used to determine whether a 
veteran had diabetes in a given FY from 1998 to 2012. To be classified as having 
diabetes in any year a patient has to have had: 1) two or more ICD-9-CM codes for 
diabetes (250.x) in the current and the prior year, or 2) a prescription for an antiglycemic 
agent other than biguanide (i.e., metformin), thiazolidinediones (TZDs; glitazones, e.g., 
pioglitazone, rosiglitazone), or alpha-glucosidase inhibitors (gliflozins, e.g.,, acarbose) in 
the current year, or 3) a prescription for biguanides, thiazolidinediones, or alpha-
glucosidase inhibitors in the current year. In addition DEpiC patients could have been in 
DEpiC in any previous FY or had any of the following in the 24-month period including 
the current year and the prior year: a) at least one ICD-9-CM code for diabetes, b) any 
hemoglobin A1c test greater than 7.0%, and c) two or more blood glucose tests greater 
than 200 mg/dL. DEpiC has been shown to reliably identify diabetic patients in the VHA 
(Miller, Safford, & Pogach, 2004). 
Study sample 
The sample draws from the pool of veterans who initiated oral antidiabetic drug 
(OAD) in FY 2010. Initiation of OAD is established by first obtaining all OAD and 
insulin prescriptions in the VHA from FY 2002 to FY 2012. All patients whose first 
prescription was an OAD (and not insulin) issued in FY 2010 are included. The sample is 
further limited to those with diabetes—as determined by the inclusion in DEpiC at any 
point during the OAD-initiating year. I exclude patients without any subsequent 
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outpatient OAD during the two-year follow-up period after the initial prescription. This 
eliminates those with one-off prescriptions and ensures that the remaining patients are 
sufficiently exposed to medication management. Lastly, patients who died before the end 
of the follow-up are excluded, resulting in a sample of 76,672 patients (Figure 2). 
Differences between the study sample and the excluded patients, while not substantial, 
are noted: Those who do not continue to receive OADs in a VHA outpatient setting after 
initiation appear to be slightly older (two years), wealthier ($4,000 more annual income), 
and have less severe diabetes (5% less insulin users and 7% less inpatient OAD 
recipients, Table A1). 
Prescribing models 
I categorize patients into one of five mutually exclusive prescribing models: 
physician (MD)-only, NP/MD team, PA/MD team, NP-only, and PA-only prescribing. 
NP prescribing models and PA prescribing models are analyzed separately; in each 
analysis, the two NP or PA prescribing models are compared to MD-only prescribing. To 
be considered as having received medications under any of the prescribing models, a 
patient has to receive OAD prescriptions exclusively from the specified prescriber type. 
For example, patients in the NP/MD group cannot have any other OAD prescription from 
other non-physician providers such as PAs. Since NPs and PAs are the two predominant 
non-physician prescribers of OADs, I compare patients who receive OAD prescriptions 
only from MDs, NPs, or PAs. 
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OAD prescription 
I obtain all outpatient OAD prescriptions in the two years following initiation. 
Each prescription contains the description of the agent prescribed, dose, quantity, days-
supply, dispense date, and prescriber type (e.g., MD, NP).  
 For patients who received more than one OAD agent on the same day, I count 
their prescriptions as a single combination prescription. For example, if a patient received 
two prescriptions, one for metformin and another for glyburide, he is considered to have 
received one prescription for a metformin/glyburide combination. This prevents any 
provider to be double-counted if they prescribe more than one medication on the same 
encounter. 
 The mean number of total prescriptions, the mean number of unique prescribers, 
the mean number of OAD classes, and the mean number of OAD agents are calculated 
for patients under each of the five prescribing models. Unique prescribers are determined 
based on their provider IDs. See Table A3 for a complete list of OAD agents by class. 
Baseline characteristics 
I include age, sex, race, marital status, and income (in FY 10 dollars) at the time 
of OAD initiation to describe the sample characteristics at baseline. In addition, an 
indicator of inpatient OAD receipt and an indicator of insulin use during follow-up are 
used as measures of the severity of diabetes. An array of diabetes-related comorbidities is 
examined to determine any differences in the level of sickness among the patients across 
the three prescribing models. For each condition, having two or more ICD-9-CM codes 
(Table A2) during the two-year period before the initiation of OAD qualifies a patient as 
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having the condition. 
Statistical analysis 
In both NP and PA analyses, I use the Kruskal-Wallis test to test the differences in 
mean numbers of total prescriptions, unique prescribers, and OAD drug classes/agents 
across the three prescribing models. Due to the large number of insufficient counts in 
some combinations of OAD drug classes and agents, the association between prescribing 
model and OAD class/agent is not tested. All significance tests are performed using SAS 
9.3 (Cary, NC). 
 
Results 
Sample characteristics 
Of the 63,104 patients in the NP sample, 72% of the patients received OAD 
prescriptions solely from MDs, followed by 15% and 13% of the patients receiving 
prescriptions from a team of NP and MD prescribers and from NP prescribers only, 
respectively (Table 2.1).  Compared to the two single prescriber type groups, patients 
who receive team prescribing are slightly younger (mean age of 60 vs. 62), less likely to 
be married (5% less married), and have lower annual income ($40,784 vs. $44,400-
$47,200). They also appear to have more severe diabetes as indicated by higher 
percentages of insulin and inpatient OAD users.  
The highlighted differences in patient characteristics appear to hold in the PA 
analysis (Table 2.2). However, the proportions of patients managed under PA prescribing 
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models relative to MD-only prescribing are substantially lower with 7% PA/MD and 5% 
PA-only patients compared to 15% NP/MD and 13% NP-only. 
Prescribing pattern by provider type 
74% of the initial OAD prescriptions are issued by a physician (Table 2.3). In 
comparison, NPs initiate about 18% of the patients on OADs and PAs 8%. Metformin is 
the most frequently prescribed initial OAD, followed by the sulfonylurea glipizide and 
glipizide/metformin combination. While the initial therapy choice appears to be similar 
across MD, NP, and PA prescribers, MDs do prescribe about 1.5% more 
biguanide/sulfonylurea combinations as the initial OAD compared to the rest of the 
prescriber types.  
The prescribing pattern over the course of the two years following initiation 
exhibits a similar pattern to that of the initial OAD prescriptions. The proportion of 
OADs prescribed by MDs remains the same at 74% while NPs and PAs each prescribe 
1% less; the remaining 2% of the OAD prescriptions are issued by pharmacists (Table 
2.4). MDs prescribe approximately 7 OAD prescriptions (including the initial 
prescription) per patient on average over the course of two years, while NPs and PAs 
prescribe 1.6 and 0.62 prescriptions, respectively. 
Prescribing pattern by prescribing model 
Patients managed under NP/MD team prescribing receive 1.3 and 1.9 times more 
OAD prescriptions compared to those under the MD-only and NP-only prescribing 
models, respectively (Table 2.5). In addition, those in NP/MD team prescribing see one 
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more unique prescriber (of any type) than those in sole-provider prescribing. The 
proportions of all agents and classes prescribed during the two-year follow-up indicate 
that an NP/MD team prescribes 3–5% less biguanides in favor of more sulfonylureas and 
biguanide/sulfonylurea combinations. TZDs appear to be prescribed at similar levels 
across the three prescribing models in the NP sample.  
Almost identical patterns are observed in the PA analysis: Patients under PA/MD 
prescribing model, compared to those under sole-provider prescribing models, receive 
approximately 1.5 more OAD prescriptions, see an additional unique prescriber, and take 
more sulfonylureas and biguanide/sulfonylurea combinations and less biguanides (Table 
2.6). 
 
Discussion and conclusion 
In this chapter, I compare the prescribing patterns of OADs between team-based 
prescribing and sole-provider prescribing. By describing the OAD prescriptions over a 
two-year period following initiation by agent, class, and volume, I find that patients 
whose medications are managed by a team of physician and non-physician prescribers 
receive a significantly higher total number of outpatient OAD prescriptions on average. I 
also find that team prescribing patients receive less metformin and more sulfonylureas 
and metformin/sulfonylurea combinations than sole-provider prescribing patients.  
The team prescribing group's higher mean total number of OAD prescriptions per 
patient in conjunction with the greater volume of sulfonylurea prescriptions, either as a 
monotherapy or a combination with metformin, may be indicative of a more responsive 
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medication management. Facilitated by NPPs, team prescribing might help patients adjust 
their medication treatment in a more-timely manner and realize better health outcomes 
compared to sole-provider prescribing. Better outcomes, in turn, may result in cost 
savings in the long term due to fewer complications and improved overall health. 
However, the potential savings may be offset by higher total prescription costs associated 
with more aggressive treatment and frequent adjustments. Moreover, previous findings 
suggest that NPPs are more likely to order imaging and screening tests than physicians, 
further diminishing any cost savings through prevented complications and improved 
health (Laurant, et al., 2009; Venning, Durie, Roland, Roberts, & Leese, 2000; Hemani, 
Rastegar, Hill, & Al-Ibrahim, 1999). Therefore, the expected direction of the net cost is 
ambiguous. 
Despite their statistical significance, the differences in the rates of different 
classes and agents as well as the differences in the total OAD prescriptions among 
prescribing models may be misleading due to the lack of risk adjustment for the baseline 
patient characteristics. The significantly higher mean total OAD prescriptions and higher 
unadjusted rate of sulfonylureas among patients managed under team prescribing in both 
NP and PA samples likely reflect at least in part the greater severity of diabetes. If 
patients with more severe diabetes and/or higher number of comorbid conditions were 
disproportionately assigned to team prescribing, they would be more likely to receive 
earlier intensification of OAD treatment. In addition, facility-level characteristics such as 
size and quality of care may independently predict treatment pattern over the course of 
the two years after OAD initiation. Such factors are potential sources of treatment 
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selection bias that should be addressed to obtain valid estimates of any outcome of 
interest. In Chapters 3 and 4, I use the instrumental variables method to adjust for 
treatment selection bias in estimating the effects of prescribing model on outcomes and 
costs. 
Adopting the existing model of continuity of care, Beadles et al. (2014) 
conceptualize continuity of medication management (COMM) as consisting of three 
domains of continuity: Interpersonal, management, and information. Their model posits 
that all three domains are related to each other and independently influence COMM. The 
measure of COMM is operationalized as the number of prescribers in a given time 
period; a review of the literature suggests that a greater number of prescribers 
significantly increases the number of ER visits and the risk of medication error, 
duplication, and adverse drug events (Beadles, Voils, Crowley, Farley, & Maciejewski, 
2014). In the current study, the differences in the mean number of unique prescribers seen 
by patients across different prescribing models, while statistically significant, are not 
sufficiently large to suggest any fragmentation of care, and are unadjusted for known risk 
factors for ER use. However, I argue that team prescribing, by definition, poses the risk 
of decreased continuity of medication management.  
Merely forming a group of providers does not constitute a functioning team. In a 
primary care setting, the members of an effective care team understand and respect 
members’ roles, recognize that teamwork requires work, have the practical “know-how” 
for sharing patient care, understand primary health care, and communicate with each 
other regularly (Sargeant, Loney, & Murphy, 2008). These characteristics overlap with 
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the three dimensions of COMM in several ways. Understanding and respecting team 
members directly relates to the interpersonal dimension of COMM; while the 
interpersonal dimension refers to the personal trust and familiarity between patients and 
their providers, respect among team members likely extends to their patients as well. 
Understanding primary care and regular communication contribute to management 
continuity. Lastly, information continuity can be achieved by having the practical “know-
how” for sharing patient care and effective communication skills. Therefore, it is 
reasonable to assume that, as the team size increases (i.e., the number of providers), the 
likelihood of discontinuity of medication management increases as the coordination of 
care between team members becomes more complex. Although continuity of care is out 
of scope of this dissertation, I note its relevance in the context of team-based medication 
management. 
Descriptions of the prescribing pattern of OADs in VHA in this chapter serve as a 
reference point in placing in context the results from Chapters 3 and 4. While I observe 
significantly higher numbers of total prescriptions and second-line medications under 
team prescribing suggestive of more responsive medication management, I also find signs 
of potential treatment selection bias as reflected in the marked differences in the baseline 
level of comorbidity and severity of diabetes. To disentangle the effect of prescribing 
modality from potential biases in the sample, I implement the instrumental variables 
method in the following chapters to obtain the regression-adjusted estimates of the 
prescribing model effect on outcomes and costs. 
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Figure 2. Derivation of the study sample 	 	
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Table 2.1. Sample characteristics at baseline: Nurse practitioner 
 
MD only NP/MD NP only 
N (%) 45,624 (72) 9,503 (15) 7,977 (13) 
Age (SD) 61.6 (10.4) 59.9 (10.3) 62.1 (10.7) 
Sex (%) 
   
Male 43,798 (96) 9,015 (95) 7,537 (94) 
Female 1,826 (4) 488 (5) 440 (6) 
Race (%) 
   
White 31,296 (69) 6,410 (67) 5,759 (72) 
Black 7,769 (17) 1,827 (19) 1,292 (16) 
Hispanic 2,547 (6) 442 (5) 282 (4) 
Other 1,411 (3) 295 (3) 202 (3) 
Unknown or missing 2,601 (6) 529 (6) 442 (6) 
Marital status (%) 
   
Married 27,533 (60) 5,258 (55) 4,821 (60) 
Unmarried 18,091 (40) 4,245 (45) 3,156 (40) 
Income (SD) 44,423 (75,881) 40,784 (70,762) 47,206 (80,607) 
Insulin Use (%) 5,916 (13) 1,843 (19) 957 (12) 
Inpatient OAD (%) 4,344 (10) 1,674 (18) 554 (7) 
Comorbidities (%) 
   
Hypertension 22,751 (52) 4,268 (45) 4,160 (52) 
Hyperlipidemia 20,053(46) 3,543 (37) 3,664 (46) 
Cardiovascular 7,384 (17) 1,375 (14) 1,303 (16) 
Heart disease 5,757 (13) 1,066 (11) 992 (12) 
Sexual impotence 2,471 (6) 472 (5) 441 (6) 
Neuropathy  2,422 (6) 496 (5) 400(5) 
Peripheral neuropathies 1,768 (4) 351 (4) 284 (4) 
Cerebrovascular  1,072 (2) 228 (2) 233 (3) 
Nephropathy-1 1,129 (3) 196 (2) 163 (2) 
Peripheral vascular disease 986 (2) 187 (2) 166 (2) 
Congestive heart failure 899 (2) 233 (2) 164 (2) 
Cerebrovascular disease 935 (2) 187 (2) 189 (2) 
Chronic renal disease 934 (2) 165 (2) 131 (2) 
Retinopathy 778 (2) 161 (2) 138 (2) 
Cellulitis and abscess 544 (1) 159 (2) 92 (1) 
Nephropathy-3 573 (1) 113 (1) 83 (1) 
Myocardial infarction 399 (1) 95 (1) 97 (1) 
Other selected infections 283 (1) 92 (1) 50 (1) 
Diabetic eye disease 258 (1) 43 (0) 32 (0) 
Gangrene & lower limb ulcer 160 (0) 40 (0) 20 (0) 
Nephropathy-2 86 (0) 5 (0) 15 (0) 
Hypoglycemia (new def) 34 (0) 8 (0) 2 (0) 
Cardiac surgery 24 (0) 9 (0) 1 (0) 
Hypoglycemia 24 (0) 4 (0) 2 (0) 
Metabolic 6 (0) 2 (0) 0 (0) 
Other metabolic complications 6 (0) 2 (0) 0 (0) 	 	
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Table 2.2. Sample characteristics at baseline: Physician assistant 
 
MD only PA/MD PA only 
N (%) 45,624 (87) 3,813 (7) 2,868 (5) 
Age (SD) 61.6 (10.4) 59.9 (10.5) 62.6 (10.6) 
Sex (%) 
   
Male 43,798 (96) 3,680 (97) 2,790 (97) 
Female 1,826 (4) 133 (3) 78 (3) 
Race (%) 
   
White 31,296 (69) 2,653 (70) 2,138 (75) 
Black 7,769 (17) 680 (18) 414 (14) 
Hispanic 2,547 (6) 145 (4) 79 (3) 
Other 1,411 (3) 112 (3) 55 (2) 
Unknown or missing 2,601 (6) 223 (6) 182 (6) 
Marital status (%) 
   
Married 27,533 (60) 2,120 (56) 1,756 (61) 
Unmarried 18,091 (40) 1,693 (44) 1,112 (39) 
Income (SD) 44,423 (75,881) 40,705 (62,992) 47,727 (84,496) 
Insulin Use (%) 5,916 (13) 720 (19) 324 (11) 
Inpatient OAD (%) 4,344 (10) 700 (18) 211 (7) 
Comorbidities (%) 
   
Hypertension 22,751 (50) 1,621 (43) 1,434 (50) 
Hyperlipidemia 20,053 (44) 1,376 (36) 1,284 (45) 
Cardiovascular 7,384 (16) 540 (14) 496 (17) 
Heart disease 5,757 (13) 411 (11) 387 (13) 
Sexual impotence 2,471 (5) 185 (5) 137 5) 
Neuropathy  2,422 (5) 178 (5) 141 (5) 
Peripheral neuropathies 1,768 (4) 120 (3) 114 (4) 
Cerebrovascular  1,072 (2) 73 (2) 69 (2) 
Nephropathy-1 1,129 (2) 81 (2) 60 (2) 
Peripheral vascular disease 986 (2) 79 (2) 70 (2) 
Congestive heart failure 899 (2) 76 (2) 52 (2) 
Cerebrovascular disease 935 (2) 67 (2) 60 (2) 
Chronic renal disease 934 (2) 61 (2) 49 (2) 
Retinopathy 778 (2) 68 (2) 46 (2) 
Cellulitis and abscess 544 (1) 58 (2) 23 (1) 
Nephropathy-3 573 (1) 47 (1) 32 (1) 
Myocardial infarction 399 (1) 26 (1) 29 (1) 
Other selected infections 283 (1) 29 (1) 15 (1) 
Diabetic eye disease 258 (1) 21 (1) 14 (0) 
Gangrene & lower limb ulcer 160 (0) 13 (0) 7 (0) 
Nephropathy-2 86 (0) 2 (0) 8 (0) 
Hypoglycemia (new def) 34 (0) 6 (0) 5 (0) 
Cardiac surgery 24 (0) 1 (0) 1 (0) 
Hypoglycemia 24 (0) 0 (0) 2 (0) 
Metabolic 6 (0) 0 (0) 0 (0) 
Other metabolic complications 6 (0) 0 (0) 0 (0) 
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Table 2.3. Initiating oral antidiabetic drug by prescriber type 
 
Overall MD NP PA PD Other 
N† (%) 76,672 56,429 (74) 13,712 (18) 5,822 (8) 578 (1) 131 (0) 
Class‡ (%) 
      
BIGU 50,481 (66) 37,052 (66) 9,286 (68) 3,691 (63) 382 (66) 70 (53) 
SULF 14,839 (19) 10,847 (19) 2,602 (19) 1,253 (22) 105 (18) 32 (24) 
BIGU/SULF 10,032 (13) 7,527 (13) 1,615 (12) 804 (14) 63 (11) 23 (18) 
TZDS 577 (1) 423 (1) 103 (1) 40 (1) 9 (2) 2 (2) 
BIGU/SULF/TZDS 159 (0) 120 (0) 26 (0) 9 (0) 3 (1) 1 (1) 
AGIN 150 (0) 131 (0) 11 (0) 6 (0) 2 (0) 0 (0) 
SULF/TZDS 97 (0) 76 (0) 10 (0) 5 (0) 5 (1) 1 (1) 
BIGU/TZDS 94 (0) 70 (0) 17 (0) 5 (0) 2 (0) 0 (0) 
DPP4 77 (0) 54 (0) 17 (0) 1 (0) 5 (1) 0 (0) 
AGIN/BIGU/SULF 43 (0) 34 (0) 8 (0) 1 (0) 0 (0) 0 (0) 
Agent‡ (%) 
      
METF 50,481 (66) 37,052 (66) 9,286 (68) 3,691 (63) 382 (66) 70 (53) 
GLIP 11,092 (14) 8,116 (14) 1,984 (14) 883 (15) 90 (16) 19 (15) 
GLIP/METF 7,167 (9) 5,381 (10) 1,152 (8) 562 (10) 55 (10) 17 (13) 
GLYB 3,605 (5) 2,617 (5) 604 (4) 357 (6) 14 (2) 13 (10) 
GLYB/METF 2,795 (4) 2,095 (4) 453 (3) 233 (4) 8 (1) 6 (5) 
PIOG 570 (1) 418 (1) 103 (1) 38 (1) 9 (2) 2 (2) 
ACAR 150 (0) 131 (0) 11 (0) 6 (0) 2 (0) 0 (0) 
GLIM 127 (0) 99 (0) 14 (0) 13 (0) 1 (0) 0 (0) 
GLIP/METF/PIOG 99 (0) 75 (0) 17 (0) 6 (0) 1 (0) 0 (0) 
METF/PIOG 89 (0) 65 (0) 17 (0) 5 (0) 2 (0) 0 (0) 
† Number of prescriptions 
‡ Only the 10 most frequent classes/agents reported. See Table A3 for a complete list of class and 
agent names. 
MD – Physician 
NP – Nurse practitioner 
PA – Physician assistant 
PD – Pharmacist 
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Table 2.4. Prescribing patterns of all outpatient oral antidiabetic drug prescriptions 
during a two-year follow-up by provider type 
 Overall MD NP PA PD Other 
N† (%) 705,712 519,998 (74) 120,706 (17) 47,605 (7) 15,929 (2) 1,474 (0) 
Total OAD scripts 
(SD) 9.2 (5.2) 6.8 (5.6) 1.6 (3.5) 0.6 (2.3) 0.2 (1.1) 0.0 (0.4) 
Unique classes (SD) 1.7 (1.0) 1.6 (0.9) 1.4 (0.8) 1.4 (0.8) 1.4 (0.8) 1.3 (0.8) 
Unique agents (SD) 1.7 (1.0) 1.6 (1.0) 1.5 (0.8) 1.4 (0.8) 1.4 (0.8) 1.3 (0.8) 
Class‡ (%)       
BIGU 418,738 (59) 309,699 (60) 72,828 (60) 27,915 (59) 7,645 (48) 651 (44) 
SULF 196,420 (28) 142,714 (27) 33,707 (28) 14,017 (29) 5,522 (35) 460 (31) 
BIGU/SULF 59,975 (8) 44,828 (9) 9,576 (8) 4,152 (9) 1,265 (8) 154 (10) 
TZDS 16,682 (2) 12,379 (2) 2,573 (2) 906 (2) 712 (4) 112 (8) 
AGIN 3,292 (0) 2,675 (1) 377 (0) 122 (0) 100 (1) 18 (1) 
DPP4 3,143 (0) 2,194 (0) 486 (0) 97 (0) 344 (2) 22 (1) 
SULF/TZDS 1,545 (0) 1,161 (0) 222 (0) 85 (0) 71 (0) 6 (0) 
BIGU/TZDS 1,417 (0) 1,040 (0) 207 (0) 86 (0) 66 (0) 18 (1) 
BIGU/SULF/TZDS 1,107 (0) 801 (0) 186 (0) 69 (0) 37 (0) 14 (1) 
GLP1 772 (0) 545 (0) 163 (0) 26 (0) 38 (0) 0 (0) 
Agent‡ (%)       
METF 418,738 (59) 309,699 (60) 72,828 (60) 27,915 (59) 7,645 (48) 651 (44) 
GLIP 152,688 (22) 110,842 (21) 26,336 (22) 10,647 (22) 4,523 (28) 340 (23) 
GLIP/METF 45,004 (6) 33,603 (6) 7,129 (6) 3,133 (7) 1,023 (6) 116 (8) 
GLYB 41,782 (6) 30,382 (6) 7,102 (6) 3,210 (7) 978 (6) 110 (7) 
PIOG 16,574 (2) 12,301 (2) 2,558 (2) 891 (2) 712 (4) 112 (8) 
GLYB/METF 14,584 (2) 10,935 (2) 2,389 (2) 981 (2) 241 (2) 38 (3) 
ACAR 3,269 (0) 2,655 (1) 377 (0) 119 (0) 100 (1) 18 (1) 
SITA 3,118 (0) 2,172 (0) 484 (0) 97 (0) 344 (2) 21 (1) 
GLIM 1,845 (0) 1,397 (0) 264 (0) 153 (0) 21 (0) 10 (1) 
METF/PIOG 1,404 (0) 1,030 (0) 204 (0) 86 (0) 66 (0) 18 (1) 
† Number of prescriptions 
‡ Only the 10 most frequent classes/agents reported. See Table A3 for a complete list of class and 
agent names. 
MD – Physician 
NP – Nurse practitioner 
PA – Physician assistant 
PD – Pharmacist  
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Table 2.5. Prescribing patterns of all outpatient oral antidiabetic drug prescriptions 
during a two-year follow-up by prescribing model: Nurse practitioner 
 
MD only NP/MD NP only p-value 
N† (%) 401,237 (71) 96,094 (17) 65,632 (12) 
 
Total OAD scripts (SD) 8.8 (5.0) 10.1 (5.2) 8.2 (4.7) <.0001 
Unique prescribers (SD) 1.5 (0.8) 2.7 (0.9) 1.2 (0.5) <.0001 
Unique classes (SD) 1.6 (0.9) 1.8 (1.0) 1.5 (0.9) <.0001 
Unique agents (SD) 1.6 (1.0) 1.8 (1.1) 1.5 (0.9) <.0001 
Class‡ (%) 
   
N/A 
BIGU 244,526 (61) 54,904 (57) 41,695 (64) 
 
SULF 107,165 (27) 27,939 (29) 17,315 (26) 
 
BIGU/SULF 32,754 (8) 9,054 (9) 4,486 (7) 
 
TZDS 9,620 (2) 2,073 (2) 1,263 (2) 
 
AGIN 2,010 (1) 419 (0) 193 (0) 
 
DPP4 1,384 (0) 488 (1) 228 (0) 
 
SULF/TZDS 833 (0) 208 (0) 82 (0) 
 
BIGU/TZDS 749 (0) 204 (0) 93 (0) 
 
BIGU/SULF/TZDS 579 (0) 156 (0) 109 (0) 
 
GLP1 285 (0) 184 (0) 26 (0) 
 
Agent‡ (%) 
   
N/A 
METF 244,526 (61) 54,904 (57) 41,695 (64) 
 
GLIP 83,227 (21) 21,722 (23) 13,529 (21) 
 
GLIP/METF 24,505 (6) 6,604 (7) 3,366 (5) 
 
GLYB 22,755 (6) 5,924 (6) 3,658 (6) 
 
PIOG 9,565 (2) 2,054 (2) 1,263 (2) 
 
GLYB/METF 8,032 (2) 2,363 (2) 1,107 (2) 
 
ACAR 2,007 (1) 419 (0) 193 (0) 
 
SITA 1,365 (0) 488 (1) 226 (0) 
 
GLIM 1,100 (0) 285 (0) 126 (0) 
 
METF/PIOG 745 (0) 200 (0) 92 (0) 
 
        † Number of prescriptions 
        ‡ Only the 10 most frequent classes/agents reported. See Table A3 for a complete list of  
           class and agent names. 
        MD – Physician 
        NP – Nurse practitioner 
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Table 2.6. Prescribing pattern of all outpatient oral antidiabetic drug prescriptions during 
a two-year follow-up by prescribing model: Physician assistant 
 
MD only PA/MD PA only p-value 
N† (%) 401,237 (87) 38,491 (8) 23,691 (5) 
 
Total OAD scripts (SD) 8.8 (5.0) 10.1 (5.4) 8.3 (4.8) <.0001 
Unique prescribers (SD) 1.5 (0.8) 2.6 (0.9) 1.1 (0.3) <.0001 
Unique classes (SD) 1.6 (0.9) 1.8 (1.0) 1.5 (0.9) <.0001 
Unique agents (SD) 1.6 (1.0) 1.9 (1.1) 1.5 (0.9) <.0001 
Class‡ (%) 
   
N/A 
BIGU 244,526 (61) 21,433 (56) 14,120 (60) 
 
SULF 107,165 (27) 11,583 (30) 7,014 (30) 
 
BIGU/SULF 32,754 (8) 3,930 (10) 1,855 (8) 
 
TZDS 9,620 (2) 725 (2) 477 (2) 
 
AGIN 2,010 (1) 162 (0) 43 (0) 
 
DPP4 1,384 (0) 202 (1) 31 (0) 
 
SULF/TZDS 833 (0) 104 (0) 25 (0) 
 
BIGU/TZDS 749 (0) 62 (0) 53 (0) 
 
BIGU/SULF/TZDS 579 (0) 60 (0) 27 (0) 
 
GLP1 285 (0) 76 (0) 0 (0) 
 
Agent‡ (%) 
   
N/A 
METF 244,526 (61) 21,433 (56) 14,120 (60) 
 
GLIP 83,227 (21) 8,986 (23) 5,425 (23) 
 
GLIP/METF 24,505 (6) 3,111 (8) 1,361 (6) 
 
GLYB 22,755 (6) 2,454 (6) 1,512 (6) 
 
PIOG 9,565 (2) 703 (2) 469 (2) 
 
GLYB/METF 8,032 (2) 793 (2) 468 (2) 
 
ACAR 2,007 (1) 155 (0) 43 (0) 
 
SITA 1,365 (0) 201 (1) 31 (0) 
 
GLIM 1,100 (0) 133 (0) 77 (0) 
 
METF/PIOG 745 (0) 59 (0) 53 (0) 
 
         † Number of prescriptions 
         ‡ Only the 10 most frequent classes/agents reported. See Table A3 for a complete list of  
            class and agent names. 
         MD – Physician 
         PA – Physician assistant 
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CHAPTER THREE: EFFECT OF TEAM-BASED MEDICATION 
MANAGEMENT ON DIABETES-RELATED CLINICAL OUTCOMES 
  
Introduction 
A team-based approach has increasingly become a preferred model of primary 
care. Research has suggested that shifting clinical responsibilities to non-physician 
providers (NPPs) such as nurse practitioners and physician assistants may alleviate the 
current and future shortage of primary care physicians (Bodenheimer & Smith, 2013; 
Green, Savin, & Lu, 2013). Delegating care responsibilities to other team members not 
only eases the burden on physicians (MDs), but also creates an opportunity for NPPs to 
practice their training and skills to the fullest extent. The team-based approach may be 
especially effective in chronic care because NPPs’ strengths in communication and 
patient education can be beneficial in facilitating clinical and self-management, which are 
two of the critical components in chronic care (Wagner E. H., 2000).  
NPPs with proper training are competent clinicians capable of providing direct 
patient care without physician supervision. In the Veterans Health Administration 
(VHA), which is one of the leading employers of NPPs in the U.S., NPs have been shown 
to perform equally as well as their physician counterparts. In examining the effect of 
provider type on clinical outcomes of patients with diabetes and/or hypertension, Fletcher 
et al. (2011) find no significant differences in blood pressure, creatinine, or HbA1c 
measures between NP-managed patients and MD-managed patients. In a more recent 
study that compares the mean HbA1c levels among diabetic patients managed by NPs, 
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PAs, and MDs in the VHA, Yang et al. (2018) find no differences in the mean HbA1c 
levels over a four-year follow-up after the initial diagnosis of diabetes. Mundinger et al. 
(2000) report similar findings in a non-VHA, randomized study showing that patients 
assigned to the NP clinic do not significantly differ from those assigned to the MD clinic 
on satisfaction, self-reported health status, or any of the health service utilization 
measures—primary care visits, specialty visits, ED and urgent care visits, and 
hospitalizations—during either the first six months or the first year after study 
enrollment. Another randomized control trial in which diabetes nurse specialist patients 
are compared to standard care led by internists in managing diabetes shows that while 
patients in both groups achieve significant reductions in mean HbA1c, cholesterol, and 
diabetes-related symptoms during a one-year follow-up, the reductions between the 
groups are not significant (Houweling, et al., 2009). Other studies using either a shorter 
follow-up or repeated measures at three-month intervals also find significant 
improvements in glycemic control in both MD and NPP patients and insignificant 
differences between groups (Chan, Yee, Leung, & Day, 2006; Vrijhoef, Diederiks, 
Spreeuwenberg, & Wolffenbuttel, 2001). 
Much research has examined NPP prescribing. In comparison to MDs, NPs and 
PAs prescribe similarly on average by volume—Cipher and Hooker (2006) report no 
significant differences in the mean number of medications prescribed per primary care 
visit. Moreover, a comprehensive review finds little to no evidence of any differences in 
the type and dose of medications prescribed by physicians and nurses (Gielen, Dekker, 
Francke, Mistiaen, & Kroezen, 2014). On the safety and quality of NPP prescribing, 
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previous studies have shown that NPP prescribing is clinically safe, appropriate, and of 
high quality (Latter, Maben, Myall, & Young, 2007; Latter S. , 2008). Using a modified 
Medication Appropriate Index, a validated instrument for assessing prescribing 
appropriateness, Latter et al. (2007) analyze 12 annotated transcripts of nurse prescribing 
consultations across multiple sites and find that prescribing decisions made by nurses are 
in general clinically appropriate. Latter (2008) finds that nurse prescribers use a wide 
range of assessment and diagnostic skills and competencies to identify and diagnose a 
primary concern and make quality prescribing decisions. Several studies have shown that 
NPP prescribing can be beneficial to patients (O'Connell, Creedon, McCarthy, & Lehane, 
2009; Courtenay, Stenner, & Carey, 2010; Carey, Courtenay, James, Hills, & Roland, 
2008). Four studies included in a systematic review of the literature find that nurse 
prescribing not only saves time and increases convenience for patients, but also improves 
medication compliance and prevents relapses (O'Connell, Creedon, McCarthy, & Lehane, 
2009). Nurse prescribing increases access to medications and reduce wait times because 
patients no longer have to wait for the nurses to obtain prescriptions from the attending 
physicians (Courtenay, Stenner, & Carey, 2010). Lastly, nurse prescribing reduces 
medication errors; Carey et al. (2008) compare the total number of oral hypoglycemic 
agent and insulin medication errors—including incorrect/unclear prescribing, 
unsigned/incomplete charts, and incorrect dose adjustment—before and after an 
organizational intervention incorporating medication management by diabetes nurse 
specialists into an inpatient setting and find a significant reduction of 74% in this small 
quasi-experimental study of 56 patients.  
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While previous studies have shown NPP care and prescribing to be comparable to 
MD care, research on the effect of NPP/MD team prescribing on outcomes is limited. In 
this chapter, I examine the effect of team prescribing on clinical health outcomes in 
VHA. To determine whether team prescribing achieves better outcomes compared to 
sole-provider prescribing, I compare the changes in four different diabetes-related lab 
measures over a two-year follow-up in diabetic Veterans who initiate oral antidiabetic 
drug treatment. Given the evidence to date suggesting that NPP prescribing may improve 
health outcomes through increased adherence, reduced medication errors, and better self-
management, I hypothesize that NPP/MD team medication management would achieve 
better outcomes compared to sole-provider medication management. Therefore, I predict 
the diabetes-related outcomes of patients under team prescribing to be significantly better 
than those of patients under sole-provider prescribing. 
 
Methods 
Data 
The pharmacy extract (PHA) of the Managerial Cost Accounting System (MCA, 
formerly Decision Support System or DSS) in the Veterans Health Administration 
(VHA) contains prescription information such as medication description, dose, quantity, 
and days’ supply, as well as limited information on patient, provider, and cost. I 
supplement the pharmacy data with patient demographic and socioeconomic data 
constructed from VHA data sources, MedSAS Inpatient and MedSAS Outpatient 
datasets, as well as the inpatient and outpatient Medicare datasets. Since demographic 
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information—date of birth, sex, and race—do not change over time, VHA data from 
fiscal years (FY) 1991 to 2012 and Medicare data from 1996 to 2004 are used to obtain 
the most consistent and accurate data. I use the Laboratory Results extract (LAR) of the 
MCA to construct the four diabetes-related clinical measure variables: changes in 
hemoglobin A1c (HbA1c), in low-density lipoprotein (LDL), in outpatient serum glucose 
(GLU), and serum creatinine (CRE) from baseline to follow-up. 
Study sample 
Derivation of the base study sample is described in detail in Chapter 2: Diabetic 
veterans who initiated oral antidiabetic drugs (OADs) in FY10, stayed alive during a 2-yr 
follow-up, had at least one subsequent outpatient OAD prescription after initiation, and 
received OP OAD exclusively from physicians (MDs), nurse practitioners (NPs), 
physician assistants (PAs), an MD/NP, or an MD/PA team. The sample in this chapter is 
a subset of the base sample: Patients who have a complete pair of baseline and follow-up 
measures for any of the four lab tests—HbA1c, LDL, GLU, and CRE. Those who did not 
have a complete pair of measures for all four tests are excluded from the sample. 
Dependent variables 
For each lab test, the dependent variable is constructed by subtracting the baseline 
measure from the follow-up measure—this represents the change over the 2-year follow-
up. Defining the index date as the initiation date of OAD, the most recent measure in the 
6 months before the index date is assigned as the baseline. Because it is unrealistic to 
expect a follow-up measure to occur exactly on the 731st day (the 2-year mark) from the 
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baseline date, I broaden the search window to the 6 months before and 6 months after the 
end-of-study (731 days after the index date); the closest measure to the end-of-study date 
is assigned as the follow-up measure. To minimize the effect of extreme outliers without 
substantially altering the original data, I conservatively top-code and bottom-code the lab 
values at the 99th and 1st percentiles, respectively. 
Independent variables 
The prescribing model variable constructed in Chapter 2 is the primary predictor 
of interest. I examine NP prescribing models and PA prescribing models separately. The 
three mutually-exclusive prescribing models in each analysis include MD-only, NPP/MD 
team, and NPP-only models. 
Baseline lab measure may affect the regression estimates in two ways. First, 
providers may prescribe and adjust medications differently depending on how high or 
low the patient’s baseline level is. Second, any changes in lab measure during the follow-
up may be correlated with the patient’s initial level. Therefore, I include a continuous 
measure of the lab test at baseline to control for such differences.  
I include age, sex, race, marital status, and income (in FY2010 dollars) in FY2010 
as the baseline patient-level covariates. In addition, an indicator of inpatient OAD receipt 
and an indicator of insulin use during the follow-up are used as measures of the severity 
of diabetes. An array of diabetes-related comorbidities is used to adjust for any 
differences in the level of sickness among the patients across the prescribing models. For 
each condition, having 2 or more ICD-9-CM codes (Table A2) during the 2-year period 
before the initiation of OAD qualifies a patient as having the condition. 
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Statistical analysis 
NP and PA analyses are conducted separately in estimating the mean change in 
each of the four lab measures. In each analysis, team prescribing (NP/MD or PA/MD) is 
compared independently to the two sole-provider prescribing models (MD only and NP 
or PA only). In addition, I compare the two sole-provider prescribing models (MD only 
and NP only or PA only), resulting in three total comparisons for each analysis sample. I 
use SAS 9.4 (Cary, NC) to prepare the analytical data and Stata 15 (College Station, TX) 
to perform all regression analyses. I use the significance level of 5% to conduct all 
hypothesis testing. 
I assume the prescribing model variable to be endogenous. It is likely that the 
selection into one of the three prescribing models— the team model or either of the two 
sole-provider models—does not occur randomly. Rather, several facility-level factors 
such as staffing, size, and budget may systematically predict treatment selection. For 
example, patients who go to a rural clinic at which only NPs are stationed have no choice 
but to receive medications exclusively from an NP. On the other hand, patients living in a 
metropolitan area with access to a larger medical center might be more likely to receive 
team care.  
In addition, differences in quality of care and physician preference in delegating 
prescribing duties to NPP prescribers across different facilities may also influence 
whether patients receive team prescribing. Assuming that team medication management 
is considered to be preferred model over sole-provider medication management, a facility 
of higher quality may be more likely to deploy team medication management. Separately, 
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physicians’ willingness to grant NPPs prescribing autonomy is likely to affect the degree 
of NPPs’ involvement in medication management. Quality of care and physician 
preference are examples of confounders that are difficult to measure and typically 
unavailable as observed data.  
Treatment selection bias and confounding, both measured and unmeasured, 
should be taken into account in any modeling to obtain unbiased estimates. Omission of 
any variables that affect the treatment selection process might result in biased estimates 
of the treatment effect. In this paper, I address the potential endogeneity of treatment in 
two ways. First, I limit the analysis to facilities at which all three treatment options are 
available. Having all three prescribing models available to patients may indicate that the 
facility has sufficiently large budget, which is likely to be correlated with facility size, to 
maintain the staffing level required for team care. It might also reflect higher quality of 
care associated with facilities that deploy different modes of care corresponding to their 
patient mix. Limiting the analysis to such facilities by design should reduce heterogeneity 
across facilities, thereby attenuating the treatment selection bias. Second, I use the 
instrumental variables method to adjust for any unmeasured confounders that affect the 
assignment of prescribing model in the study sample.   
Candidate instrumental variable 1: Professional Practice Index (PPI) 	
Originally developed by Sekscenski et al. (1994), the NPP Professional Practice 
Indices—a separate index for each of NPs, PAs, and certified nurse midwives—measure 
each state's professional practice environment of the three NPP professions on three 
dimensions: legal authority (or scope of practice), reimbursement, and prescriptive 
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authority (NCHWA, 2004). They range from 0 (“no practice environment") to 100 
(“optimal practice environment"). Since they are state-level indices, I assign an index 
score for each VHA facility based on the state in which the facility is located.  
I predict that PPI is positively correlated with NPP use. For example, a facility 
located in a state with a more favorable practice environment for NPPs may a) employ 
more NPPs, and b) have physicians and managers who view NPPs as competent 
providers and are more willing to work with NPPs. This in turn may result in increased 
patient care responsibilities for NPPs. Patients at such a facility, therefore, are more likely 
to receive NPP care. Favorable practice environment also increases NPP use both directly 
and indirectly through labor supply. Sekscenski et al. (1994) find that states with more 
favorable NP practice laws and reimbursement policies have greater NP supplies; the 
greater NP supplies, in turn, increase NP use (Huang, Yano, Lee, Chang, & Rubenstein, 
2004).  
While VHA facilities are under the federal jurisdiction and are exempt from any 
state-level regulations, they employ providers who also practice outside of VHA. The 
positive correlation between PPI and NPP use hinges on the assumption that the staffing 
decisions of VHA facilities and the preferences of physicians who also practice at non-
VHA facilities are influenced by PPI. I assume that there exists some spillover effect of 
PPI on physicians and VHA facilities. Since facilities have discretion in amending NPPs’ 
scope of practice to meet the local needs, facilities in states with higher PPIs may be 
more willing to place greater patient care responsibilities on NPPs in response to patient 
demand and/or experiences of their non-VHA counterparts in the state. Likewise, 
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physicians with dual appointments in high-PPI states may have more experience in 
working with NPPs and advocate for more NPP use at their VHA facilities. 
Candidate instrumental variable 2: Rate of NPP OAD prescribing 	
I use the rate of OAD prescriptions by NPs/PAs at each clinic (STA6A in MCA 
PHA data) to predict which of the three prescribing models a patient receives. It is 
calculated by dividing the total number of OAD prescriptions issued by NPs/PAs by the 
total number of OAD prescriptions in FY2010, the index year. This is analogous to the 
instrument used by Stukel et al. (2007), in which the regional cardiac catheterization rate 
is used to predict the receipt of that treatment in investigating effect of cardiac 
catheterization on long-term mortality. Both instruments use variation in treatment 
pattern—facility variation in the rate of NPP OAD prescribing and regional variation in 
the rate of cardiac catheterization—to predict treatment. They are two of the four most 
commonly used instrument categories (Garabedian, Chu, Toh, Zaslavsky, & Soumerai, 
2014)—the remaining two are distance to facility (e.g., McClellan, McNeil, & 
Newhouse, (1994)) and physician-level variation (e.g., Brookhart et al. (2006)). 
Assessment of IV relevance and validity 	
An instrument has to satisfy two assumptions. First, the instrument has to be 
highly correlated with the endogenous variable. Often referred to as the relevance 
assumption, it requires that the proposed instrument reliably predicts the endogenous 
variable in question. Using a weak instrument should be avoided as it results in biased 
estimates and may amplify the bias present in OLS (Murray, 2006; Newhouse & 
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McClellan, 1998). Second, the instrument cannot be correlated with the disturbance term 
in the outcome equation. The effect of the proposed instrument on the main outcome 
variable must be only through its correlation with the endogenous predictor and cannot be 
correlated with any other unmeasured confounders (Angrist & Krueger, 2001).  
I test the first assumption by examining the significance of the coefficient on the 
instrument (α1 in (1)) and the joint F-statistic in the first stage regression. A statistically 
significant coefficient of the instrument indicates that the instrument significantly 
predicts treatment. An F-statistic greater than 10 is generally considered to be sufficient 
to conclude that the instrument is reasonably strong for a single endogenous variable 
(Stock, Wright, & Yogo, 2002).  
The second assumption, however, cannot be verified in theory because the 
relationship between the instrument and the unmeasured confounders cannot be tested. 
The literature often relies on theory and intuition behind the potential relationship (or 
lack thereof) between the instrument and the unmeasured confounders. If the instrument 
is uncorrelated with the unobserved confounders that affect the outcome, it should also be 
the case that the instrument is uncorrelated with the observed variables such as age and 
income (Newhouse & McClellan, 1998). Therefore, I examine the distributions of the 
included covariates across the quintiles of the two continuous instruments to gauge 
whether the instrument is potentially invalid. The intuition is that the baseline covariates 
should be balanced across the quintiles if the instrument has no direct influence on the 
observed variables. Based on the first stage regression results and the distribution of 
outcomes and baseline characteristics of each candidate instrument, I elect to use the rate 
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of NPP OAD prescribing for the main analysis in this chapter. 
Estimation 	
First, I estimate a naïve model, where 
∆Lab measure = α0 + α1Tx + α2X + e    (1) 
Tx denotes a binary prescribing model variable (e.g., NP/MD team prescribing if Tx=1); 
X denotes a vector of covariates including demographics, socioeconomics, severity of 
diabetes, comorbidities, and baseline lab measure. (1) assumes that Tx is exogenous and 
free of any treatment selection or unmeasured confounding biases.  
In addition, I perform two-stage least squares (2SLS) regression using the 
previously described instrument, the rate of NPP OAD prescribing. When the treatment 
variable is binary, using the predicted probabilities from a nonlinear model as the 
instrument is preferred over using the instrument directly in 2SLS because the former is 
robust to misspecification of the treatment model. Further, the 2SLS estimates resulting 
from the predicted probabilities instrument are more efficient than the estimates obtained 
from a conventional 2SLS with a first stage linear probability model (Angrist & Pischke, 
2009; Imbens & Wooldridge, 2007). Due to the binary nature of the treatment variable, 
prescribing model, I first estimate a logit regression to predict the probability of receiving 
the prescribing model of interest, where 
Pr(Tx=1 | X) = β0 + β1Z + β2X + u    (2) 
In Stage 0 ((2)), the instrument, a continuous measure of NPP OAD prescribing 
rate (Z), and all exogenous covariates (X) are included on the right-hand side to predict 
the probability of receiving the prescribing model of interest, Tx. The cumulative 
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predicted probabilities from (2) are used as a new instrument in a subsequent 2SLS, 
replacing the original instrument. Stage 1 regression predicts the endogenous prescribing 
model, where 
           Tx = γ0 + γ1Pr($% = 1	| *),  + γ2X + v   (3) 
Tx denotes prescribing model; Z, the new instrument, is the cumulative predicted 
probabilities of receiving the treatment of interest (e.g., team prescribing); X denotes a 
vector of all exogenous covariates included in (2). The outcome regression, Stage 2, 
estimates the mean change in lab measure, where 
             ∆Lab measure = δ0 + δ1$%-  + δ2X + r               (4) $%-  denotes the fitted values of Tx from (3); the vector X consists of the same set of 
covariates included in (2) and (3).  
 
Results 
Sample characteristics 
Nurse practitioner/physician 	
Table 3.1 presents the sample characteristics for the nurse practitioner analysis 
sample. Patients under NP/MD team prescribing tend to be slightly younger and poorer 
compared to those under sole-provider prescribing (NP only or MD only). They are also 
more likely to be non-White and unmarried. 
Insulin and inpatient OAD use during the 2-year follow-up are markedly higher in 
the team prescribing group. In comparing the baseline lab measures, the proportions of 
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those with HbA1c > 8.0% and glucose > 140 mg/dL are also higher under NP/MD. There 
appears to be no difference in the proportions of those with baseline LDL > 100 mg/dL 
and baseline creatinine > 1.5 mg/dL across the three prescribing models.  
Among the 18 diabetes-related comorbidities, the rates of hypertension, 
hyperlipidemia, cardiovascular disease, and heart disease are all higher under sole-
provider prescribing compared to team prescribing. Among the patients under the team 
prescribing model, the rate of hypertension is 6%-7% lower, the rate of hyperlipidemia is 
8%-10% lower, and the rate of heart disease is 1%-2% lower. The prevalence of the 
remaining 15 conditions appears to be similar among patients under the three prescribing 
models. 
Physician assistant/physician 	
Table 3.2 presents the sample characteristics for the physician assistant analysis 
sample. The patient counts of PA only and PA/MD team prescribing are 60-70% smaller 
compared to that of NP only and NP/MD team prescribing, respectively. All similarities 
and differences highlighted in nurse practitioner/physician hold true in the physician 
assistant analysis. 
Outcome measures 
The complete test rate—proportion of patients with both baseline and follow-up 
measures—appears to be similar across all three prescribing models (76%-89%) in the 
four diabetes-related clinical measures (Tables 3.3 and 3.4). 
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Nurse practitioner/physician 	
The mean number of HbA1c and LDL tests appears to be similar in all three 
prescribing groups, ranging from 4.9 to 5.6 tests over the course of the 2-year follow-up 
(Table 3.3). The mean number of glucose and serum creatinine tests is slightly higher 
(6.3 to 7.2); patients under NP/MD prescribing average about 1 additional test compared 
to those under sole-provider prescribing. 
The baseline HbA1c of those under team prescribing is 0.3–0.4% (glycated 
hemoglobin) higher compared to those in single-provider type prescribing. The same 
patients achieve 0.2% lower HbA1c over the 2-year follow-up on average (reduction of 
0.7% vs. 0.5%). Patients under team prescribing start at a substantially higher glucose 
level (179.7 mg/dL) compared to the other two prescribing models (155–166 mg/dL). 
They also achieve 8.6 to 13.8 mg/dL greater mean reduction in comparison to sole-
provider prescribing models. There appear to be no differences in LDL and creatinine 
levels across the three prescribing models, both at baseline and over time.   
Physician assistant/physician 	
Description of the lab measures and the mean number of tests in the PA analysis 
are similar to that in the NP analysis, but the differences are smaller. Compared to MD-
only and PA-only prescribing patients, PA/MD team prescribing patients receive one 
additional test for glucose and creatinine and have 0.2% and 9–12 mg/dL higher HbA1c 
and glucose levels, respectively (Table 3.4). They also achieve 0.1% greater reduction in 
HbA1c and 2.8–4.0 mg/dL greater reduction in glucose on average. 
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OLS regressions 
Nurse practitioner/physician 	
The comparison of NP/MD team prescribing to MD-only prescribing shows that 
there is no significant difference in the mean change in HbA1c, glucose, LDL, and 
creatinine measures between the two prescribing models (Table 3.5). NP-only 
prescribing, when compared to team prescribing, achieves 0.09% and 4.52 mg/dL 
significantly greater reduction in HbA1c and glucose levels, respectively. The results also 
indicate that patients under NP-only prescribing achieves 0.06% lower HbA1c level and -
3.40 mg/dL lower glucose level compared to patients under MD-only prescribing. 
Physician assistant/physician 	
There appear to be no significant differences in the mean change in lab measures 
between PA/MD prescribing and single-provider type prescribing (Table 3.5). PA-only 
prescribing performs marginally better than PA/MD team prescribing, both in magnitude 
and statistical significance, by achieving 2.86 mg/dL (p<0.1) lower glucose level over the 
2-year follow-up. 
IV regressions 
Nurse practitioner/physician 	
The significant differences between NP/MD team prescribing and NP-only 
prescribing in the mean change in HbA1c and glucose found in OLS results are no longer 
significant in the IV analysis (Table 3.6). Patients under NP-only prescribing realize 6.06 
mg/dL reduction in glucose compared to those under MD-only prescribing, which is 
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about 78% larger than the OLS estimate. In creatinine, team prescribing achieves 0.12 
mg/dL lower level than MD-only and 0.12 mg/dL higher than NP-only prescribing on 
average. Of note, when compared to MD-only prescribing, NP/MD prescribing achieves 
6.90 mg/dL lower glucose level, but it is statistically insignificant at the 5% level (p<0.1). 
Physician assistant/physician 	
None of the PA comparisons show significant differences in the mean change in 
lab measures. 
Assessment of IV relevance and validity 
To determine the relevance of the instrument, the rate of NPP OAD prescribing, I 
examine the coefficient significance of the IV and the model fit statistics in the first stage 
regressions. IV analysis in this study is conducted in two parts. Instead of using the 
instrument directly in a 2SLS regression, I use the predicted probabilities of treatment 
from a logit model as the instrument. Therefore, I assess (1) whether the rates of NP and 
PA OAD prescribing significantly predict prescribing model as estimated by a logit 
regression, and (2) whether the newly derived instrument is highly significantly 
correlated with treatment in the first stage of the 2SLS.  
I find that the rate of NP OAD prescribing significantly predicts treatment in all 
three NP comparisons across all four outcome measures (Table 3.7). I also find that the 
joint F-statistics all exceed the generally accepted threshold of 10, indicating that the 
instrument is sufficiently strong. The rate of PA OAD prescribing significantly predicts 
treatment in all PA comparisons across all four outcome measures. However, the joint F-
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statistics fail to reach the threshold of 10 for sufficient instrument strength two-thirds of 
the 12 models tested (Table 3.8). Relative weakness of the PA instrument compared to 
the NP instrument suggests that the 2SLS estimates in the PA IV analysis are potentially 
more biased than the OLS estimates. 
The key identifying assumption in the IV analysis of this study is that the rate of 
NPP OAD prescribing is uncorrelated with the unobserved predictors of the mean change 
in lab measures. While it is impossible to explicitly test such an assumption, stratifying 
the observed predictors by the instrument is an indirect way by which the assumption can 
be tested. A valid instrument should mimic randomization by creating balanced subsets 
of the sample with little to no difference in both the outcome and the observed covariates. 
A comparison of the mean change in each of the lab measures suggest that the instrument 
may be correlated with glucose, LDL, and creatinine (Table 3.9). While the comparison 
is not conditional on the included covariates, it still raises some concern that the 
instrument may not be completely uncorrelated with the unobserved measures (i.e., the 
error term) in the outcome equation. Some covariates such as insulin use and receipt of 
inpatient OAD are also significantly different across the quintiles. It is possible that this 
observation is due to chance as each quintile consists of more than 10,000 patients and 
the observed differences among the quintiles are small.   
Differences in the outcome variables across the quintiles of % PA OAD suggest 
that the PA instrument is likely not correlated with the mean changes in HbA1c and 
glucose (Table 3.10). On the other hand, the mean changes in LDL and creatinine in at 
least one quintile are different from the rest, suggesting that the instrument and the 
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outcomes are not completely independent. Significantly different rates of several 
comorbidities including hypertension, hyperlipidemia, and heart disease indicate that the 
baseline health status of patients is not fully balanced by the instrument. 
Lastly, I examine treatment group assignment by quintiles of the instrument to 
informally test the monotonicity assumption. Imbens and Angrist (1994) posit that in 
order to obtain a valid estimate of local average treatment effect, the instrument has to 
affect treatment monotonically. Figures 3 and 4 show that the number of patients in each 
treatment group either increases or decreases with the NPP OAD prescribing rate, 
suggesting that the instrument satisfies the monotonicity assumption. Relatively flatter 
lines in Figure 4 indicate that the correlation between % PA OAD prescribing and PA 
prescribing models is not as strong as the correlation between % NP OAD prescribing 
and NP prescribing models. Statistics from the Cochran-Armitage test for trend confirm 
that there exists a significant trend across the instrument quintiles (not reported).  
Assessment of the IVs in this study suggests that the extent of IV assumption 
violation is greater in the PA instrument. The rate of PA OAD prescribing exhibits a 
weaker correlation with treatment compared to the rate of NP OAD prescribing. 
Significant differences in the unadjusted mean change in at least two of the four outcome 
measures across the instrument quintiles suggest that the exclusion assumption may be 
violated in both NP and PA instruments. Therefore, 2SLS estimates presented in Table 
3.6 may be more biased compared to the OLS estimates in Table 3.5. 
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Discussion and conclusion 
In this chapter, I examine the effect of NPP/MD team prescribing of oral 
antidiabetic drugs on clinical outcomes in veterans with diabetes. I compare the mean 
change in lab measures after a 2-year follow-up between team prescribing and sole-
provider prescribing and find mixed results. While NP/MD team prescribing performs 
marginally better in reducing glucose and creatinine levels compared to MD-only 
prescribing, the differences in the mean change in HbA1c and LDL between NP/MD 
prescribing and sole-provider prescribing are insignificant in the IV analysis. I also find 
that there are no significant differences in the mean change in any of the four lab 
measures between PA/MD team prescribing and sole-provider prescribing.  
No to only marginal differences in clinical outcomes between the team 
prescribing and sole-provider prescribing are consistent with previous findings. Although 
different in team composition, Chen et al. (2010) find that patients under the care of a 
teamlet of residents and health coaches do not achieve any significant improvement in 
HbA1c or LDL and only marginally improve BP compared to those under resident-only 
care. A Cochrane review of 41 studies that investigate the effect of shared care 
interventions concludes that shared care has no significant benefit in control of clinical 
outcomes such as HbA1c, cholesterol, and weight (Smith, Allwright, & O' Dowd, 2007). 
More broadly defined than team care, shared care consists of any arrangement in which 
specialists and primary care providers can readily communicate and cooperate with each 
other in patient management. The primary care provider and specialists can be at the 
same clinic or at different clinics. Lubloy et al. (2016) study the impact of the strength of 
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ties, defined by the number of shared patients, between general practitioners (GP) and 
specialists (SP) on patient health status; they report no significant differences in health 
status between patients in strong GP-SP connections and those in weak GP-SP 
connections.  
Statistically insignificant differences in controlling clinical measures between 
team prescribing and sole-provider prescribing may be due to the variation in how team 
management of medication is coordinated in teams across VHA facilities. Deploying an 
interdisciplinary team by itself does not necessarily lead to an effective team. Several 
factors predict team performance such as coordination, respect and trust among team 
members, and communication (Belanger & Rodriguez, 2008; Al Sayah, Szafran, 
Robertson, Bell, & Williams, 2014; Sargeant, Loney, & Murphy, 2008). While I attempt 
to control for facility variation by clustering the estimates by facility, such statistical 
adjustment may not be sufficient in fully adjusting for the differences in implementation 
and performance of team care. In addition, this study assumes team structure and the 
presence of team medication management solely on the basis of the receipt of 
prescriptions from multiple providers. As a result, the precision with which I identify the 
effect of team medication management is less than ideal. Moreover, the prescriptions 
issued by PAs as indicated in the data may not reflect the PAs’ independent prescribing 
decision but that of their attending physicians. Anecdotal references suggest that while 
NPs are more likely to practice independently, and therefore make independent 
prescribing decisions, PAs’ autonomy in practice is less certain. One way to increase 
precision and accuracy of identification, although out of scope for this dissertation, is to 
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gather more information through interviews and site visits to explicitly determine team 
structure and prescriptive autonomy of NPPs. Findings from this study should be 
interpreted in light of these limitations inherent in administrative data. 
The mean reduction of 0.5% in HbA1c levels under NPP care in this study is 
relatively small compared to the current literature. Several studies that examine glycemic 
control under diabetes nurse specialists (DNS) report HbA1c reductions ranging from 
0.6% to 1.5%. Chan et al. (2006) report a reduction of 0.8% in HbA1c after a 12-week 
follow-up. Another study finds that patients under DNS prescribing achieve a 0.6% 
reduction in HbA1c over an average of 100-day follow-up (Wilkinson, Carryer, & 
Adams, 2014). Houweling et al. (2009) also investigate glycemic control in patients 
under DNS care and find that patients achieve 1.5% reduction in HbA1c after a 1-year 
follow-up. While a direct comparison cannot be made between the current finding and the 
reported findings due to different study settings, the larger reductions in HbA1c level in 
other studies might be associated with a more comprehensive scope of the NPP 
intervention in each of the aforementioned studies. While this study focuses on only the 
medication management aspect of NPP care, other studies have included additional tasks 
such as patient education and follow-up treatment efforts in concert with medication 
management as NPP care.  
This study attempts to obtain causal estimates of the effect of team prescribing on 
diabetes outcomes by using the instrumental variables (IV) approach. I show that the 
instrument used in the analysis, the rate of NPP OAD prescribing, strongly and 
significantly predicts the receipt of team prescribing. Although with limited consistency, 
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the instrument appears to balance the study sample on the observed covariates across its 
quintiles. If the IV estimates are to be believed, one might conclude that team prescribing 
makes little to no difference in improving diabetes outcomes compared to sole-provider 
prescribing—except on creatinine—and prefer whichever prescribing model is more cost-
efficient. However, he should keep in mind that there is no perfect instrument. That is, 
treatment selection bias is likely to be still present in the estimates obtained from IV 
regressions. As evident in the sample characteristics, the team prescribing groups, 
NP/MD and PA/MD, consist of patients with more severe diabetes—the rates of high 
HbA1c (>8.0), receipt of insulin and hospitalization during follow-up are all higher 
compared to sole-provider groups. Such differences between the team and non-team 
patients suggest that severe cases of diabetes may be referred to team care. Credibility of 
the reported estimates is limited by the extent to which the instrument successfully 
removes treatment selection bias. Additional measures of potential confounders and/or an 
alternative instrument to adjust for nonrandom assignment of prescribing model may 
improve the estimates in explaining the causal relationship between prescribing model 
and clinical outcomes.   
The conclusion remains largely unchanged even if the IV estimates are deemed 
unreliable and one defaults to the OLS estimates. The OLS estimates suggest that team 
prescribing performs similarly to sole-provider prescribing (i.e., there are no significant 
differences in reducing clinical measures), but it performs worse in controlling HbA1c 
and glucose levels. In the current study NP-only prescribing emerges as the most 
effective prescribing model in reducing HbA1c and glucose levels—it achieves greater 
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reduction in both measures when compared to team and MD-only prescribing 
independently. On the other hand, PA-only prescribing is associated with only a marginal 
improvement in reducing glucose level relative to team prescribing.    
The exclusion of patients seen at facilities without all three prescribing models in 
either the NP analysis or the PA analysis has likely reduced generalizability of the 
reported results. The unavailability of one or more prescribing models may be correlated 
with any number of factors such as staffing, budget, size, rurality, and quality of care. For 
example, patients living in rural areas with access to smaller facilities that have limited 
resources and are potentially of lower quality may be disproportionately poorer and/or 
sicker relative to those living in urban areas. Therefore, findings from this chapter should 
not be generalized to all Veterans with diabetes.  
Increasing the use of advanced non-physician providers (NPPs) such as nurse 
practitioners and physician assistants has been suggested as an effective and potentially 
cost-saving solution to alleviate the current and future physician shortage. In a team-
based primary care setting NPPs have the potential to not only ease the burden on 
physicians substantially, but also improve patient outcomes by facilitating patient self-
management and promptly making appropriate adjustments to treatment. In this study, 
however, I find that team-based prescribing does not significantly improve selected 
diabetes-related clinical outcomes compared to sole-provider prescribing. Put differently, 
it performs no worse than conventional single-provider prescribing. Implementing team 
prescribing may still be preferred over sole-provider prescribing if other benefits such as 
cost savings can be realized. In the following chapter, I examine how health care costs of 
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the patients under team prescribing compare to that of the patients those under sole-
provider prescribing.  
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Table 3.1. Sample characteristics: Nurse practitioner 
 
MD only NP/MD NP only 
N (%) 29,572 (69) 7,225 (17) 6,040 (14) 
Have both baseline and follow-up (%) 
   
HbA1c 25,393 (86) 6,166 (85) 5,367 (89) 
Glucose 25,013 (85) 6,268 (87) 5,359 (89) 
LDL 23,319 (79) 5,483 (76) 4,930 (82) 
Creatinine 25,807 (87) 6,260 (87) 5,380 (89) 
Age (SD) 61.4 (10.0) 59.8 (10.1) 61.8 (10.2) 
Sex (%) 
   
Male 28,376 (96) 6,841 (95) 5,694 (94) 
Female 1,196 (4) 384 (5) 346 (6) 
Race (%) 
   
White 20,895 (71) 4,933 (68) 4,351 (72) 
Black 5,108 (17) 1,405 (19) 1,042 (17) 
Hispanic 1,148 (4) 275 (4) 177 (3) 
Other 858 (3) 222 (3) 148 (2) 
Unknown 1,563 (5) 390 (5) 322 (5) 
Marital Status (%) 
   
Married 17,675 (60) 3,959 (55) 3,615 (60) 
Unmarried 11,897 (40) 3,266 (45) 2,425 (40) 
Income (SD) 42,982 (73,959) 40,192 (70,777) 45,966 (78,000) 
Insulin Use (%) 4,006 (14) 1,426 (20) 764 (13) 
Inpatient OAD (%) 3,265 (11) 1,344 (19) 483 (8) 
Baseline lab measures (%) 
   
HbA1c 
   
< 6.5% 4,941 (17) 1,065 (15) 1,045 (17) 
6.5% - 8.0% 14,249 (48) 3,158 (44) 3,157 (52) 
> 8.0% 6,203 (21) 1,943 (27) 1,165 (19) 
Glucose 
   
> 140 mg/dL 13,512 (46) 3,589 (50) 2,424 (40) 
LDL 
   
> 100 mg/dL 11,172 (38) 2,815 (39) 2,441 (40) 
Creatinine 
   
> 1.5 mg/dL 1,181 (4) 270 (4) 220 (4) 
Comorbidities (%) 
   
Hypertension 16,225 (55) 3,532 (49) 3,412 (56) 
Hyperlipidemia 14,396 (49) 2,973 (41) 3,063 (51) 
Heart disease 4,160 (14) 883 (12) 816 (14) 
Sexual impotence 1,829 (6) 405 (6) 379 (6) 
Peripheral neuropathies 1,307 (4) 294 (4) 249 (4) 
Congestive heart failure 681 (2) 195 (3) 135 (2) 
Peripheral vascular disease 724 (2) 151 (2) 135 (2) 
Cerebrovascular disease 688 (2) 146 (2) 151 (3) 
Chronic renal disease 692 (2) 138 (2) 113 (2) 
Cellulitis and abscess 415 (1) 129 (2) 84 (1) 
Myocardial infarction 296 (1) 81 (1) 80 (1) 
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Other selected infections 222 (1) 79 (1) 47 (1) 
Diabetic eye disease 172 (1) 36 (0) 28 (0) 
Gangrene & lower limb ulcer 123 (0) 35 (0) 18 (0) 
Hypoglycemia, new definition 23 (0) 6 (0) 2 (0) 
Cardiac surgery 20 (0) 9 (0) 1 (0) 
Hypoglycemia 22 (0) 2 (0) 2 (0) 
Other metabolic complications 3 (0) 2 (0) 0 (0) 	  
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Table 3.2. Sample characteristics: Physician assistant 
 
MD only PA/MD PA only 
N (%) 20,153 (81) 2,779 (11) 2,092 (8) 
Have both baseline and follow-up (%) 
   
HbA1c 17,250 (86) 2,349 (85) 1,852 (89) 
Glucose 16,270 (81) 2,307 (83) 1,755 (84) 
LDL 15,786 (78) 2,121 (76) 1,663 (79) 
Creatinine 17,353 (86) 2,343 (84) 1,815 (87) 
Age (SD) 61.2 (9.9) 60.2 (10.2) 62.3 (10.0) 
Sex (%) 
   
Male 19,284 (96) 2,677 (96) 2,036 (97) 
Female 869 (4) 102 (4) 56 (3) 
Race (%) 
   
White 14,029 (70) 1,937 (70) 1,541 (74) 
Black 3,707 (18) 505 (18) 327 (16) 
Hispanic 774 (4) 98 (4) 53 (3) 
Other 581 (3) 81 (3) 41 (2) 
Unknown 1,062 (5) 158 (6) 130 (6) 
Marital Status (%) 
   
Married 11,922 (59) 1,567 (56) 1,287 (62) 
Unmarried 8,231 (41) 1,212 (44) 805 (38) 
Income (SD) 42,547 (72,786) 40,736 (64,180) 43,862 (76,165) 
Insulin Use (%) 2,756 (14) 518 (19) 250 (12) 
Inpatient OAD (%) 2,228 (11) 528 (19) 177 (8) 
Baseline lab measures (%) 
   
HbA1c 
   
< 6.5% 3,422 (17) 465 (17) 359 (17) 
6.5% - 8.0% 9,658 (48) 1,203 (43) 1,048 (50) 
> 8.0% 4,170 (21) 681 (25) 445 (21) 
Glucose 
   
> 140 mg/dL 9,098 (45) 1,304 (47) 937 (45) 
LDL 
   
> 100 mg/dL 7,677 (38) 1,064 (38) 771 (37) 
Creatinine 
   
> 1.5 mg/dL 795 (4) 118 (4) 82 (4) 
Comorbidities (%) 
   
Hypertension 11,006 (55) 1,307 (47) 1,141 (55) 
Hyperlipidemia 9,834 (49) 1,115 (40) 1,019 (49) 
Heart disease 2,873 (14) 325 (12) 312 (15) 
Sexual impotence 1,272 (6) 156 (6) 112 (5) 
Peripheral neuropathies 915 (5) 102 (4) 93 (4) 
Congestive heart failure 479 (2) 63 (2) 39 (2) 
Peripheral vascular disease 511 (3) 62 (2) 73 (3) 
Cerebrovascular disease 471 (2) 54 (2) 48 (2) 
Chronic renal disease 490 (2) 46 (2) 39 (2) 
Cellulitis and abscess 282 (1) 48 (2) 17 (1) 
Myocardial infarction 214 (1) 19 (1) 27 (1) 
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Other selected infections 151 (1) 23 (1) 15 (1) 
Diabetic eye disease 133 (1) 15 (1) 11 (1) 
Gangrene & lower limb ulcer 79 (0) 7 (0) 6 (0) 
Hypoglycemia, new definition 14 (0) 4 (0) 4 (0) 
Cardiac surgery 8 (0) 0 (0) 1 (0) 
Hypoglycemia 16 (0) 0 (0) 2 (0) 
Other metabolic complications 1 (0) 0 (0) 0 (0) 	  
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Table 3.3. Distribution of diabetes-related lab measures: Nurse practitioner 
 
MD only NP/MD NP only 
N 29,572 7,225 6,040 
HbA1c 
   
n (%) 25,393 (86) 6,166 (85) 5,367 (89) 
 Mean total number of tests (SD) 5.2 (1.7) 5.6 (1.8) 5.4 (1.7) 
Baseline mean (SD) 7.6 (1.7) 7.9 (1.9) 7.5 (1.5) 
Follow-up mean (SD) 7.1 (1.4) 7.3 (1.5) 7.0 (1.3) 
Change mean (SD) -0.5 (1.8) -0.7 (2.1) -0.5 (1.6) 
Glucose 
   
n (%) 25,807 (87) 6,260 (87) 5,380 (89) 
 Mean total number of tests (SD) 6.4 (4.0) 7.1 (4.3) 6.3 (3.4) 
Baseline mean (SD) 165.6 (71.0) 179.7 (83.9) 154.7 (61.7) 
Follow-up mean (SD) 142.7 (53.7) 148.2 (61.0) 136.9 (48.2) 
Change mean (SD) -22.9 (76.6) -31.5 (91.3) -17.7 (67.4) 
LDL 
   
n (%) 23,319 (79) 5,483 (76) 4,930 (82) 
 Mean total number of tests (SD) 4.9 (1.6) 5.1 (1.9) 5.0 (1.7) 
Baseline mean (SD) 102.8 (35.7) 105.1 (35.7) 104.3 (35.2) 
Follow-up mean (SD) 90.0 (32.2) 91.2 (32.9) 91.3 (32.1) 
Change mean (SD) -12.8 (36.4) -13.9 (36.4) -13.1 (35.4) 
Creatinine 
   
n (%) 25,013 (85) 6,268 (87) 5,359 (89) 
 Mean total number of tests (SD) 6.5 (3.8) 7.2 (4.4) 6.5 (3.6) 
Baseline mean (SD) 1.0 (0.3) 1.0 (0.3) 1.0 (0.3) 
Follow-up mean (SD) 1.1 (0.3) 1.0 (0.3) 1.1 (0.3) 
Change mean (SD) 0.0 (0.3) 0.0 (0.3) 0.0 (0.2) 
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Table 3.4. Distribution of diabetes-related lab measures: Physician assistant 
 
MD only PA/MD PA only 
N 20,153 2,779 2,092 
HbA1c 
   
n (%) 17,250 (86) 2,349 (85) 1,852 (89) 
 Mean total number of tests (SD) 5.2 (1.7) 5.6 (1.8) 5.3 (1.7) 
Baseline mean (SD) 7.6 (1.7) 7.8 (1.9) 7.6 (1.6) 
Follow-up mean (SD) 7.1 (1.4) 7.2 (1.5) 7.1 (1.3) 
Change mean (SD) -0.5 (1.8) -0.6 (2.0) -0.5 (1.7) 
Glucose 
   
n (%) 17,353 (86) 2,343 (84) 1,815 (87) 
 Mean total number of tests (SD) 6.4 (4.1) 7.0 (4.2) 6.2 (3.2) 
Baseline mean (SD) 165.9 (71.3) 174.0 (78.8) 162.5 (67.4) 
Follow-up mean (SD) 142.0 (54.0) 147.3 (59.4) 139.8 (50.3) 
Change mean (SD) -23.9 (77.1) -26.7 (85.1) -22.7 (72.0) 
LDL 
   
n (%) 15,786 (78) 2,121 (76) 1,663 (79) 
 Mean total number of tests (SD) 4.9 (1.7) 5.2 (1.8) 4.9 (1.7) 
Baseline mean (SD) 103.3 (35.9) 104.4 (37.0) 101.4 (34.5) 
Follow-up mean (SD) 90.3 (32.4) 90.4 (33.1) 89.8 (30.5) 
Change mean (SD) -13.0 (36.5) -14.0 (37.3) -11.6 (35.0) 
Creatinine 
   
n (%) 16,270 (81) 2,307 (83) 1,755 (84) 
 Mean total number of tests (SD) 6.5 (3.8) 7.1 (4.3) 6.3 (3.2) 
Baseline mean (SD) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 
Follow-up mean (SD) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 
Change mean (SD) 0.0 (0.3) 0.0 (0.3) 0.0 (0.3) 
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Table 3.5. OLS regression results of mean change in lab measures 
 
(1) (2) (3) (4) 
Comparison ΔHbA1c ΔGLU ΔLDL ΔCRE 
NP/MD v. MD† 0.028 0.973 0.063 -0.001 
(s.e.) (0.022) (0.843) (0.500) (0.003) 
NP/MD v. NP† 0.088*** 4.521*** -0.550 0.003 
(s.e.) (0.027) (1.027) (0.603) (-0.248) 
NP v. MD† -0.055*** -3.400*** 0.538 -0.006 
(s.e.) (0.020) (0.787) (0.564) (0.004) 
PA/MD v. MD† -0.016 1.744 0.041 -0.001 
(s.e.) (0.032) (1.188) (0.765) (0.006) 
PA/MD v. PA† 0.023 2.857* -0.771 0.004 
(s.e.) (0.042) (1.509) (1.144) (0.008) 
PA v. MD† -0.041 -1.224 0.637 -0.006 
(s.e.) (0.030) (1.406) (0.709) (0.007) 
          † Reference group 
          (1) - (4) adjusted for baseline covariates and lab measures 
          * p < 0.1, ** p <0.05, *** p <0.01 	  
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Table 3.6. 2SLS regression results of mean change in lab measures 
 
(1) (2) (3) (4) 
Comparison ΔHbA1c ΔGLU ΔLDL ΔCRE 
NP/MD v. MD† 0.025 -6.896* 3.824 -0.122*** 
(s.e.) (0.135) (3.944) (2.852) (0.033) 
NP/MD v. NP† 0.022 7.994 -4.208 0.118*** 
(s.e.) (0.137) (6.043) (4.477) (0.033) 
NP v. MD† 0.013 -6.058** 2.500 -0.061*** 
(s.e.) (0.076) (3.096) (1.561) (0.024) 
PA/MD v. MD† 0.182 10.736 7.452 -0.068 
(s.e.) (0.237) (8.858) (6.132)  (0.066) 
PA/MD v. PA† -0.192 -10.576 -2.160 0.038 
(s.e.) (0.266) (12.149) (5.658) (0.065) 
PA v. MD† 0.054 3.604 2.046 -0.030 
(s.e.) (0.151) (6.199) (3.735) (0.039) 
 † Reference group 
 (1) - (4) adjusted for baseline covariates and lab measures 
 * p < 0.1, ** p <0.05, *** p <0.01 	  
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Table 3.7. First-stage results from IV regressions: Nurse practitioner 
Comparison Outcome IV Model N IV p-value c F 
NP/MD v. MD† HbA1c % NP OAD logit 31,599 0.000 0.68 -   
Pr(MDNP) OLS 31,599 0.000 - 29.20  
GLU % NP OAD logit 32,067 0.000 0.69 -   
Pr(MDNP) OLS 32,067 0.000 - 26.99  
LDL % NP OAD logit 28,802 0.000 0.68 -   
Pr(MDNP) OLS 28,802 0.000 - 23.15  
CRE % NP OAD logit 31,281 0.000 0.68 -   
Pr(MDNP) OLS 31,281 0.000 - 23.98 
NP/MD v. NP† HbA1c % NP OAD logit 11,533 0.000 0.67 -   
Pr(MDNP) OLS 11,533 0.000 - 30.97  
GLU % NP OAD logit 11,640 0.000 0.68 -   
Pr(MDNP) OLS 11,640 0.000 - 40.08  
LDL % NP OAD logit 10,413 0.000 0.65 -   
Pr(MDNP) OLS 10,413 0.000 - 21.98  
CRE % NP OAD logit 11,627 0.000 0.66 -   
Pr(MDNP) OLS 11,627 0.000 - 32.08 
NP v. MD† HbA1c % NP OAD logit 30,760 0.000 0.76 -   
Pr(NP) OLS 30,760 0.000 - 50.24  
GLU % NP OAD logit 31,187 0.000 0.77 -   
Pr(NP) OLS 31,187 0.000 - 45.11  
LDL % NP OAD logit 28,249 0.000 0.77 -   
Pr(NP) OLS 28,249 0.000 - 45.72  
CRE % NP OAD logit 30,372 0.000 0.76 -   
Pr(NP) OLS 30,372 0.000 - 40.52 
    † Reference group 	  
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Table 3.8. First-stage results from IV regressions: Physician assistant 
Comparison Outcome IV Model N IV p-value c F 
PA/MD v. MD† HbA1c % PA OAD logit 19,599 0.000 0.68 -   
Pr(MDPA) OLS 19,599 0.000 - 10.01  
GLU % PA OAD logit 19,696 0.000 0.68 -   
Pr(MDPA) OLS 19,696 0.000 - 8.24  
LDL % PA OAD logit 17,907 0.000 0.68 -   
Pr(MDPA) OLS 17,907 0.000 - 8.23  
CRE % PA OAD logit 18,577 0.000 0.67 -   
Pr(MDPA) OLS 18,577 0.000 - 7.37 
PA/MD v. PA† HbA1c % PA OAD logit 4,201 0.000 0.66 -   
Pr(MDPA) OLS 4,201 0.000 - 9.22  
GLU % PA OAD logit 4,158 0.000 0.67 -   
Pr(MDPA) OLS 4,158 0.000 - 12.26  
LDL % PA OAD logit 3,784 0.000 0.65 -   
Pr(MDPA) OLS 3,784 0.000 - 8.11  
CRE % PA OAD logit 4,062 0.000 0.66 -   
Pr(MDPA) OLS 4,062 0.000 - 13.13 
PA v. MD† HbA1c % PA OAD logit 19,102 0.000 0.74 -   
Pr(PA) OLS 19,102 0.000 - 9.25  
GLU % PA OAD logit 19,168 0.000 0.75 -   
Pr(PA) OLS 19,168 0.000 - 11.26  
LDL % PA OAD logit 17,449 0.000 0.74 -   
Pr(PA) OLS 17,449 0.000 - 9.83  
CRE % PA OAD logit 18,025 0.000 0.74 -   
Pr(PA) OLS 18,025 0.000 - 9.41 
    † Reference group 
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Table 3.9. Outcomes and baseline characteristics by quintiles of % NP OAD 
 Q1 Q2 Q3 Q4 Q5  
 (0.005-0.069) (0.072-0.137) (0.137-0.201) (0.202-0.282) (0.283-0.804) p-value 
N (%) 10,746 (19) 11,420 (21) 10,873 (20) 11,219 (20) 11,306 (20)  
Have both baseline and follow-up (%)       
HbA1c 6,867 (64) 7,471 (65) 7,319 (67) 7,556 (67) 7,713 (68) <.0001 
Glucose 6,775 (63) 7,874 (69) 7,765 (71) 7,049 (63) 7,984 (71) 0.0007 
LDL 6,431 (60) 7,031 (62) 6,699 (62) 6,665 (59) 6,906 (61) <.0001 
Creatinine 6,169 (57) 7,780 (68) 7,183 (66) 7,654 (68) 7,854 (69) <.0001 
Mean Change in measures       
HbA1c -0.50 (1.88) -0.53 (1.86) -0.55 (1.78) -0.51 (1.81) -0.51 (1.74) 0.1367 
Glucose -22.22 (80.44) -25.75 (78.19) -23.69 (76.86) -22.98 (78.34) -23.18 (77.11) 0.0242 
LDL -13.85 (37.48) -12.36 (34.95) -12.93 (36.35) -12.23 (36.35) -13.79 (36.08) 0.0497 
Creatinine 0.03 (0.24) 0.01 (0.34) 0.02 (0.25) 0.00 (0.22) 0.00 (0.23) <.0001 
Age (SD) 61.0 (10.3) 61.2 (10.4) 61.7 (10.6) 61.4 (10.6) 61.6 (10.4) <.0001 
Sex (%)       
Male 10,225 (95) 10,901 (95) 10,395 (96) 10,745 (96) 10,813 (96) 0.2161 
Female 521 (5) 519 (5) 478 (4) 474 (4) 493 (4)  
Race (%)       
White 6,945 (65) 8,063 (71) 7,925 (73) 7,876 (70) 8,108 (72) <.0001 
Black 2,057 (19) 2,023 (18) 1,890 (17) 1,928 (17) 1,897 (17)  
Hispanic 771 (7) 235 (2) 260 (2) 448 (4) 384 (3)  
Other 304 (3) 429 (4) 319 (3) 342 (3) 261 (2)  
Unknown 669 (6) 670 (6) 479 (4) 625 (6) 656 (6)  
Marital Status (%)       
Married 6,520 (61) 6,954 (61) 6,427 (59) 6,535 (58) 6,629 (59) <.0001 
Unmarried 4,226 (39) 4,466 (39) 4,446 (41) 4,684 (42) 4,677 (41)  
Income (SD) 41,118 (65,620) 44,336 (76,507) 46,485 (82,538) 45,246 (78,056) 44,868 (77,414) 0.3604 
Insulin Use (%) 1,469 (14) 1,490 (13) 1,649 (15) 1,560 (14) 1,656 (15) <.0001 
Inpatient OAD (%) 1,136 (11) 1,124 (10) 1,306 (12) 1,230 (11) 1,160 (10) <.0001 
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Comorbidities (%)       
Hypertension 5,154 (48) 5,695 (50) 5,441 (50) 5,591 (50) 5,633 (50) 0.0111 
Hyperlipidemia 4,427 (41) 5,046 (44) 4,753 (44) 4,874 (43) 4,797 (42) <.0001 
Heart disease 1,276 (12) 1,506 (13) 1,357 (12) 1,356 (12) 1,439 (13) 0.0258 
Sexual impotence 575 (5) 587 (5) 604 (6) 601 (5) 625 (6) 0.6523 
Peripheral neuropathies 389 (4) 427 (4) 401 (4) 422 (4) 448 (4) 0.7297 
Cerebrovascular disease 238 (2) 220 (2) 219 (2) 241 (2) 251 (2) 0.4540 
Peripheral vascular disease 183 (2) 223 (2) 239 (2) 251 (2) 263 (2) 0.0078 
Congestive heart failure 214 (2) 238 (2) 225 (2) 237 (2) 237 (2) 0.9758 
Chronic renal disease 184 (2) 233 (2) 213 (2) 243 (2) 216 (2) 0.1688 
Cellulitis and abscess 123 (1) 143 (1) 143 (1) 137 (1) 164 (1) 0.3250 
Myocardial infarction 73 (1) 102 (1) 107 (1) 115 (1) 131 (1) 0.0052 
Other selected infections 82 (1) 79 (1) 72 (1) 73 (1) 76 (1) 0.8672 
Diabetic eye disease 66 (1) 55 (0) 49 (0) 69 (1) 48 (0) 0.1275 
Gangrene & lower limb ulcer 29 (0) 38 (0) 38 (0) 40 (0) 55 (0) 0.1012 
Hypoglycemia, new definition 6 (0) 16 (0) 6 (0) 5 (0) 8 (0) 0.0585 
Cardiac surgery 8 (0) 4 (0) 6 (0) 7 (0) 6 (0) 0.7985 
Hypoglycemia 5 (0) 3 (0) 9 (0) 7 (0) 4 (0) 0.3495 
Other metabolic complications 0 (0) 1 (0) 2 (0) 2 (0) 2 (0) 0.6892 
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Table 3.10. Outcomes and baseline characteristics by quintiles of % PA OAD 
 Q1 Q2 Q3 Q4 Q5  
 (0.003-0.040) (0.044-0.071) (0.071-0.113) (0.113-0.154) (0.154-0.506) p-value 
N (%) 6,447 (20) 6,578 (20) 6,528 (20) 6,622 (20) 6,456 (20)  
Have both baseline and follow-up (%)       
HbA1c 4,059 (63) 4,303 (65) 4,389 (67) 4,454 (67) 4,246 (66) <.0001 
Glucose 4,062 (63) 4,555 (69) 4,350 (67) 4,600 (69) 3,944 (61) <.0001 
LDL 3,547 (55) 3,815 (58) 4,210 (64) 4,088 (62) 3,910 (61) <.0001 
Creatinine 3,698 (57) 4,037 (61) 4,577 (70) 4,351 (66) 3,669 (57) <.0001 
Mean Change in measures       
HbA1c -0.51 (1.80) -0.50 (1.90) -0.47 (1.81) -0.54 (1.80) -0.50 (1.79) 0.3577 
Glucose -25.59 (78.58) -25.15 (80.67) -22.25 (76.99) -24.37 (75.59) -23.00 (75.93) 0.4894 
LDL -15.13 (36.42) -13.05 (36.27) -11.18 (35.99) -12.68 (37.19) -13.28 (36.40) <.0001 
Creatinine 0.02 (0.24) -0.01 (0.42) 0.02 (0.27) 0.01 (0.23) 0.00 (0.22) <.0001 
Age (SD) 60.8 (10.3) 61.3 (10.2) 61.3 (10.6) 61.1 (10.2) 62.1 (10.7) <.0001 
Sex (%)       
Male 6,150 (95) 6,317 (96) 6,268 (96) 6,372 (96) 6,204 (96) 0.1368 
Female 297 (5) 261 (4) 260 (4) 250 (4) 252 (4)  
Race (%)       
White 3,971 (62) 4,389 (67) 4,551 (70) 4,978 (75) 4,846 (75) <.0001 
Black 1,442 (22) 1,294 (20) 1,132 (17) 1,016 (15) 973 (15)  
Hispanic 299 (5) 258 (4) 276 (4) 214 (3) 179 (3)  
Other 289 (4) 222 (3) 195 (3) 141 (2) 118 (2)  
Unknown 446 (7) 415 (6) 374 (6) 273 (4) 340 (5)  
Marital Status (%)       
Married 3,816 (59) 3,769 (57) 3,802 (58) 3,999 (60) 4,019 (62) <.0001 
Unmarried 2,631 (41) 2,809 (43) 2,726 (42) 2,623 (40) 2,437 (38)  
Income (SD) 42,149 (70,130) 47,253 (80,626) 43,219 (72,094) 44,388 (75,217) 44,084 (76,481) 0.0950 
Insulin Use (%) 846 (13) 906 (14) 860 (13) 937 (14) 917 (14) 0.2071 
Inpatient OAD (%) 715 (11) 656 (10) 670 (10) 672 (10) 748 (12) 0.0104 
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Comorbidities (%)       
Hypertension 3,068 (48) 3,115 (47) 3,314 (51) 3,292 (50) 3,240 (50) <.0001 
Hyperlipidemia 2,579 (40) 2,730 (42) 2,895 (44) 2,943 (44) 2,919 (45) <.0001 
Heart disease 818 (13) 733 (11) 887 (14) 812 (12) 904 (14) <.0001 
Sexual impotence 355 (6) 345 (5) 414 (6) 320 (5) 334 (5) 0.0024 
Peripheral neuropathies 203 (3) 274 (4) 247 (4) 242 (4) 285 (4) 0.0022 
Cerebrovascular disease 156 (2) 129 (2) 135 (2) 126 (2) 122 (2) 0.1842 
Peripheral vascular disease 152 (2) 130 (2) 156 (2) 118 (2) 153 (2) 0.0474 
Congestive heart failure 135 (2) 128 (2) 125 (2) 134 (2) 140 (2) 0.8395 
Chronic renal disease 132 (2) 137 (2) 163 (2) 119 (2) 112 (2) 0.0182 
Cellulitis and abscess 89 (1) 75 (1) 71 (1) 73 (1) 88 (1) 0.3373 
Myocardial infarction 53 (1) 62 (1) 57 (1) 57 (1) 67 (1) 0.7213 
Other selected infections 40 (1) 40 (1) 40 (1) 36 (1) 49 (1) 0.6266 
Diabetic eye disease 41 (1) 43 (1) 39 (1) 31 (0) 39 (1) 0.6654 
Gangrene & lower limb ulcer 19 (0) 23 (0) 21 (0) 22 (0) 22 (0) 0.9859 
Hypoglycemia, new definition 5 (0) 9 (0) 6 (0) 5 (0) 5 (0) 0.7486 
Cardiac surgery 4 (0) 2 (0) 2 (0) 0 (0) 1 (0) 0.2886 
Hypoglycemia 4 (0) 3 (0) 4 (0) 3 (0) 5 (0) 0.9376 
Other metabolic complications 0 (0) 0 (0) 1 (0) 1 (0) 0 (0) 0.5640 
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Figure 3. Treatment assignment by % NP OAD quintiles 
 
 
Figure 4. Treatment assignment by % PA OAD quintiles 
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CHAPTER FOUR: EFFECT OF TEAM-BASED MEDICATION MANAGEMENT 
ON AGGREGATE HEALTH CARE COSTS 
 
Introduction 
Medication management is an essential aspect of chronic care. Patients with 
chronic conditions are more likely to have multiple comorbid conditions and take 
multiple medications (Doos, Roberts, Corp, & Kadam, 2014; Ostwald, Wasserman, & 
Davis, 2006). Medication management in such patients can be beneficial because it can 
help prevent medication errors and make prompt adjustments to medication therapy. 
Providers optimize medication treatment by closely monitoring the patient’s reaction to 
the prescribed drug and adjusting the treatment accordingly—initiating a new drug to 
augment existing prescription, switching to another drug, or terminating current drugs as 
the providers deem necessary. Management of medications also entails educating and 
communicating with the patient regarding the potential benefits and harms of the 
prescribed medications and how to manage them. Delivery of information on chronic 
drug therapy has been shown to affect medication adherence and self-confidence 
(Schneider, Wensing, Quinzler, Bieber, & Szecsenyi, 2007; Pileggi, Caligiuri, Nobile, & 
Pavia, 2018). Comprehensive medication management, when implemented properly, 
embodies the “proactive practice team” and the “informed active patient” that Wagner 
(1999) conceptualizes as the key components of chronic care.  
 For non-physician providers (NPPs), including nurse practitioners (NPs), 
physician assistants (PAs), and pharmacists, having the sufficient level of prescribing 
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authority that allows them to make the necessary adjustments to medication treatment is 
crucial in providing effective management of medications. It not only enables them to 
make changes promptly without having to wait for physician approval, but also increases 
their professional autonomy and allows them to practice to the fullest extent of their 
training. Previous studies have compared clinical outcomes in patients receiving NPP 
prescribing to those receiving physician (MD) prescribing and found mixed results. 
Pharmacist-led MM in patients with diabetes and hypertension has been shown to achieve 
significant reductions in HbA1c level and blood pressure (Yoder, Dixon, Barnette, & 
Beardsley, 2012; Theising, Fritschle, Scholfield, Hicks, & Schymik, 2015). Omran et al. 
(2015) report a significant improvement in blood pressure and attribute it to pharmacists’ 
medication management activities in adding or switching medications as well as making 
dosage adjustments. Several studies examine NP-led management of diabetes, which 
includes prescribing of medications, and find no significant improvement in glycemic 
control, quality of life, or length of stay (Houweling, et al., 2009; Laurant, et al., 2009; 
Carey, Courtenay, James, Hills, & Roland, 2008; Yang, et al., 2018). 
 The effect of NPP prescribing on resource use and cost is equally mixed. While 
some previous findings report lower total cost and total direct drug costs associated with 
NPP-led medication management, other findings suggest that such cost savings may be 
off-set by increased use of tests and imaging services (Chen, McNeese-Smith, Cowan, 
Upenieks, & Afifi, 2009; Johannigman, et al., 2010; Cowan, et al., 2006; Venning, Durie, 
Roland, Roberts, & Leese, 2000; Hemani, Rastegar, Hill, & Al-Ibrahim, 1999). In a 
recent VHA study of cardiovascular disease and diabetes patients, Virani et al. (2018) 
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find that patients seen by advanced practice providers receive significantly fewer primary 
care and specialty care visits compared to physician-managed patients. However, the 
reported differences of 0.1 visits or less suggest that the utilization of services under both 
provider types is practically the same. A systematic review of the literature on the impact 
of NPPs on health services use concludes that the evidence on resource utilization and 
cost is uncertain (Laurant, et al., 2009).  
 With a team-based approach in health care becoming increasingly common, 
medication management by an interdisciplinary team of providers is a natural extension 
of team-based care that could potentially improve patient outcomes and/or save health 
care costs. However, evidence on the effect of medication management modality on care 
costs is limited. This study aims to expand the evidence base by examining the health 
care costs incurred by diabetic patients whose oral antidiabetic drugs are managed by a 
NPP/MD team of prescribers. First, I model the total outpatient cost in a two-year follow-
up and compare the mean outpatient cost of patients under team prescribing to that of 
patients under sole-provider prescribing. As any cost saving resulting from better patient 
health under team-based medication management may be offset by increased resource 
use, I hypothesize that the mean total outpatient cost in patients managed under team 
prescribing is not significantly less than that of patients managed under sole-provider 
prescribing. Second, I estimate the likelihood of incurring any inpatient cost during the 
follow-up in patients under team prescribing relative to patients managed under sole-
provider prescribing. As the previous findings report mixed results on patient outcomes, I 
hypothesize that the team prescribing patients are no more likely to be admitted relative 
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to the sole-provider patients. This study leverages on the large observational data of the 
Veterans Health Administration to analyze NP/MD and PA/MD team prescribing 
separately. In addition, it uses the instrumental variable (IV) method to address treatment 
selection bias and unmeasured confounding that may be present in an observational 
study. 
 
Methods 
Data 
This study draws from multiple data sources of the Veterans Health 
Administration (VHA). Outpatient and inpatient costs from the Managerial Cost 
Accounting Office (MCA) are supplemented with demographic, socioeconomic, and 
clinical data from the MedSAS Inpatient and Outpatient datasets. In addition, the 
pharmacy extract of the MCA is used to determine the prescribing model, described in 
Independent variables, under which each patient’s oral antidiabetic drugs (OAD) are 
managed. Lastly, the Nosos scores constructed by the VA’s Health Economics Resource 
Center are used for comorbidity risk adjustment. 
Study sample 
The study sample from Chapter 3 serves as the base sample. It consists of 
veterans who: 1) had diabetes in fiscal year (FY) 2010, 2) initiated OAD in FY10, 3) had 
at least one subsequent outpatient OAD prescription, 4) did not die during a 2-year 
follow-up, and 5) received OAD prescriptions exclusively from any combination of MDs, 
		
85 
NPs, and PAs. For the current study, I exclude those who had zero total outpatient cost 
over the 2-year follow-up. Those with extreme outpatient costs are also excluded. 
Compared to the final study sample, the excluded appear to include a higher proportion 
of minorities who earn less income and use more VHA services (Table C1). 
Dependent variables 
I use variable direct outpatient cost as the dependent variable in the primary 
analysis. There are three types of cost variables in MCA’s cost extracts: Fixed direct, 
fixed indirect, and variable direct. Direct and indirect fixed costs such as administrative 
costs and the overhead do not vary by the volume or level of patient care. Variable direct 
cost, on the other hand, includes all costs related to patient care activity and varies 
depending on the intensity and amount of time and resources used. To capture the 
variation in patient care cost across different prescribing models I aggregate variable 
direct outpatient costs over a 2-year follow-up for each patient. Aggregate costs, in 
contrast to costs attributable to diabetes care, serve as a proxy for the effectiveness of the 
overall patient management over the follow-up period given the adequate risk 
adjustments at baseline. However, it is limited by the extent to which the resource use 
and service utilization are controlled in regression models. While I adjust for patients’ 
service utilization in regression analysis, I do not observe any differences in resource use 
at the provider level. To that end, differences in aggregate costs may be due to not only 
the differences in patients’ health, but also the differences in the providers’ resource use. 
The total outpatient cost is trimmed at the 1st and the 99th percentiles to limit any 
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influence of the extreme patients at both ends, resulting in a loss of approximately 2% of 
the sample (Table C2).  
The dependent variable in the secondary analysis is a binary indicator for having 
any inpatient cost over a two-year follow-up period. The total inpatient cost for each 
patient is obtained by aggregating the variable direct inpatient costs over the course of the 
follow-up. In effect, the indicator for any inpatient cost reflects any hospitalization. 
Because 80% or more of the patients in both NP and PA samples have zero total inpatient 
cost (i.e., no hospitalization during the follow-up), the generalized linear models run in 
this chapter either fail to converge or result in unstable estimates. An alternative strategy 
would be to implement a two-part model a la Belotti et al. (2015), but I elect not to 
implement it due to the uncertainty in its performance in the context of IV estimation. Yet 
another alternative approach would be to limit the estimation to the positive inpatient 
costs; this approach would result in a loss of 80% or more of the study sample. Instead, I 
construct a binary indicator for hospitalization based on the observed inpatient costs; 
occurrence of any hospitalization may reflect the effectiveness of patient management in 
team prescribing relative to sole-provider prescribing.  
Independent variables 
The key predictor of interest is prescribing model. I assign patients into one of 
three prescribing models based on the prescribers of their OAD prescriptions: NPP 
(NP/PA)-only, NPP/MD team, and MD-only. This results in three prescribing models in 
the NP analysis (NP-only, NP/MD team, and MD-only) and three prescribing models in 
the PA analysis (PA-only, PA/MD team, and MD-only).  
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 Baseline patient characteristics include age, gender, income, marital status, and 
enrollment priority groups. Similar to health insurance, priority groups in the VA 
describes a Veteran’s eligibility for different levels of coverage in receiving care. Several 
factors are considered in determining for which priority group a veteran qualifies. The 
major factors include the service-connected disability status, disability rating ranging 
from 0-100%, and income (Appendix D). 
 In addition, I include the total number of outpatient visits, the total number of 
inpatient admissions, and an indicator of any insulin use over the course of a 2-year 
follow-up to control for any differences in utilization and severity of diabetes between 
patients under different prescribing models. 
 I use the Nosos scores to control for the level of comorbidity among patients. The 
Nosos score is a recalibrated CMS Hierarchical Condition Categories version 21/22 
(CMS-HCC V21/V22) for the VA patient population. It is calculated by using 
demographics, pharmacy categories, mental health diagnoses, and annual costs in 
addition to CMS-HCC V21/V22 scores as controls in a regression model. It has been 
shown to perform comparably to the proprietary risk score DxCH by Verisk (Wagner, et 
al., 2016). 
Statistical analysis 
I examine two different outcomes in NP and PA samples separately. I perform 
multivariable regression analysis in three independent comparisons to test whether one 
prescribing model is significantly different from the reference prescribing model. For 
example, in the NP analysis I compare NP/MD team prescribing to MD-only prescribing, 
		
88 
NP/MD team prescribing to NP-only prescribing, and NP-only prescribing to MD-only 
prescribing. Such binary comparisons are performed as opposed to a single multinomial 
comparison for the ease of implementation and interpretation.  
In the primary analysis I model the total outpatient cost using three different 
regression models—an ordinary least squares (OLS) regression on the raw cost, an OLS 
on the log-transformed cost, and a generalized linear model (GLM) on the raw cost. I 
assess model performance by comparing the mean predictive ratio (MPR), mean absolute 
prediction error (MAPE), and root mean square error (RMSE). I perform logistic 
regression in the secondary analysis to estimate the probability of incurring any inpatient 
cost. All analyses implement the IV method to adjust for the endogeneity of prescribing 
model. I use SAS 9.4 (Cary, NC) to prepare the analytical data and Stata 15 (College 
Station, TX) to perform all regression analyses. I use the significance level of 5% to 
conduct all hypothesis testing.  
Health care costs are unique from other commonly studied health outcomes in that 
they tend to be heavily skewed and over-dispersed in distribution. Not all patients use 
health care services on a regular basis, and therefore, incur cost. Consequently, the 
majority of patients incur zero cost. Even in a sample of patients with known health 
conditions in which patients are expected to receive at least some amount of health care, 
costs are typically skewed by the few severely ill patients who require chronic care. As 
such, modeling cost requires a careful examination of the distribution of the cost and the 
potential confounders such as the level of comorbidities and other patient characteristics. 
No two cost distributions are the same. Therefore, choosing the most appropriate model 
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depends on the distributional attributes of the given cost data. Mihaylova et al. (2011) 
identify and provide a comprehensive review of 12 categories of analytical approaches in 
the literature. The three most common strategies in modeling health care cost include 
OLS regression, OLS regression on transformed cost using some transformation function, 
and a family of generalized linear models. 
Further, I assume the prescribing model each patient receives to be non-random or 
endogenous in this study. Several factors could potentially affect which prescribing 
model a patient receives. First, the unavailability of some treatment options may limit the 
patient to receive only a certain treatment. Treatment selection bias occurs when there 
exists some factor that systematically predicts the receipt of treatment and the outcome in 
this case, cost. Such a non-random assignment of treatment, if not controlled, may bias 
the regression estimates of the treatment effect.  For example, patients who seek care at a 
clinic that does not offer a team-based prescribing due to the lack of staffing or resources 
may only receive a sole-provider prescribing. Second, the decision to manage a patient’s 
medications as a team or assigning the medication management to a sole provider may 
reflect the facility’s level of care quality. It is plausible that, given the availability of 
different options, some decision process takes place at each facility to determine the 
model of medication management. For some facilities, limited staffing or resources may 
be the determining factor, while for other facilities some guideline or policy reflecting 
their quality of care might determine which model of medication management a patient 
receives. Staffing, resource use, and quality are potential sources of unmeasured 
confounding that, if not taken into account, may result in biased estimates of treatment. 
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To address such concerns I take a two-pronged approach in this study. First, I 
limit the analysis sample to include patients who received care at the facilities that 
provided all three prescribing models in FY10. This ensures that all the outcomes I 
observe are of the patients who could have been exposed to all treatment options. Second, 
using the rate of OAD prescribing by NPPs at the clinic level as the instrument, I 
implement the IV method in all regression models to adjust for any non-random 
assignment of prescribing model. See Chapter 3 for a detailed description of the 
instrument and its validity checks. 
Estimation 	
 To adjust for the endogenous prescribing model, I implement the IV method in all 
regression analyses (O'Malley, Frank, & Normand, 2011; Garrido, Deb, Burgess, & 
Penrod, 2012). The estimation strategy is similar to that in Chapter 3. First, I perform 
logit regression in the “preliminary stage,” Stage 0, where, 
Pr(Tx=1 | X) = α0 + α1Z + α2X + e    (1) 
Tx denotes the receipt of the prescribing model of interest; Z, the instrument, 
denotes the rate of NPP OAD; X denotes a vector of all covariates. In a subsequent 
regression, Stage 1, I regress the observed endogenous treatment variable (Tx in (1)) on 
the cumulative predicted probabilities of treatment from (1) and the same set of 
covariates where, 
Tx = β0 + β1Pr($% = 1	| *),  + β2X + u   (2) 
In (2), Pr($% = 1	| *), , the cumulative predicted probabilities, replaces the 
original instrument—the rate of NPP OAD—to predict endogenous prescribing model. 
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Using the cumulative predicted probabilities from a nonlinear model as the new 
instrument gives a more efficient estimate and is preferred over using the original 
instrument directly in a conventional 2SLS because the nonlinear Stage 0 is robust to 
misspecification of the treatment model. The 2SLS estimates resulting from the predicted 
probabilities instrument are more efficient than the estimates obtained from a 
conventional 2SLS with a first stage linear probability model (Angrist & Pischke, 2009; 
Imbens & Wooldridge, 2007). 
Lastly, I conduct OLS regression modeling in Stage 2 when estimating outpatient 
cost or log-outpatient cost, where, 
Outpatient cost or log(outpatient cost) = γ0 + γ1$%-  + γ2X + v (3) 
For the OLS model estimating the log-transformed outpatient cost, I use the 
Duan’s (1983) smearing estimator to retransform the estimates obtained from the log-
2SLS. The use of a single smearing estimator assumes that the error term in the cost 
equation is homoscedastic—that is, the error term is assumed to be uncorrelated with any 
covariate. However, the results of the Park test (not reported) indicated that the error term 
may be heteroscedastic arising from multiple explanatory variables. Not adjusting for 
heteroscedastic error can lead to substantially biased estimates (Manning, 1998). While 
an adjustment can be made by calculating a separate smearing factor for each source of 
heteroscedasticity to reduce bias, identifying and adjusting for multiple sources of 
heteroscedasticity can be difficult (Buntin & Zaslavsky, 2004). Using the standard 
smearing adjustor, I acknowledge the likely presence of bias in the log-2SLS estimates. 
 For comparison, I also estimate the outcome equation using a GLM and the fitted 
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values from (3) as the instrument variable, where 
E(Outpatient cost | X) = µ = δ0 + δ1$%-  + δ2X + r  (4) 
A generalized linear model is an alternative approach that provides more 
consistent estimates in the presence of heteroscedastic error (Manning & Mullahy, 2001). 
One drawback of GLM is that it suffers from poor precision if the error term on the 
logged scale is heavy tailed (kurtosis >3). Nonetheless, it is a more direct estimation 
method that is easy to implement and avoids retransformation issues compared to the log 
2SLS approach. Moreover, it provides flexibility in modeling an outcome variable that 
varies nonlinearly with the predictors of interest and assumes non-normal distribution of 
errors. The nonlinearity in response variable is modeled by specifying the appropriate 
link function; similarly, the non-normal distribution of the error term is addressed via the 
selection of the appropriate distribution. In this study, I use GLM with the gamma 
variance distribution and the log link. The distribution of variance and the link function 
are selected based on the Pregibon, modified Part, and Hosmer-Lemeshow tests as 
outlined by Manning, Basu, and Mullahy (2005).  
As a cautionary note, previous studies have shown that this type of 2-stage 
prediction substitution (2SPS) is inconsistent when the fitted values from a linear 
treatment equation (e.g., (2)) are entered in a subsequent nonlinear outcomes equation 
(e.g., (4)) (Amemiya, 1974; Marra & Radice, 2011; Terza, Basu, & Rathouz, 2008). 
Instead of performing such a 2SPS, they have demonstrated through simulations that 2-
stage residual inclusion (2SRI), in which the residuals from the treatment equation are 
entered in the outcomes equation in addition to the endogenous variable, results in more 
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consistent estimates. However, O’Malley, Frank, and Normand (2011) provide some 
evidence that 2SRI is sensitive to the underlying distribution of the outcome variable. 
Furthermore, Garrido, Deb, Burgess, and Penrod (2012) show the outcome from 2SRI are 
affected by the type of residual used. Compared to 2SLS and 2SPS, 2SRI performs worst 
when the outcome is heavily skewed (e.g., cost). While inconsistent, I model outpatient 
cost using (4) as a comparison to the two conventional 2SLS regressions—2SLS on raw 
cost and 2SLS on log-transformed cost.  
To assess model performance I compare three goodness-of-fit measures from each 
regression model: MPR, MAPE, and RMSE. I randomly split the study sample into an 
80% development sample and a 20% validation sample. Once the regressions are run on 
the development sample, I use the coefficient estimates to predict outpatient cost in the 
validation sample. For each patient in the validation sample, the three goodness-of-fit 
measures are calculated (Montez-Rath, 2006). An MPR greater than 1 indicates an over-
prediction (and vice versa); larger MAPE and RMSE represent poorer fit. 
As a secondary analysis, I perform a multivariable logistic regression analysis to 
predict the probability of incurring any inpatient cost in a two-year follow-up. Since the 
dependent variable is an indicator for having any inpatient cost, the categorized number 
of inpatient admissions on the right-hand-side is omitted. 
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Results 
Sample characteristics 
Compared to those under a sole-provider prescribing, the patients under NP/MD 
team prescribing consist of slightly more Blacks and are on average approximately two 
years younger in age and less likely to be married (Table 4.1). They also appear to be a 
lower income group; they earn $3,000-$5,000 less, have a higher proportion of patients in 
Priority Group 5 (annual income below the VA’s income limit, receive VA pension 
benefits, or Medicaid eligible). The team prescribing patients use VHA services more 
(10-12 outpatient visits and 0.2-0.3 inpatient admissions more than the sole-provider 
prescribing patients) and have more severe diabetes (6-7% higher insulin use). Similar 
patterns persist in the PA analysis sample (Table 4.2). In summary, the patients who 
receive team prescribing tend to be younger, poorer, and sicker.  
The mean outpatient cost of patients under team prescribing appears to be higher 
than that of sole-provider prescribing. Patients under NP/MD prescribing incur $1,500-
$1,800 more than sole-provider prescribing in the NP sample (Table 4.1). PA/MD 
prescribing patients also incur more outpatient cost when compared to sole-provider 
prescribing in the PA sample (Table 4.2), although the difference between PA/MD 
prescribing and MD-only prescribing is not as large as the difference between NP/MD 
prescribing and MD-only prescribing ($500 versus $1,200). In both NP and PA samples, 
a higher proportion of the team prescribing patients incur any inpatient cost over the 
course of the follow-up compared to the sole-provider prescribing models (20% versus 
12-15%). 
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Regression to estimate outpatient cost 
Table 4.3 summarizes the estimates of the prescribing model effect on outpatient 
cost. The sign and significance of the coefficient estimates across the three regression 
models—2SLS on the raw cost, 2SLS on the log-transformed cost, and GLM on the raw 
cost—are consistent throughout. While the outpatient cost of NP/MD team prescribing 
appears to be higher and PA/MD team prescribing lower than that of sole-provider 
prescribing, none of the comparisons achieve statistical significance (Table 4.3).  
Table 4.4 presents the average marginal effects of all right-hand-side variables in 
the GLM regression of the three NP prescribing models. Each estimate represents the 
incremental change in mean outpatient cost in raw dollars. Although statistically 
insignificant, the positive coefficients of the NP/MD team prescribing indicate that team 
prescribing may be independently more costly than each of the sole-provider prescribing 
models.  
On the other hand, the marginal effects of the PA prescribing models indicate that 
the mean outpatient costs of PA/MD team prescribing and PA-only prescribing may be 
lower than that of MD-only prescribing (p<0.1; Table 4.5). There is no significant 
difference in outpatient cost between PA/MD team prescribing and PA-only prescribing. 
The health care utilization and the baseline health variables—a logged number of total 
outpatient visits, categorized inpatient admission counts (zero admission as the reference 
group), a dummy variable for any insulin use, and a logged Nosos score—are positively 
significant across all three comparisons in both NP and PA analyses, suggesting that the 
sicker patients incur significantly higher outpatient cost.  
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All three regression models over-estimate the observed outpatient cost as 
indicated by the overall MPRs greater than 1 (Table 4.6). The degree of over-estimation 
in the 2SLS model tends to be less than that of log 2SLS and GLM—the predicted 
outpatient cost from 2SLS models is greater than the observed cost by 27%-33% whereas 
the over-prediction in the log 2SLS and GLM models ranges from 39%-43%. However, 
an examination of MPRs, MAPEs, and RMSEs by deciles of predicted outpatient cost 
shows that the 2SLS model over-predicts more than the log-2SLS and GLM models in 
Deciles 3 through Decile 9 (Tables C5, C6, and C7). The log-2SLS and GLM perform 
similarly in all six prescribing model comparisons with all three goodness-of-fit measures 
practically overlapping each other throughout the entire range of the predicted outpatient 
cost (Figures C1, C2, and C3). 
Logistic regression to predict the probability of incurring any inpatient cost 
Table 4.7 presents the odds ratios of prescribing model effects on the probability 
of having any inpatient cost. None of the six estimates achieve statistical significance, 
suggesting that prescribing model is not associated with the probability of incurring 
inpatient cost. The C-statistic of 0.85 for all six logistic models indicates a reasonably 
good model fit—a C-statistic greater than 0.7 is generally considered a good fit. The full 
logistic regression results are reported in Tables C3 and C4. 
 
Discussion and conclusion 
This study examines the effect of prescribing model on the total outpatient cost 
and the probability of incurring inpatient cost over a two-year follow-up. I find no 
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significant differences in outpatient cost or the probability of incurring inpatient cost 
between the NP/MD team prescribing model and either of the two sole-provider 
prescribing models—MD-only and NP-only. I also find the observed differences in 
outpatient cost and the probability of incurring inpatient cost between NP-only and MD-
only prescribing models to be insignificant. Results from the PA analysis show that the 
mean outpatient cost of the patients under PA/MD prescribing may be lower than that of 
the patients under MD-only prescribing. In addition, outpatient cost under PA-only 
prescribing appears to be lower than that under MD-only prescribing. None of the 
prescribing models in the PA analysis are significantly associated with the probability of 
incurring inpatient cost. Taken together, the results support the hypotheses in this chapter 
that 1) mean outpatient cost of the patients managed under team prescribing is not 
significantly less than that of those managed under sole-provider prescribing, and 2) team 
prescribing patients are no more likely to be admitted in the two years following OAD 
initiation than sole-provider prescribing patients.  
 While no direct comparison exists in the literature due to differences in the 
definition of outcomes and/or methods, several studies have also compared NPP care to 
MD care in resource utilization and cost. Cowan et al. (2006) report a significantly lower 
length of stay (LOS) in patients under NP/MD team care. They report hospital cost 
savings of $1,591 per patient under NP/MD team care as a result of the lower LOS. 
Unlike the current study, which uses the direct variable cost as the outcome, they quantify 
the cost savings by subtracting the lost revenue resulting from a shorter LOS from the 
“backfill profit” generated by admitting more patients. The assumption as stated by the 
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authors is that more revenue is generated in the first four days versus later LOS days. One 
key difference between the current study and the study by Cowan et al. (2006) is that the 
NPs did not prescribe medication in the latter study to preserve teaching opportunities for 
the residents and interns. In a follow-up study, which includes active monitoring of drug 
therapy as one of the NP interventions, Chen et al. (2009) compare several drug cost 
outcomes—including the overall drug cost, antibiotic cost, and high drug cost—and find 
that patients in the NP/MD group spend significantly less on both overall drug cost and 
antibiotic cost and are less likely to incur high drug cost. The latter study parallels the 
current study more closely in that it also explores the NP/MD team effect on direct costs. 
However, Chen et al. (2009) do not provide the marginal effects of NP/MD care on cost; 
their findings of lower costs in patients under NP/MD care are based on the sign and 
significance of the coefficient estimates from a log-transformed linear cost models. The 
current study employs a rigorous cost modeling strategy that includes the estimation of 
three different regression models and the assessment of model performance.  
 Other studies investigate the effect of NPP care on utilization measures, not 
explored in the current study. Hemani et al. (1999) and Venning et al. (2000) both report 
a significantly higher number of tests and imaging services in patients managed by NPs 
compared to those managed by MDs. Hemani et al. (1999) speculate that the higher 
number of tests and investigations may be due to a greater uncertainty NPs encounter in 
their practice. Virani et al. (2018) compare the number of visits (primary care and 
specialty) and tests (lipid panel and HbA1c or stress test) in two separate samples of 
cardiovascular disease and diabetes patients in the VA. The authors point out that while 
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the differences in the number of visits and tests are significant, the magnitude of the 
differences are practically zero. The unadjusted numbers of outpatient visits and inpatient 
admissions between MD-only prescribing and NP-only prescribing patients appear to be 
consistent with the findings reported by Virani et al. (2018). The difference in the mean 
outpatient visits between MD-only prescribing and PA-only prescribing is greater 
compared to the difference between MD-only and NP-only prescribing. Such difference 
could simply be an artifact of the differences in baseline health and other patient 
characteristics between NP-only prescribing and PA-only prescribing patients; on the 
other hand, it may be an indication that NPs and PAs practice in different ways that result 
in different outcomes. 
 Comparing the marginal effects of prescribing model on outpatient cost raises 
further speculation that there might exist some differences in NPs and PAs. The mean 
outpatient cost of the patients under NP-only prescribing is higher than that of the 
patients under MD-only prescribing in the NP analysis, whereas the mean outpatient cost 
of the patients under PA-prescribing is lower than that of MD-only prescribing patients in 
the PA analysis. When NPPs (NPs or PAs) work with MDs as a team in managing their 
patients’ medications, the difference becomes even greater—only the estimates in the PA 
analysis are marginally significant (p<0.1).While some caution should be exercised in 
over-analyzing the results, especially if the estimates are insignificant, the differences in 
the NP-based prescribing models and the PA-based models with respect to MD-only 
prescribing may suggest that NPs and PAs should be analyzed separately. One source of 
the discrepancy might result from potential differences in how MDs work with NPs and 
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PAs. Physician assistants by name have an implied hierarchical relationship with 
physicians whereas nurse practitioners do not. In a collaborative setting, MDs may 
experience less friction with PAs than NPs, who may practice more independently. A 
qualitative inquiry into MDs’ experiences in working with different types of NPPs may 
provide a useful insight in understanding any differences between NP/MD teams and 
PA/MD teams.  
 This study relies heavily on the assumption that patients receive team-based MM 
solely based on the prescribers indicated in their OAD prescriptions. In the pharmacy 
data I do not observe whether NPP-issued prescriptions reflect independent prescribing 
decisions of the prescribing NPP or the attending physician. It is possible that at least 
some NPP-issued prescriptions reflect the decision of the attending physician instead of 
the issuing NPP due to the cases in which NPPs issue prescriptions on the physician’s 
behalf or renew existing prescriptions without any re-evaluation of the treatment. The 
NPP-issued prescriptions that in fact reflect physician’s decision may lead to 
misclassification of the patient’s prescribing model, which in turn may result in 
underestimates of the team-based MM effect.  
 IV estimates are as good as the instruments that are used to obtain them. In 
Chapter 3 I show that the rate of OAD prescribing by NPPs, the instrument used in the 
current study, performs reasonably well in adjusting for treatment selection bias in the 
assignment of prescribing model. It significantly predicts prescribing model and both 
outcomes and baseline characteristics appear to be uncorrelated with the instrument, 
although some differences in the severity of diabetes measures including insulin use and 
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receipt of inpatient OAD, which are likely important cost predictors, still remain among 
the instrument quintiles. No instrument is perfect—some residual treatment selection bias 
or confounding may persist, obscuring the true effect of prescribing model. Re-estimation 
of the regression models using one or more alternative instruments may serve as a 
confirmatory analysis that could strengthen the findings of the current study. 
 The risk measures used in this chapter may be insufficient in controlling for the 
baseline health and severity of diabetes of the patients across different prescribing model, 
thereby resulting in inadequate adjustment of potential confounders of cost. While the 
Nosos score used in all regression models is a validated risk measure, its composite 
nature may have rendered any small but significant variation in certain conditions 
difficult to capture. Moreover, insulin use alone may not adequately measure severity of 
diabetes. Use of additional measures such as the diabetes complications severity index 
and/or selected disease-specific indicators, as used in Chapter 3, may be considered.    
 In this study, I find no significant differences in the mean outpatient cost and the 
likelihood of incurring any inpatient cost between patients under team prescribing and 
sole-provider prescribing. Despite the statistical insignificance, the opposing signs of the 
coefficient estimates of the mean outpatient cost of NP/MD prescribing patients and the 
mean outpatient cost of PA/MD prescribing patients relative to that of MD-only 
prescribing patients suggest that there may be differences in how NP/MD and PA/MD 
teams perform medication management and manage patients in general. A further 
investigation in examining how different team composition may affect costs is warranted. 	  
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Table 4.1. Sample characteristics: Nurse practitioner 
 
MD only NP/MD NP only 
N (%) 28,981 (69) 7,056 (17) 5,909 (14) 
Outpatient cost (SD) 5,857 (5,910) 7,006 (6,635) 5,454 (5,532) 
Inpatient Cost 
   
 n > $0 (%) 4,375 (15) 1,505 (21) 694 (12) 
Mean (SD) 16,430 (34,200) 19,282 (78,936) 16,105 (26,865) 
Age (SD) 61.4 (9.9) 59.7 (10.1) 61.8 (10.2) 
Sex (%) 
   
Male 27,819 (96) 6,681 (95) 5,571 (94) 
Female 1,162 (4) 375 (5) 338 (6) 
Race (%) 
   
White 20,515 (71) 4,821 (68) 4,259 (72) 
Black 4,997 (17) 1,363 (19) 1,017 (17) 
Hispanic 1,113 (4) 269 (4) 173 (3) 
Other 840 (3) 217 (3) 145 (2) 
Unknown 1,516 (5) 386 (5) 315 (5) 
Marital Status (%) 
   
Married 17,355 (60) 3,879 (55) 3,538 (60) 
Unmarried 11,626 (40) 3,177 (45) 2,371 (40) 
Income (SD) 43,170 (74,342) 40,464 (71,466) 45,806 (76,910) 
Priority Status† (%) 
   
1 6,437 (22) 1,462 (21) 1,148 (19) 
2 2,372 (8) 546 (8) 494 (8) 
3 3,992 (14) 950 (13) 788 (13) 
4 571 (2) 207 (3) 117 (2) 
5 9,184 (32) 2,539 (36) 1,856 (31) 
6 1,387 (5) 323 (5) 292 (5) 
7 1,130 (4) 250 (4) 234 (4) 
8 3,708 (13) 728 (10) 926 (16) 
9 200 (1) 51 (1) 54 (1) 
Medicare Eligibility (%) 18,346 (63) 4,183 (59) 3,693 (62) 
Insulin Use (%) 3,899 (13) 1,374 (19) 749 (13) 
VHA utilization 
   
Outpatient visits (SD) 46.5 (37.9) 56.3 (45.5) 44.7 (36.1) 
Inpatient admissions (SD) 0.3 (0.9) 0.5 (1.3) 0.2 (0.8) 
Nosos (SD) 1.0 (1.3) 1.3 (1.6) 1.0 (1.1) 
 	  
		
103 
Table 4.2. Sample characteristics: Physician assistant 
 
MD only PA/MD PA only 
N (%) 19,760 (81) 2,706 (11) 2,052 (8) 
Outpatient cost (SD) 5,924 (5,965) 6,467 (6,267) 4,843 (4,795) 
Inpatient Cost 
   
 n > $0 (%) 2,983 (15) 544 (20) 236 (12) 
Mean (SD) 17,098 (48,674) 21,171 (44,898) 15,478 (26,750) 
Age (SD) 61.2 (9.9) 60.2 (10.2) 62.4 (9.9) 
Sex (%) 
   
Male 18,913 (96) 2,606 (96) 1,996 (97) 
Female 847 (4) 100 (4) 56 (3) 
Race (%) 
   
White 13,791 (70) 1,896 (70) 1,514 (74) 
Black 3,625 (18) 483 (18) 321 (16) 
Hispanic 749 (4) 94 (3) 53 (3) 
Other 565 (3) 79 (3) 37 (2) 
Unknown 1,030 (5) 154 (6) 127 (6) 
Marital Status (%) 
   
Married 11,713 (59) 1,522 (56) 1,267 (62) 
Unmarried 8,047 (41) 1,184 (44) 785 (38) 
Income (SD) 42,722 (73,087) 40,679 (64,614) 43,920 (75,837) 
Priority Status† (%) 
   
1 4,431 (22) 514 (19) 384 (19) 
2 1,603 (8) 214 (8) 190 (9) 
3 2,719 (14) 376 (14) 305 (15) 
4 399 (2) 69 (3) 47 (2) 
5 6,218 (31) 936 (35) 633 (31) 
6 960 (5) 131 (5) 90 (4) 
7 780 (4) 130 (5) 82 (4) 
8 2,520 (13) 323 (12) 309 (15) 
9 130 (1) 13 (0) 12 (1) 
Medicare Eligibility (%) 12,337 (62) 1,585 (59) 1,342 (65) 
Insulin Use (%) 2,681 (14) 493 (18) 248 (12) 
VHA utilization 
   
Outpatient visits (SD) 46.9 (38.0) 54.8 (46.2) 40.4 (31.6) 
Inpatient admissions (SD) 0.3 (0.9) 0.5 (1.1) 0.2 (0.7) 
Nosos (SD) 1.1 (1.3) 1.2 (1.6) 0.9 (0.9) 
            † See Appendix D for definitions 	  
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Table 4.3. Regression estimates of prescribing model on outpatient cost 
 
(1) (2) (3)  
2SLS LOG 2SLS‡ GLM‡ 
NP/MD v. MD† 505.953 0.044 0.040 
(s.e.) (598.007) (0.112) (0.105) 
NP/MD v. NP† 168.639 0.095 0.015 
(s.e.) (877.646) (0.208) (0.191) 
NP v. MD† 80.020 0.006 0.034 
(s.e.) (409.698) (0.085) (0.082) 
PA/MD v. MD† -1831.246 -0.296 -0.304* 
(s.e.) (1153.793) (0.187) (0.176) 
PA/MD v. PA† 437.699 0.188 0.151 
(s.e.) (1034.049) (0.186) (0.175) 
PA v. MD† -1236.692* -0.230 -0.245* 
(s.e.) (732.239) (0.141) (0.135) 
       † Reference group 
       ‡ Estimates in log scale 
       (1) - (3) adjusted for covariates 
       *** p <0.01, ** p<0.05, * p<0.1 	  
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Table 4.4. Average marginal effects of GLM regression estimates on outpatient cost: 
Nurse practitioner 
 
NP/MD v. MD only† NP/MD v. NP only† NP only v. MD only†  
b/se b/se b/se 
Prescribing model 247.161 94.306 198.760  
(651.019) (1231.813) (486.243) 
Age (centered at 65) 8.019** 0.772 3.675  
(3.330) (7.669) (3.085) 
Female -156.635 -229.080 -74.039  
(107.179) (211.355) (116.371) 
Race_Black -57.727 71.428 14.923  
(85.565) (122.412) (83.752) 
Race_Hispanic -518.448** -398.571 -367.798*  
(213.377) (275.351) (199.759) 
Race_Other 85.356 -243.221 187.458  
(147.426) (204.347) (146.344) 
Race_unknown -234.476* -515.990*** -163.017  
(134.174) (146.736) (129.164) 
Unmarried -78.437 83.374 -46.032  
(51.825) (78.684) (49.049) 
10K<=Income<=30K 91.016 56.566 29.727  
(74.056) (111.668) (68.779) 
Income>30K -23.583 99.504 -12.073  
(71.197) (104.414) (64.220) 
Income unknown 49.648 283.205** 9.475  
(82.435) (126.549) (76.774) 
Priority status 1 585.682*** 710.754*** 546.347***  
(82.481) (115.994) (74.881) 
Priority status 2 -191.520** -11.146 -192.174**  
(89.610) (134.741) (82.986) 
Priority status 3 -43.974 -101.031 -26.573  
(79.090) (133.857) (70.091) 
Priority status 4 372.837** 188.550 484.018***  
(172.525) (243.873) (171.989) 
Priority status 6 175.521 163.014 188.093*  
(114.933) (189.730) (112.274) 
Priority status 7 343.793** 421.878** 253.791*  
(149.590) (211.405) (132.319) 
Priority status 8 -364.197*** -182.085 -209.903**  
(93.177) (138.924) (83.146) 
Priority status 9 83.528 533.977 248.275  
(250.335) (632.878) (328.763) 
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Medicare Eligibility 241.862*** 338.745*** 280.263***  
(57.871) (104.131) (61.253) 
log(OP visits) 5577.991*** 5852.335*** 5296.151***  
(90.505) (178.583) (83.887) 
IP admission=1 1378.905*** 1472.938*** 1288.205***  
(80.192) (140.454) (84.127) 
IP admission>=2 1357.880*** 1265.634*** 1260.884***  
(105.595) (213.828) (101.705) 
Insulin use 444.524*** 589.638*** 469.997***  
(72.797) (98.429) (69.682) 
log(Nosos) 355.821*** 287.767*** 459.319***  
(62.571) (89.937) (59.365)     
N 36,037 12,965 34,890 
Deviance 11927.972 4205.186 11640.274 
Deviance/df 0.331 0.325 0.334 
*** <0.01, ** <0.05, * <0.1 
† Reference group 	  
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Table 4.5. Average marginal effects of GLM regression estimates on outpatient cost: 
Physician assistant 
 
PA/MD v. MD only† PA/MD v. PA only† PA only v. MD only†  
b/se b/se b/se 
Prescribing model -1859.851* 892.707 -1455.263*  
(1083.223) (1030.261) (805.217) 
Age (centered at 65) 7.337** 1.287 6.054  
(3.688) (7.886) (3.782) 
Female 18.996 -30.022 89.117  
(134.453) (464.714) (148.797) 
Race_Black -107.669 -92.762 -105.926  
(109.025) (169.211) (106.887) 
Race_Hispanic -483.434 -108.038 -540.022*  
(304.422) (423.491) (279.561) 
Race_Other 60.045 -257.649 15.286  
(196.571) (306.153) (179.343) 
Race_unknown -386.223*** -409.077* -292.126**  
(141.772) (238.106) (146.179) 
Unmarried -40.381 91.389 -65.262  
(59.272) (115.608) (60.709) 
10K<=Income<=30K -45.903 -3.206 45.117  
(94.332) (206.705) (89.839) 
Income>30K -96.223 154.642 -38.761  
(94.795) (182.516) (91.687) 
Income unknown 51.190 424.758** 104.350  
(106.553) (209.921) (109.088) 
Priority status 1 440.041*** 591.312*** 499.442***  
(101.523) (193.524) (90.927) 
Priority status 2 -134.825 457.245 -71.008  
(114.496) (284.353) (110.610) 
Priority status 3 45.839 -164.553 101.422  
(100.048) (204.438) (98.428) 
Priority status 4 744.633*** 540.528 737.888***  
(257.213) (388.816) (253.689) 
Priority status 6 220.212 9.250 226.600  
(154.639) (254.402) (157.665) 
Priority status 7 144.672 -42.719 76.053  
(157.870) (341.712) (163.084) 
Priority status 8 -324.907*** -174.997 -237.458**  
(117.287) (186.145) (113.064) 
Priority status 9 -175.836 -450.422 -288.173  
(280.498) (702.193) (291.839) 
Medicare Eligibility 239.304*** 299.060** 267.728***  
(65.525) (145.340) (63.747) 
log(OP visits) 5531.383*** 5193.029*** 5293.698***  
(113.088) (166.240) (100.365) 
IP admission=1 1361.312*** 1356.146*** 1225.890*** 
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(106.188) (219.533) (101.386) 
IP admission>=2 1324.865*** 752.754*** 1312.071***  
(132.401) (261.683) (128.777) 
Insulin use 479.775*** 161.902 459.004***  
(97.044) (180.371) (92.710) 
log(Nosos) 489.052*** 330.492*** 546.745***  
(70.526) (115.362) (73.443)     
N 22,466 4,758 21,812 
Deviance 7391.243 1539.444 7202.789 
Deviance/df 0.329 0.325 0.331 
*** <0.01, ** <0.05, * <0.1 
† Reference group 	  
		
109 
Table 4.6. Overall goodness of fit measures of cost regression models 
 
2SLS LOG 
2SLS 
GLM 
NP/MD v. MD 
   
MPR 1.29 1.40 1.41 
MAPE 2,817 2,591 2,599 
RMSE 4,247 4,462 4,471 
NP/MD v. NP 
   
MPR 1.27 1.41 1.40 
MAPE 2,939 2,741 2,749 
RMSE 4,434 4,540 4,592 
NP v. MD 
   
MPR 1.30 1.39 1.41 
MAPE 2,717 2,505 2,523 
RMSE 4,079 4,230 4,275 
PA/MD v. MD 
   
MPR 1.28 1.39 1.39 
MAPE 2,892 2,695 2,688 
RMSE 4,375 4,544 4,606 
PA/MD v. PA 
   
MPR 1.33 1.43 1.42 
MAPE 2,851 2,718 2,707 
RMSE 4,278 4,357 4,394 
PA v. MD 
   
MPR 1.27 1.41 1.40 
MAPE 2,769 2,566 2,545 
RMSE 4,200 4,426 4,422 
       MPR - Mean predictive ratio 
       MAPE - Mean absolute prediction error 
       RMSE - Root mean square error 	  
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Table 4.7. Abbreviated logistic regression results to estimate the probability of positive inpatient 
cost 
 
NP PA  
NP/MD v. 
MD 
NP/MD v. 
NP 
NP v. 
MD 
PA/MD v. 
MD 
PA/MD v. 
PA 
PA v. 
MD  
OR/se OR/se OR/se OR/se OR/se OR/se 
Prescribing 
model 
0.743 1.420 0.631 1.153 0.700 0.949 
 
(0.340) (0.894) (0.205) (0.784) (0.525) (0.548)        
N 36,037 12,965 34,890 22,466 4,758 21,812 
LROC 0.8518 0.8550 0.8507 0.8468 0.8561 0.8475 
*** <0.01 ** <0.05 * <0.1 
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CHAPTER 5: CONCLUSION 
Expanding the clinical roles of NPPs including NPs and PAs has been suggested 
to address the persistent shortage of primary care physicians in the U.S. (Bodenheimer & 
Smith, 2013; Green, Savin, & Lu, 2013). Shortage of physicians has consequential 
impact on both patients and physicians; it increases patient wait times, reduces quality of 
care, and increases physician burnout (ACP, 2008). NPPs have been shown to be 
competent clinicians who provide health care services with the quality at least 
comparable to their physician counterparts as measured by improvements in patient 
outcomes (Laurant, et al., 2009). With increasingly more health care systems adopting 
team-based approaches in providing care, NPPs are well-positioned to serve as the 
facilitators of effective team care. In particular, they have the potential to enhance 
medication management in chronic care by applying their patient-oriented training and 
professionally developed communication skills to help patients manage their treatment. 
As I conceptualize in Chapter 1, NPPs can play a critical role in chronic care as members 
of an interdisciplinary care team. Patients with chronic conditions typically take multiple 
medications due to their higher disease burden – compared to their healthy peers they are 
more likely to have comorbidities, which may include other chronic conditions (Wolff, 
Starfield, & Anderson, 2002; Vogeli, et al., 2007). Taking multiple medications increases 
the complexity of the drug therapy, posing a greater challenge for the patients in 
managing their medications. Patients with complex drug therapy such as the chronically 
ill are likely to benefit from comprehensive team-based medication management, which 
entails extensive monitoring of the patient’s reaction to the prescribed drugs, prompt 
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adjustments of the treatment, and patient education. Given sufficient practice autonomy 
that enables them to make independent clinical decisions to the extent allowed by their 
training and certification, NPPs may not only mitigate the consequences of physician 
shortage, but also improve patient outcomes and/or save costs. While previous studies 
have examined the substitutability of MDs with NPPs and its effects on outcomes and 
costs, only a limited number of studies have investigated the effects of NPP/MD team 
care. Moreover, there exists even a smaller set of studies that explicitly analyzes the team 
prescribing aspect of care. This dissertation contributes to the literature by exploring the 
effects of prescribing modality on clinical outcomes and total costs of care using the vast 
observational data in the Veterans Health Administration (VHA).  
 In Chapter 2, I describe the prescribing patterns of OADs in VHA, both overall 
and by prescribing modality. I find that, while the prescribing pattern of OADs is 
generally similar between team prescribing and sole-provider prescribing, patients 
managed under either NP/MD team or PA/MD team prescribing receive: 1) more 
sulfonylureas, 2) less metformin, and 3) more prescriptions overall on average. In 
diabetes drug therapy, metformin is a widely-accepted first-line OAD. When the 
prescriber deems necessary to intensify the medication treatment, metformin is replaced 
by or augmented with a second-line agent (e.g., sulfonylureas or dipeptidyl peptidase-4 
inhibitors) (VA/DOD, 2010). I hypothesize that such intensification of medication 
therapy through substitution and/or augmentation of medications is likely to occur sooner 
under team medication management owing to the NPP-facilitated coordination of 
medication management and collaboration between NPPs and MDs. Therefore, I predict 
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a higher total number prescriptions and a higher number of second-line drug prescriptions 
in the 2 years following OAD initiation. The results from Chapter 2 appear to support the 
predictions with one caveat: the results do not adjust for the baseline patient 
characteristics. Unadjusted differences in the rates of metformin and sulfonylureas 
between different prescribing models provide useful insights in understanding the general 
trends and patterns of OAD prescribing. However, to ascertain the true effect of 
prescribing model the differences in the baseline patient characteristics such as severity 
of diabetes and comorbidities need to be controlled for. While I do not carry out any 
regression analysis in estimating, for example, the number of total sulfonylurea 
prescriptions using prescribing model as the main predictor, I implement the instrumental 
variable method in Chapters 3 and 4 to adjust for treatment selection bias, a likely 
contributor of the differences in baseline characteristics observed in Chapter 2. 
 Treatment selection bias and unmeasured confounding in observational studies is 
a common issue in which some factor(s) systematically influences the predictor of 
interest, typically an intervention or treatment. As a result, the assignment of treatment 
becomes non-random. It’s an omitted variables problem that is often difficult to 
overcome due to the unavailability of data or the impracticality of measuring such 
factors. Moreover, it may be impossible to identify all potential confounders that bias the 
causal relationship between the predictor and the outcome. Randomized control trials 
(RCTs) avoid such biases by design – treatment assignment is based solely on the chosen 
randomization mechanism. While RCTs are common in clinical research, they are rarely 
conducted in policy research due to ethical and economic reasons. The RAND Health 
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Insurance Experiment and the more recent Oregon Health Insurance Experiment are two 
well-known examples of RCTs in health policy research that use random assignment of 
health insurance benefits to study the effects of health insurance options on health 
outcomes, utilization, and costs. Unlike these studies, which obtain randomization by 
experimental design, this dissertation likely suffers from potential confounding or 
treatment selection bias in the assignment of prescribing model. As reflected in the 
description of the baseline characteristics in Chapter 2, patients who receive team 
prescribing appear to be different from those receiving sole-provider prescribing. 
Assuming that there exist multiple factors beyond the measured characteristics that 
systematically predict the receipt of sole-provider or team prescribing, I implement the 
instrumental variables (IV) method in Chapters 3 and 4 to adjust for the suspected 
treatment selection bias and unmeasured confounding.   
The IV method, when performed with strong and valid instruments, allows for the 
estimation of treatment effect in the absence of random assignment of treatment without 
having to specify all relevant explanatory variables (Angrist & Krueger, 2001). A strong 
instrument reliably predicts treatment; a valid instrument affects the outcome only 
through treatment. Using the prescription data in FY 2010, the year in which the 
assignment of prescribing model is determined, to construct an instrument that predicts 
the receipt of NPP prescribing—the clinic-level rate of OAD prescriptions issued by 
NPPs. I demonstrate in Chapter 3 that the instrument satisfies the two IV assumptions in 
that it strongly and significantly predicts prescribing model and appears to be 
uncorrelated with both outcome and explanatory variables. 
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 I find mixed results in investigating the effect of prescribing model on diabetes-
related clinical measures and costs. In Chapter 3, I perform regression analysis to 
estimate the differences in the mean change in the levels of HbA1c, glucose, LDL, and 
creatinine among all possible pairs of NPP/MD team, NP-only, and MD-only prescribing 
models over a two-year follow-up. I find that NP-only prescribing achieves significantly 
greater reductions in glucose level compared to MD-only prescribing. I also find that 
patients under NP/MD prescribing realize a greater reduction in glucose compared to 
those under MD-only prescribing, but the significance of the difference is marginal 
(p<0.1). In addition, while NP/MD prescribing achieves a greater reduction in creatinine 
level than MD-only prescribing, the magnitude of the reduction is smaller compared to 
NP-only prescribing. None of the PA prescribing models perform significantly different 
from MD-only prescribing in reducing any of the lab measures. Findings from the cost 
analysis in Chapter 4 suggest marginally significant to no effect of prescribing model on 
costs. While none of the NP prescribing models has any significant effect on mean 
outpatient cost, PA/MD team and PA-only prescribing have marginally significant lower 
mean outpatient costs compared to MD-only prescribing. I find no significant differences 
in the likelihood of incurring any inpatient cost during the follow-up in either NP or PA 
analysis. Taken together, I report no conclusive evidence that patients under NPP/MD 
team prescribing achieve better intermediate health outcomes as measured by the changes 
in the selected lab measures or incur lower mean outpatient cost compared to patients 
under sole-provider prescribing. 
 Findings of this dissertation should be interpreted with some limitations in mind. 
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First, the premise that some patients receive medication management under NPP/MD 
team prescribing while others receive medication management under a single provider-
type prescribing is solely based on the provider type listed in the prescription data. I do 
not observe from the data whether a patient is actually assigned to a care team that 
performs medication management activities. As a result, the assignment of prescribing 
model may be subject to misclassification. It is plausible that some prescriptions issued 
by NPs or PAs do not reflect the prescribing decision of the issuing NPs/PAs but that of 
their attending physician. Conversely, some prescriptions issued by MDs may indeed 
reflect the prescribing decisions of the managing NPPs. The patients in both scenarios 
would be misclassified as the recipients of team prescribing, when in fact they are 
receiving sole-provider prescribing. Second, medication management activities may vary 
in form and intensity across facilities. While I attempt to statistically adjust for the site-
level variation by clustering the coefficient estimates, thereby obtaining the robust 
standard errors, these estimates are still approximations. Third, the estimates of the 
prescribing model effect reported in Chapters 3 and 4 represent IV estimates that rely on 
the strength and validity of the instrument. Because I construct the instrument using the 
same pharmacy data used for determining the assignment of prescribing model, it is 
likely that the instrument is not completely exogenous from the relationship between 
prescribing model and the outcomes examined in this dissertation. In this sense, the 
instrument at least mildly violates the exclusion criterion, which requires an instrument to 
be completely uncorrelated with the unmeasured variation in the outcome. Based on the 
results of the IV assessment in Chapter 3, the instrument appears to be sufficiently strong 
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and exogenous (or “almost valid”), suggesting that the bias resulting from a mild 
violation of the exclusion criterion may be minimal (Murray, 2006).  
 Future research in exploring the effect of prescribing modality on health outcomes 
and costs might involve the use of an alternative instrument, conducting a longitudinal 
analysis, and examining qualitative differences in how MDs work with different types of 
NPPs. Obtaining similar results using an alternative instrument to adjust for selection bias 
in the prescribing model assignment would strengthen the current findings. Using the 
alternative instrument in conjunction with the instrument used in this dissertation would 
be another approach that might improve estimation. A longitudinal analysis using the 
difference-in-differences method in which patients under sole-provider prescribing are 
used as controls is an alternative approach to adjust for any systematic differences in 
patients under different prescribing models. Lastly, a qualitative analysis may be 
performed to investigate any differences in how MDs collaborate with different types of 
NPPs. Despite their statistical insignificance, the opposite signs of the estimates of the 
mean outpatient cost of NP/MD team prescribing and PA/MD team prescribing relative 
to that of MD-only prescribing suggest that team composition may affect patient 
management. A qualitative inquiry into such potential differences would complement the 
findings from this dissertation in understanding how team medication management 
affects outcomes and costs. 
 In efforts to increase access to VHA care and mitigate the effects of primary care 
physician shortage, VHA has granted full practice authority to advanced practice 
registered nurses (APRNs)—certified nurse practitioners, clinical nurse specialists, and 
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certified nurse-midwives—effective January 13, 2017 (FR, 2016). 38 CFR Part 17, the 
amendment to VA’s medical regulations, permits full practice authority to APRNs to 
diagnose, treat, and prescribe medications to the extent of their training, education, and 
certification without physician oversight. As the proposal and much of the work in this 
dissertation precede the amendment, the reported findings do not reflect any potential 
effect of the policy change. While the newly granted practice authority has likely enabled 
NPs to carry out medication management activities more freely, its impact on physician 
perception and attitude towards NPPs as independent providers remains unclear. In 
addition to the aforementioned areas of future research, an evaluation of the effect of 
NPP/MD team prescribing post policy change is warranted. 
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APPENDIX A 
Table A1. Comparison of patient characteristics at baseline between the sample and the excluded 
 
Overall Excluded    
N 76,672 6,660 
Age (SD) 61.2 (10.5) 63.6 (12.5) 
Sex (%) 
  
Male 73,367 (96) 6,315 (95) 
Female 3,305 (4) 345 (5) 
Race (%) 
  
White 52,806 (69) 4,584 (69) 
Black 13,348 (17) 1,098 (16) 
Hispanic 3,850 (5) 312 (5) 
Other 2,256 (3) 229 (3) 
Unknown or missing 4,412 (6) 437 (7) 
Marital status (%) 
  
Married 45,317 (59) 4,071 (61) 
Unmarried 31,355 (41) 2,589 (39) 
Income (SD) 43,961 (75,398) 47,891 (81,022) 
Insulin Use (%) 11,589 (15) 658 (10) 
Inpatient OAD (%) 8,601 (11) 274 (4) 
Comorbidities (%) 
  
Hypertension 37,341 (49) 3,061 (46) 
Hyperlipidemia 32,565 (42) 2,664 (40) 
Cardiovascular 12,103 (16) 1,140 (17) 
Heart disease 9,386 (12) 845 (13) 
Sexual impotence 4,021 (5) 265 (4) 
Neuropathy  3,973 (5) 280 (4) 
Peripheral neuropathies 2,876 (4) 187 (3) 
Cerebrovascular  1,815 (4) 188 (3) 
Nephropathy-1 1,752 (2) 222 (3) 
Peripheral vascular disease 1,618 (2) 159 (2) 
Congestive heart failure 1,565 (2) 167 (3) 
Cerebrovascular disease 1,557 (2) 163 (2) 
Chronic renal disease 1,441 (2) 185 (3) 
Retinopathy 1,306 (2) 132 (2) 
Cellulitis and abscess 983 (1) 95 (1) 
Nephropathy-3 919 (1) 146 (2) 
Myocardial infarction 728 (1) 72 (1) 
Other selected infections 519 (1) 74 (1) 
Diabetic eye disease 414 (1) 37 (1) 
Gangrene & lower limb ulcer 267 (0) 38 (1) 
Nephropathy-2 120 (0) 76 (1) 
Hypoglycemia (new def) 65 (0) 7 (0) 
Cardiac surgery 43 (0) 2 (0) 
Hypoglycemia 34 (0) 7 (0) 
Metabolic 9 (0) 1 (0) 
Other metabolic complications 9 (0) 1 (0) 
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Table A2. Diagnosis codes of selected diabetes-related comorbidities 
Diabetes morbidities, short list  
Retinopathy 250.5x, 361.xx, 362.01, 362.02, 362.1, 362.53, 362.81, 362.82, 362.83, 369, 369.xx, 379.23 
Nephropathy-1 (codes) 250.4, 580-583.xx, 585-586.xx, 593.9  
Nephropathy-2 (any creatinine >1.5 in 12 months before index date) >1.5 in 12 months before index date 
Nephropathy-3 (any microalbumin ratio >=30 in 12 months before index date) >=30 in 12 months before index date 
Neuropathy  250.6, 337.0, 337.1, 356.9, 357.2, 358.1, 354.0-355.xx, 458, 536.3, 564.5, 596.54, 713.5, 951.0, 951.1, 951.3 
Cerebrovascular  431, 433, 434, 435, 436 
Cardiovascular 410-414, 427.1,427.3,427.4,427.5,428,,429.2,440, 441 
Peripheral vascular disease 040.0,444.22, 250.7,442.3,443.81,443.9,892.1, 707.1,785.4 
Metabolic 250.1-250.3x 
Diabetes morbidities, alternate  
Hypertension 401-405.xx, 437.2 
Hyperlipidemia 272.0-272.4x 
Myocardial infarction (exception) (HTIY + HTYG) Single code: inpatient: 410, 410.xx, 411.0, 427.5 
 Single code: inpatient: 412, 412.xx 
 Single code: outpatient: 410, 410.xx, 411.0, 412, 412.xx, 427.5 
Congestive heart failure 428,428.xx,402.01,402.11,402.91,404.01,404.11,404.91 
Heart disease 411, 411.xx (except 411.0), 413-414.xx 
Cardiac surgery (exception) Single code: 36.01, 36.02, 36.05, 36.10-36.16, 36.19 
 Single code: 33510-33519, 33521-33523, 33533-33536, 33572, 92973-
92975, 92977, 92980-92982, 92984, 92986, 92995, 92996 
Cerebrovascular disease 430,431,432,433.01,433.11,433.21,433.31,433.81,433.91,434.01,434.11,434.91,435, 435.xx,436,437.1,438 
Chronic renal disease 581-583.xx, 585-587.xx, 996.73, 996.81, V42.0, V45.1 
Peripheral neuropathies 354-356.xx 
Sexual impotence 302.71, 302.72, 607.84 
Peripheral vascular disease 250.7, 440, 440.xx, 443, 443.xx, 785.4, 997.2 
Diabetic eye disease 250.5, 362.0, 379.23 
Gangrene & lower limb ulcer 040.0,440.23,440.24,707.1,892.1,785.4 
Cellulitis and abscess 682.0-682.9 
Other selected infections 038.0-038.9, 117.7, 421.0, 480.0-487.8, 575.0, 590.0-590.2, 590.9, 608.83, 728.86, 730.0-730.2, 790.7 
Hypoglycemia  (exception) Single code:  251 
Other metabolic complications 250.1-250.3 
Hypoglycemia, new definition (exception) see sheet: "Hypoglycemia Definitions"; HYPOA 
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Table A3. List of oral antidiabetic drugs 
Class Agent 
Alpha-glucosidase inhibitor (AGIN) ACARBOSE 
 MIGLITOL 
 VOGLIBOSE 
Biguanides (BIGU) METFORMIN 
Dipeptidyl peptidase-4 (DPP4) LINAGLIPTIN 
 SAXAGLIPTIN 
 SITAGLIPTIN 
 VALDIGLIPTIN 
Dopamine receptor agonist (DRAG) BROMOCRIPTINE 
Glucagon-like peptide-1 (GLP1) EXENATIDE 
 LIRAGLUTIDE 
 LIXISENATIDE 
Meglitinides (MEGL) MITIGLINIDE 
 NATEGLINIDE 
 REPAGLINIDE 
Sulfonylureas (SULF) ACETOHEXAMIDE 
 CHLORPROPAMIDE 
 GLIMEPIRIDE 
 GLIPIZIDE 
 GLYBURIDE 
 TOLAZAMIDE 
 TOLBUTAMIDE 
Thiazolidinediones (TZDS) TROGLITAZONE 
 ROSIGLITAZONE 
 PIOGLITAZONE 
 NETOGLITAZONE 
 
 
 
		
122 
Table A4. Sample characteristics at baseline: Pharmacist 
 
MD only PD/MD PD only 
N 45,624 (93) 3,146 (6) 79 (0) 
Age (SD) 61.6 (10.4) 59.5 (10.1) 62.2 (10.7) 
Sex (%) 
   
Male 43,798 (96) 3,005 (96) 75 (95) 
Female 1,826 (4) 141 (4) 4 (5) 
Race (%) 
   
White 31,296 (69) 1,980 (63) 53 (67) 
Black 7,769 (17) 687 (22) 15 (19) 
Hispanic 2,547 (6) 187 (6) 4 (5) 
Other 1,411 (3) 88 (3) 2 (3) 
Unknown or missing 2,601 (6) 204 (6) 5 (6) 
Marital status (%) 
   
Married 27,533 (60) 1,786 (57) 51 (65) 
Unmarried 18,091 (40) 1,360 (43) 28 (35) 
Income (SD) 44,423 (75,881) 41,490 (68,702) 41,419 (50,816) 
Insulin Use (%) 5,916 (13) 855 (27) 19 (24) 
Inpatient OAD (%) 4,344 (10) 400 (13) 5 (6) 
Comorbidities (%) 
   
Hypertension 22,751 (50) 1,459 (46) 43 (54) 
Hyperlipidemia 20,053 (44) 1,226 (39) 49 (62) 
Cardiovascular 7,384 (16) 466 (15) 15 (19) 
Heart disease 5,757 (13) 358 (11) 9 (11) 
Sexual impotence 2,471 (5) 150 (5) 4 (5) 
Neuropathy  2,422 (5) 137 (4) 2 (3) 
Peripheral neuropathies 1,768 (4) 102 (3) 2 (3) 
Cerebrovascular  1,072 (2) 65 (2) 1 (1) 
Nephropathy-1 1,129 (2) 58 (2) 2 (3) 
Peripheral vascular disease 986 (2) 58 (2) 3 (4) 
Congestive heart failure 899 (2) 60 (2) 2 (3) 
Cerebrovascular disease 935 (2) 57 (2) 1 (1) 
Chronic renal disease 934 (2) 47 (1) 1 (1) 
Retinopathy 778 (2) 53 (2) 0 (0) 
Cellulitis and abscess 544 (1) 40 (1) 0 (0) 
Nephropathy-3 573 (1) 41 (1) 2 (3) 
Myocardial infarction 399 (1) 36 (1) 3 (4) 
Other selected infections 283 (1) 13 (0) 0 (0) 
Diabetic eye disease 258 (1) 25 (1) 0 (0) 
Gangrene & lower limb ulcer 160 (0) 12 (0) 0 (0) 
Nephropathy-2 86 (0) 1 (0) 0 (0) 
Hypoglycemia (new def) 34 (0) 3 (0) 0 (0) 
Cardiac surgery 24 (0) 3 (0) 0 (0) 
Hypoglycemia 24 (0) 1 (0) 0 (0) 
Metabolic 6 (0) 0 (0) 0 (0) 
Other metabolic complications 6 (0) 0 (0) 0 (0) 
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Table A5. Prescribing pattern of all outpatient oral antidiabetic drug prescriptions during a two-
year follow-up by prescribing model: Pharmacist 
 
MD only PD/MD PD 
N† (%) 401,237 (91) 37,524 (9) 406 (0) 
Total OAD scripts (SD) 8.8 (5.0) 11.9 (6.0) 5.1 (3.6) 
Unique prescribers (SD) 1.5 (0.8) 2.9 (1.1) 1.2 (0.5) 
Unique classes (SD) 1.6 (0.9) 2.2 (1.2) 1.4 (0.8) 
Unique agents (SD) 1.6 (1.0) 2.2 (1.3) 1.4 (0.8) 
Class‡ (%) 
   
BIGU 244,526 (61) 19,142 (51) 248 (61) 
SULF 107,165 (27) 11,940 (32) 115 (28) 
BIGU/SULF 32,754 (8) 3,740 (10) 22 (5) 
TZDS 9,620 (2) 1,342 (4) 5 (1) 
AGIN 2,010 (1) 241 (1) 1 (0) 
DPP4 1,384 (0) 397 (1) 7 (2) 
SULF/TZDS 833 (0) 154 (0) 0 (0) 
BIGU/TZDS 749 (0) 133 (0) 3 (1) 
BIGU/SULF/TZDS 579 (0) 81 (0) 5 (1) 
GLP1 285 (0) 89 (0) 0 (0) 
Agent‡ (%) 
   
METF 244,526 (61) 19,142 (51) 248 (61) 
GLIP 83,227 (21) 9,405 (25) 100 (25) 
GLIP/METF 24,505 (6) 2,799 (7) 21 (5) 
GLYB 22,755 (6) 24,99 (7) 15 (4) 
PIOG 9,565 (2) 1,340 (4) 5 (1) 
GLYB/METF 8,032 (2) 937 (2) 1 (0) 
ACAR 2,007 (1) 228 (1) 1 (0) 
SITA 1,365 (0) 396 (1) 7 (2) 
GLIM 1,100 (0) 36 (0) 0 (0) 
METF/PIOG 745 (0) 132 (0) 3 (1) 
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APPENDIX B 
Table B1. Comparison of baseline characteristics between the sample and the excluded 
 NP PA 
 Overall Excluded Overall Excluded 
N 42,837 12,727 25,024 7,607 
Have both baseline and follow-up 
(%) 
    
HbA1c 36,926 (86) 0 (0) 21,451 (86) 0 (0) 
Glucose 36,640 (86) 0 (0) 20,332 (81) 0 (0) 
LDL 33,732 (79) 0 (0) 19,570 (78) 0 (0) 
Creatinine 37,447 (87) 0 (0) 21,511 (86) 0 (0) 
Age (SD) 61.2 (10.0) 62.1 (11.6) 61.2 (10.0) 61.9 (11.7) 
Sex (%)     
Male 40,911 (96) 12,168 (96) 23,997 (96) 7,314 (96) 
Female 1,926 (4) 559 (4) 1,027 (4) 293 (4) 
Race (%)     
White 30,179 (70) 8,738 (69) 17,507 (70) 5,228 (69) 
Black 7,555 (18) 2,240 (18) 4,539 (18) 1,318 (17) 
Hispanic 1,600 (4) 498 (4) 925 (4) 301 (4) 
Other 1,228 (3) 427 (3) 703 (3) 262 (3) 
Unknown 2,275 (5) 824 (6) 1,350 (5) 498 (7) 
Marital Status (%)     
Married 25,249 (59) 7,816 (61) 14,776 (59) 4,629 (61) 
Unmarried 17,588 (41) 4,911 (39) 10,248 (41) 2,978 (39) 
Income (SD) 42,926 (74,025) 
49,539 
(83,351) 
42,453 
(72,165) 
50,218 
(83,706) 
Insulin Use (%) 6,196 (14) 1,628 (13) 3,524 (14) 942 (12) 
Inpatient OAD (%) 5,092 (12) 864 (7) 2,933 (12) 528 (7) 
Baseline lab measures (%)     
HbA1c     
< 6.5% 7,051 (61)  4,246 (17)  
6.5% - 8.0% 20,564 (48)  11,909 (48)  
> 8.0% 9,311 (22)  5,296 (21)  
Glucose     
> 140 mg/dL 19,525 (46)  11,339 (45)  
LDL     
> 100 mg/dL 16,428 (38)  9,512 (38)  
Creatinine     
> 1.5 mg/dL 1,671 (4)  995 (4)  
Comorbidities (%)     
Hypertension 23,169 (54) 4,345 (34) 13,454 (54) 2,575 (34) 
Hyperlipidemia 20,432 (48) 3,465 (27) 11,968 (48) 2,098 (28) 
		
125 
Heart disease 5,859 (14) 1,075 (8) 3,510 (14) 644 (8) 
Sexual impotence 2,613 (6) 379 (3) 1,540 (6) 228 (3) 
Peripheral neuropathies 1,850 (4) 237 (2) 1,110 (4) 141 (2) 
Congestive heart failure 1,011 (2) 140 (1) 581 (2) 81 (1) 
Peripheral vascular disease 1,010 (2) 149 (1) 646 (3) 63 (1) 
Cerebrovascular disease 985 (2) 184 (1) 573 (2) 95 (1) 
Chronic renal disease 943 (2) 146 (1) 575 (2) 88 (1) 
Cellulitis and abscess 628 (1) 82 (1) 347 (1) 49 (1) 
Myocardial infarction 457 (1) 71 (1) 260 (1) 36 (0) 
Other selected infections 348 (1) 34 (0) 189 (1) 16 (0) 
Diabetic eye disease 236 (1) 51 (0) 159 (1) 34 (0) 
Gangrene & lower limb ulcer 176 (0) 24 (0) 92 (0) 15 (0) 
Hypoglycemia, new definition 31 (0) 10 (0) 22 (0) 8 (0) 
Cardiac surgery 30 (0) 1 (0) 9 (0) 0 (0) 
Hypoglycemia 26 (0) 2 (0) 18 (0) 1 (0) 
Other metabolic complications 5 (0) 2 (0) 1 (0) 1 (0) 
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Table B2. Outcomes and baseline characteristics by quintiles of Professional Practice Index: 
Nurse practitioner 
 Q1 Q2 Q3 Q4 Q5 
 (43.0-60.0) (61.0-65.0) (66.0-72.0) (73.0-84.0) (86.0-92.0) 
N (%) 11,316 (20) 12,003 (22) 8,571 (15) 13,202 (24) 10,472 (19) 
Have both baseline and follow-up 
(%) 
     
HbA1c 7,564 (67) 7,555 (63) 6,084 (71) 8,837 (67) 6,886 (66) 
Glucose 7,895 (70) 8,218 (68) 6,316 (74) 8,577 (65) 6,441 (62) 
LDL 7,103 (63) 7,536 (63) 5,323 (62) 7,775 (59) 5,995 (57) 
Creatinine 7,477 (66) 7,772 (65) 5,855 (68) 8,979 (68) 6,557 (63) 
Mean Change in measures (SD)      
HbA1c -0.52 (1.82) -0.49 (1.8) -0.46 (1.68) -0.52 (1.88) -0.59 (1.85) 
Glucose -23.80 (80.18) 
-23.80 
(76.24) 
-21.44 
(72.24) 
-22.93 
(80.77) 
-26.19 
(79.46) 
LDL -11.19 (36.32) 
-13.50 
(37.12) 
-14.12 
(35.92) 
-14.27 
(35.77) 
-12.01 
(35.75) 
Creatinine 0.01 (0.24) 0.00 (0.33) 0.01 (0.24) 0.03 (0.22) 0.01 (0.25) 
Age (SD) 60.7 (10.5) 60.9 (10.4) 62.0 (10.5) 61.8 (10.5) 61.7 (10.2) 
Sex (%)      
Male 10,783 (95) 11,416 (95) 8,202 (96) 12,681 (96) 9,997 (95) 
Female 533 (5) 587 (5) 369 (4) 521 (4) 475 (5) 
Race (%)      
White 7,225 (64) 7,565 (63) 6,970 (81) 9,177 (70) 7,980 (76) 
Black 3,190 (28) 2,374 (20) 1,045 (12) 2,109 (16) 1,077 (10) 
Hispanic 146 (1) 850 (7) 100 (1) 559 (4) 443 (4) 
Other 221 (2) 402 (3) 176 (2) 541 (4) 315 (3) 
Unknown 534 (5) 812 (7) 280 (3) 816 (6) 657 (6) 
Marital Status (%)      
Married 6,925 (61) 7,145 (60) 5,357 (63) 7,502 (57) 6,136 (59) 
Unmarried 4,391 (39) 4,858 (40) 3,214 (37) 5,700 (43) 4,336 (41) 
Income (SD) 41,650 (67,200) 
41,038 
(73,471) 
46,342 
(77,995) 
46,308 
(78,660) 
47,331 
(83,623) 
Insulin Use (%) 1,752 (15) 1,465 (12) 1,221 (14) 1,960 (15) 1,426 (14) 
Inpatient OAD (%) 1,180 (10) 1,265 (11) 1,028 (12) 1,454 (11) 1,029 (10) 
Comorbidities (%)      
Hypertension 5,637 (50) 6,129 (51) 4,366 (51) 6,446 (49) 4,936 (47) 
Hyperlipidemia 4,827 (43) 5,297 (44) 4,024 (47) 5,631 (43) 4,118 (39) 
Heart disease 1,410 (12) 1,460 (12) 1,240 (14) 1,682 (13) 1,142 (11) 
Sexual impotence 719 (6) 675 (6) 440 (5) 734 (6) 424 (4) 
Peripheral neuropathies 428 (4) 459 (4) 366 (4) 487 (4) 347 (3) 
Cerebrovascular disease 251 (2) 284 (2) 163 (2) 282 (2) 189 (2) 
Peripheral vascular disease 240 (2) 248 (2) 212 (2) 271 (2) 188 (2) 
Congestive heart failure 224 (2) 258 (2) 218 (3) 266 (2) 185 (2) 
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Chronic renal disease 255 (2) 238 (2) 172 (2) 244 (2) 180 (2) 
Cellulitis and abscess 113 (1) 184 (2) 121 (1) 163 (1) 129 (1) 
Myocardial infarction 109 (1) 93 (1) 89 (1) 148 (1) 89 (1) 
Other selected infections 52 (0) 80 (1) 77 (1) 97 (1) 76 (1) 
Diabetic eye disease 45 (0) 55 (0) 42 (0) 100 (1) 45 (0) 
Gangrene & lower limb ulcer 34 (0) 31 (0) 39 (0) 55 (0) 41 (0) 
Hypoglycemia, new definition 8 (0) 12 (0) 5 (0) 8 (0) 8 (0) 
Cardiac surgery 7 (0) 2 (0) 12 (0) 7 (0) 3 (0) 
Hypoglycemia 8 (0) 11 (0) 2 (0) 7 (0) 0 (0) 
Other metabolic complications 2 (0) 3 (0) 1 (0) 0 (0) 1 (0) 	 	
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Table B3. Outcomes and baseline characteristics by quintiles of Professional Practice Index: 
Physician assistant 
 Q1 Q2 Q3 Q4 Q5 
 (36.5-54.0) (61.0-67.0) (69.0-79.0) (81.0-84.0) (85.0-94.0) 
N (%) 4,720 (14) 8,848 (27) 6,223 (19) 6,804 (21) 6,036 (18) 
Have both baseline and follow-up 
(%) 
     
HbA1c 3,202 (68) 5,636 (64) 3,960 (64) 4,720 (69) 3,933 (65) 
Glucose 3,389 (72) 5,915 (67) 4,032 (65) 4,329 (64) 3,846 (64) 
LDL 2,949 (62) 5,823 (66) 3,393 (55) 4,193 (62) 3,212 (53) 
Creatinine 3,287 (70) 5,536 (63) 3,525 (57) 4,654 (68) 3,330 (55) 
Mean Change in measures (SD)      
HbA1c -0.54 (1.89) -0.49 (1.83) -0.43 (1.81) -0.53 (1.80) -0.52 (1.77) 
Glucose -24.52 (80.92) -23.77 (76.53) -24.55 (76.69) -23.78 (77.36) -24.05 (77.52) 
LDL -13.90 (35.86) -12.23 (36.78) -13.73 (36.92) -12.72 (35.19) -13.14 (37.63) 
Creatinine 0.03 (0.23) 0.00 (0.39) 0.02 (0.23) 0.00 (0.25) 0.00 (0.23) 
Age (SD) 61.0 (10.3) 60.5 (10.4) 61.7 (10.7) 62.3 (10.4) 61.4 (10.2) 
Sex (%)      
Male 4,517 (96) 8,422 (95) 5,979 (96) 6,579 (97) 5,814 (96) 
Female 203 (4) 426 (5) 244 (4) 225 (3) 222 (4) 
Race (%)      
White 3,112 (66) 5,606 (63) 4,497 (72) 5,030 (74) 4,490 (74) 
Black 1,296 (27) 1,747 (20) 1,029 (17) 675 (10) 1,110 (18) 
Hispanic 30 (1) 661 (7) 74 (1) 397 (6) 64 (1) 
Other 52 (1) 234 (3) 310 (5) 258 (4) 111 (2) 
Unknown 230 (5) 600 (7) 313 (5) 444 (7) 261 (4) 
Marital Status (%)      
Married 2,769 (59) 5,147 (58) 3,907 (63) 3,914 (58) 3,668 (61) 
Unmarried 1,951 (41) 3,701 (42) 2,316 (37) 2,890 (42) 2,368 (39) 
Income (SD) 43,114 (67,569) 
41,523 
(70,747) 
43,171 
(69,745) 
47,066 
(80,808) 
47,039 
(84,536) 
Insulin Use (%) 675 (14) 1,137 (13) 843 (14) 858 (13) 953 (16) 
Inpatient OAD (%) 542 (11) 899 (10) 648 (10) 711 (10) 661 (11) 
Comorbidities (%)      
Hypertension 2,452 (52) 4,352 (49) 2,947 (47) 3,366 (49) 2,912 (48) 
Hyperlipidemia 2,049 (43) 3,877 (44) 2,608 (42) 3,047 (45) 2,485 (41) 
Heart disease 691 (15) 1,055 (12) 824 (13) 820 (12) 764 (13) 
Sexual impotence 352 (7) 461 (5) 322 (5) 324 (5) 309 (5) 
Peripheral neuropathies 197 (4) 334 (4) 198 (3) 275 (4) 247 (4) 
Cerebrovascular disease 101 (2) 185 (2) 124 (2) 131 (2) 127 (2) 
Peripheral vascular disease 113 (2) 180 (2) 125 (2) 152 (2) 139 (2) 
Congestive heart failure 122 (3) 178 (2) 112 (2) 110 (2) 140 (2) 
Chronic renal disease 87 (2) 176 (2) 114 (2) 159 (2) 127 (2) 
Cellulitis and abscess 54 (1) 136 (2) 56 (1) 86 (1) 64 (1) 
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Myocardial infarction 42 (1) 80 (1) 53 (1) 67 (1) 54 (1) 
Other selected infections 23 (0) 65 (1) 34 (1) 53 (1) 30 (0) 
Diabetic eye disease 40 (0) 33 (0) 39 (1) 49 (1) 32 (1) 
Gangrene & lower limb ulcer 18 (0) 33 (0) 16 (0) 24 (0) 16 (0) 
Hypoglycemia, new definition 4 (0) 9 (0) 6 (0) 8 (0) 3 (0) 
Cardiac surgery 0 (0) 0 (0) 5 (0) 2 (0) 2 (0) 
Hypoglycemia 7 (0) 5 (0) 4 (0) 2 (0) 1 (0) 
Other metabolic complications 1 (0) 0 (0) 0 (0) 0 (0) 1 (0) 
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Figure B1. Treatment assignment by quintiles of PPI: Nurse practitioner 
 
Figure B2. Treatment assignment by quintiles of PPI: Physician assistant
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APPENDIX C 
Table C1. Comparison of characteristics between the study sample and the excluded 
 
NP PA  
Overall Excluded† Overall Excluded† 
N (%) 41,946 891 24,518 506 
Outpatient cost (SD) 5,994 (6,006) 29,264 (48,629) 5,894 (5,922) 29,961 (58,184) 
Inpatient Cost 
    
 n > $0 (%) 6,574 (16) 297 (33) 3,763 (15) 171 (34) 
Mean (SD) 17,048 (47,766) 39,614 (102,054) 17,585 (47,074) 43,184 (122,511) 
Age (SD) 61.2 (10.0) 60.1 (10.7) 61.2 (9.9) 59.4 (10.5) 
Sex (%) 
    
Male 40,071 (96) 840 (94) 23,515 (96) 482 (95) 
Female 1875 (4) 51 (6) 1003 (4) 24 (5) 
Race (%) 
    
White 29,595 (71) 584 (65) 1,7201 (70) 306 (60) 
Black 7,377 (18) 178 (20) 4,429 (18) 110 (22) 
Hispanic 1,555 (4) 45 (5) 896 (4) 29 (6) 
Other 1,202 (3) 26 (3) 681 (3) 22 (4) 
Unknown 2,217 (4) 58 (7) 1,311 (5) 39 (8) 
Marital Status (%) 
    
Married 24,772 (59) 477 (53) 14,502 (59) 274 (54) 
Unmarried 17,174 (41) 414 (47) 10,016 (41) 232 (46) 
Income (SD) 43,080 (74,242) 35,644 (62,490) 42,594 (72,431) 35,434 (57,035) 
Priority Status (%) 
    
1 9,047 (21) 154 (17) 5,329 (21) 91 (18) 
2 3412 (8) 79 (9) 2,007 (8) 42 (8) 
3 5,730 (14) 130 (15) 3,400 (14) 72 (14) 
4 895 (2) 50 (6) 515 (2) 22 (4) 
5 13,579 (32) 300 (34) 7,787 (32) 170 (34) 
6 2002 (5) 28 (3) 1,181 (5) 22 (4) 
7 1614 (4) 27 (3) 992 (4) 18 (4) 
8 5,362 (13) 110 (12) 3,152 (13) 59 (12) 
9 305 (1) 13 (1) 155 (1) 10 (2) 
Medicare Eligibility (%) 26,222 (62) 505 (57) 15264 (62) 284 (56) 
Insulin Use (%) 6,022 (14) 174 (20) 3422 (14) 102 (20) 
VHA utilization 
    
Outpatient visits (SD) 47.9 (39.2) 86.7 (102.3) 47.3 (38.7) 86.6 (103.3) 
Inpatient admissions (SD) 0.3 (1.0) 1.2 (2.5) 0.3 (0.9) 1.3 (2.9) 
Nosos (SD) 1.1 (1.3) 1.9 (2.6) 1.1 (1.3) 1.8 (2.5) 
† Outpatient cost < 1st percentile, > 99th percentile, or 0  
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Table C2. Sample counts after trimming data at the 1st and the 99th percentiles of outpatient cost 
(excluding 0 costs) 
  
Before After < $380 > $38,200 
NP MD only 29,537 28,990 277 270  
NP/MD 7,216 7,057 47 112  
NP/ only 6,033 5,910 79 44   
42,786 41,957 403 426    
-1.9% 
  
PA MD only 20,129 19,767 176 186  
PA/MD 2,775 2,707 22 46  
PA only 2,084 2,053 22 9   
24,988 24,527 220 241    
-1.8% 
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Table C3. Full regression results: Nurse Practitioner 
 NP/MD Team v. MD only† NP/MD Team v. NP only† NP only v. MD only† 
 (1) (2) (3) (1) (2) (3) (1) (2) (3) 
 2SLS LOG 2SLS GLM 2SLS LOG 2SLS GLM 2SLS LOG 2SLS GLM 
 b/se b/se b/se b/se b/se b/se b/se b/se b/se 
Prescribing model 505.953 0.044 0.040 168.639 0.095 0.015 80.020 0.006 0.034 
 (598.007) (0.112) (0.105) (877.646) (0.208) (0.191) (409.698) (0.085) (0.082) 
Age (centered at 65) 1.588 0.002*** 0.001** -0.617 0.001 0.000 -1.046 0.001** 0.001 
 (3.645) (0.000) (0.001) (6.927) (0.001) (0.001) (3.400) (0.000) (0.001) 
Female 149.268 -0.016 -0.025 119.605 -0.012 -0.036 200.486 -0.004 -0.013 
 (137.017) (0.016) (0.017) (225.606) (0.029) (0.033) (139.080) (0.017) (0.020) 
Race_Black -85.422 -0.005 -0.009 138.139 0.015 0.011 -9.243 0.005 0.003 
 (89.490) (0.013) (0.014) (145.855) (0.018) (0.019) (93.469) (0.013) (0.014) 
Race_Hispanic -416.096** -0.113*** -0.084** -277.830 -0.068 -0.062 -317.878 -0.095** -0.062* 
 (204.180) (0.040) (0.034) (275.796) (0.044) (0.043) (201.128) (0.040) (0.034) 
Race_Other 116.537 0.011 0.014 -24.858 -0.017 -0.038 250.719* 0.023 0.032 
 (147.046) (0.021) (0.024) (230.277) (0.031) (0.032) (151.511) (0.023) (0.025) 
Race_unknown -199.519** -0.043** -0.038* -203.679* -0.061*** -0.080*** -144.436 -0.034* -0.028 
 (94.722) (0.018) (0.022) (116.796) (0.022) (0.023) (100.314) (0.019) (0.022) 
Unmarried -122.178** -0.012* -0.013 -51.414 0.001 0.013 -98.531** -0.010 -0.008 
 (50.015) (0.007) (0.008) (82.001) (0.011) (0.012) (49.955) (0.007) (0.008) 
10K<=Income<=30K 42.251 0.009 0.015 132.421 0.008 0.009 -53.135 0.002 0.005 
 (78.166) (0.011) (0.012) (138.124) (0.016) (0.017) (76.127) (0.010) (0.012) 
Income>30K 3.395 -0.003 -0.004 238.595* 0.016 0.015 -42.678 -0.002 -0.002 
 (73.522) (0.010) (0.011) (129.906) (0.015) (0.016) (65.891) (0.010) (0.011) 
Income unknown 160.152* 0.007 0.008 586.333*** 0.052*** 0.044** 86.337 0.001 0.002 
 (85.741) (0.011) (0.013) (145.413) (0.017) (0.020) (75.434) (0.011) (0.013) 
Priority status 1 488.141*** 0.115*** 0.094*** 616.567*** 0.130*** 0.110*** 495.144*** 0.113*** 0.093*** 
 (85.832) (0.012) (0.013) (144.648) (0.018) (0.018) (85.169) (0.012) (0.013) 
Priority status 2 -112.172 -0.012 -0.031** 37.045 0.019 -0.002 -174.037** -0.015 -0.033** 
 (88.211) (0.014) (0.014) (135.539) (0.021) (0.021) (85.721) (0.013) (0.014) 
Priority status 3 117.797 -0.009 -0.007 22.433 -0.020 -0.016 102.699 -0.003 -0.005 
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 (72.752) (0.011) (0.013) (121.512) (0.017) (0.021) (69.470) (0.011) (0.012) 
Priority status 4 510.382** 0.040 0.060** 544.120 0.015 0.029 638.144*** 0.068** 0.082*** 
 (243.166) (0.026) (0.028) (397.504) (0.041) (0.038) (237.426) (0.026) (0.029) 
Priority status 6 272.822** 0.027* 0.028 152.421 0.019 0.025 209.423* 0.026 0.032* 
 (107.806) (0.016) (0.019) (173.144) (0.026) (0.030) (107.042) (0.016) (0.019) 
Priority status 7 281.750** 0.033 0.055** 334.925 0.049 0.065** 194.950 0.026 0.043* 
 (134.305) (0.022) (0.024) (204.446) (0.033) (0.033) (119.365) (0.021) (0.022) 
Priority status 8 77.297 -0.076*** -0.059*** 90.361 -0.056** -0.028 126.915* -0.054*** -0.036** 
 (81.204) (0.014) (0.015) (138.552) (0.023) (0.022) (74.005) (0.012) (0.014) 
Priority status 9 -378.277 0.027 0.013 -856.069** -0.051 0.083 -382.367 0.024 0.042 
 (260.776) (0.038) (0.040) (407.694) (0.064) (0.098) (282.087) (0.045) (0.056) 
Medicare beneficiary 311.166*** 0.041*** 0.039*** 370.459*** 0.045*** 0.053*** 353.117*** 0.042*** 0.048*** 
 (66.686) (0.008) (0.009) (110.500) (0.013) (0.016) (67.406) (0.009) (0.010) 
log(OP visits) 4862.187*** 0.935*** 0.899*** 5075.494*** 0.946*** 0.909*** 4689.926*** 0.932*** 0.898*** 
 (87.044) (0.010) (0.011) (134.590) (0.019) (0.021) (79.105) (0.009) (0.010) 
IP admission=1 1654.179*** 0.185*** 0.222*** 1653.817*** 0.179*** 0.229*** 1630.543*** 0.178*** 0.218*** 
 (104.002) (0.012) (0.013) (176.653) (0.020) (0.021) (115.198) (0.013) (0.014) 
IP admission>=2 3564.669*** 0.190*** 0.219*** 3314.389*** 0.164*** 0.196*** 3585.103*** 0.182*** 0.214*** 
 (184.283) (0.018) (0.017) (279.100) (0.034) (0.032) (190.405) (0.018) (0.017) 
Insulin use 449.108*** 0.088*** 0.072*** 502.821*** 0.102*** 0.092*** 511.512*** 0.097*** 0.080*** 
 (93.429) (0.011) (0.012) (127.533) (0.016) (0.015) (95.295) (0.011) (0.012) 
log(Nosos) 500.132*** 0.022** 0.057*** 483.889*** 0.002 0.045*** 628.306*** 0.043*** 0.078*** 
 (75.316) (0.010) (0.010) (103.298) (0.012) (0.014) (73.438) (0.009) (0.010) 
Constant -12337.692*** 4.828*** 5.131*** -13500.745*** 4.701*** 5.035*** -11637.242*** 4.840*** 5.124*** 
 (297.884) (0.041) (0.042) (450.708) (0.077) (0.067) (286.152) (0.041) (0.042)           
N 36,037 36,037 36,037 12,965 12,965 12,965 34,890 34,890 34,890 
F statistic          
R-squared 0.499 0.616  0.510 0.618  0.496 0.608  
Deviance   11927.972   4205.186   11640.274 
Deviance/df   0.331   0.325   0.334 
*** <0.01, ** <0.05, * <0.1 
† Reference group 	  
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Table C4. Full regression results: Physician assistant 
 PA/MD Team v. MD only† PA/MD Team v. PA only† PA only v. MD only† 
 (1) (2) (3) (1) (2) (3) (1) (2) (3) 
 2SLS LOG 2SLS GLM 2SLS LOG 2SLS GLM 2SLS LOG 2SLS GLM 
 b/se b/se b/se b/se b/se b/se b/se b/se b/se 
Prescribing model -1831.246 -0.296 -0.304* 437.699 0.188 0.151 -1236.692* -0.230 -0.245* 
 (1153.793) (0.187) (0.176) (1034.049) (0.186) (0.175) (732.239) (0.141) (0.135) 
Age (centered at 65) -1.059 0.002*** 0.001** -6.724 0.001 0.000 -2.166 0.001** 0.001 
 (4.104) (0.001) (0.001) (8.557) (0.001) (0.001) (4.001) (0.001) (0.001) 
Female 322.833* 0.018 0.003 253.824 -0.006 -0.005 367.479** 0.018 0.015 
 (168.740) (0.021) (0.022) (517.449) (0.065) (0.079) (174.002) (0.023) (0.025) 
Race_Black -99.042 -0.012 -0.018 93.470 -0.003 -0.016 -87.853 -0.008 -0.018 
 (106.129) (0.016) (0.018) (206.704) (0.030) (0.029) (119.704) (0.018) (0.018) 
Race_Hispanic -249.130 -0.114** -0.079 92.442 -0.042 -0.018 -270.566 -0.118** -0.091* 
 (286.263) (0.055) (0.050) (507.596) (0.056) (0.072) (286.504) (0.056) (0.047) 
Race_Other -7.136 -0.007 0.010 -342.683 -0.034 -0.044 -21.114 -0.015 0.003 
 (189.931) (0.027) (0.032) (366.770) (0.055) (0.052) (175.621) (0.023) (0.030) 
Race_unknown -303.470** -0.064*** -0.063*** -271.405 -0.074** -0.069* -196.892 -0.051** -0.049** 
 (120.833) (0.024) (0.023) (240.851) (0.035) (0.040) (126.880) (0.025) (0.025) 
Unmarried -61.736 -0.005 -0.007 118.426 0.002 0.015 -71.354 -0.008 -0.011 
 (68.007) (0.010) (0.010) (124.742) (0.017) (0.020) (65.787) (0.009) (0.010) 
10K<=Income<=30K -78.621 -0.007 -0.007 -135.597 0.009 -0.001 14.555 0.009 0.008 
 (102.895) (0.014) (0.015) (196.433) (0.033) (0.035) (95.919) (0.013) (0.015) 
Income>30K -133.443 -0.011 -0.016 139.845 0.022 0.026 -98.498 -0.004 -0.007 
 (91.391) (0.014) (0.015) (180.503) (0.028) (0.031) (86.533) (0.013) (0.015) 
Income unknown 102.441 0.003 0.008 394.543 0.045 0.072** 107.494 0.015 0.018 
 (114.660) (0.014) (0.017) (244.700) (0.032) (0.036) (107.860) (0.014) (0.018) 
Priority status 1 332.096*** 0.099*** 0.072*** 336.781 0.125*** 0.100*** 450.163*** 0.111*** 0.084*** 
 (112.415) (0.017) (0.017) (233.714) (0.028) (0.033) (102.807) (0.016) (0.016) 
Priority status 2 -117.834 -0.004 -0.022 384.133 0.087** 0.078 -53.578 0.007 -0.012 
 (113.485) (0.018) (0.019) (258.135) (0.041) (0.049) (112.855) (0.018) (0.019) 
Priority status 3 85.895 0.008 0.007 -182.888 -0.006 -0.028 164.134* 0.019 0.017 
		
136 
 (96.221) (0.015) (0.016) (200.160) (0.030) (0.034) (95.425) (0.016) (0.017) 
Priority status 4 789.788** 0.088** 0.122*** 518.962 0.087 0.092 795.035*** 0.097*** 0.124*** 
 (328.764) (0.037) (0.042) (524.870) (0.064) (0.066) (308.219) (0.035) (0.043) 
Priority status 6 322.535** 0.028 0.036 303.250 0.014 0.002 359.848** 0.030 0.038 
 (138.527) (0.019) (0.025) (257.139) (0.041) (0.043) (140.348) (0.022) (0.027) 
Priority status 7 136.154 0.013 0.024 -116.854 -0.038 -0.007 190.527 0.007 0.013 
 (140.826) (0.024) (0.026) (273.536) (0.046) (0.058) (142.789) (0.026) (0.027) 
Priority status 8 74.214 -0.061*** -0.053*** 96.227 -0.031 -0.030 187.725* -0.048*** -0.040** 
 (99.069) (0.016) (0.019) (161.175) (0.030) (0.031) (100.574) (0.017) (0.019) 
Priority status 9 -561.015* 0.003 -0.029 -421.211 -0.068 -0.076 -601.825* -0.012 -0.048 
 (316.689) (0.051) (0.046) (653.875) (0.104) (0.119) (307.380) (0.050) (0.049) 
Medicare beneficiary 359.823*** 0.039*** 0.039*** 377.828** 0.050** 0.051** 429.096*** 0.046*** 0.045*** 
 (72.128) (0.010) (0.011) (159.839) (0.023) (0.025) (68.971) (0.010) (0.011) 
log(OP visits) 4791.298*** 0.934*** 0.903*** 4563.622*** 0.908*** 0.881*** 4608.259*** 0.920*** 0.891*** 
 (98.267) (0.012) (0.013) (173.353) (0.026) (0.023) (94.202) (0.012) (0.012) 
IP admission=1 1711.883*** 0.193*** 0.222*** 1567.606*** 0.192*** 0.230*** 1680.311*** 0.180*** 0.206*** 
 (137.750) (0.018) (0.018) (285.781) (0.032) (0.036) (141.884) (0.017) (0.018) 
IP admission>=2 3558.131*** 0.180*** 0.216*** 2494.224*** 0.083* 0.128*** 3775.862*** 0.189*** 0.221*** 
 (231.020) (0.024) (0.022) (387.491) (0.046) (0.044) (246.253) (0.024) (0.022) 
Insulin use 479.218*** 0.088*** 0.078*** -4.820 0.060** 0.027 471.618*** 0.089*** 0.077*** 
 (121.294) (0.014) (0.016) (218.533) (0.027) (0.031) (116.527) (0.013) (0.016) 
log(Nosos) 643.086*** 0.043*** 0.080*** 573.188*** 0.014 0.056*** 700.727*** 0.058*** 0.092*** 
 (90.519) (0.011) (0.011) (165.902) (0.019) (0.019) (90.236) (0.011) (0.012) 
Constant -11686.957*** 4.887*** 5.174*** -11697.811*** 4.759*** 5.046*** -11265.784*** 4.907*** 5.192*** 
 (343.554) (0.050) (0.049) (532.689) (0.082) (0.085) (349.846) (0.055) (0.054)           
N 22,466 22,466 22,466 4,758 4,758 4,758 21,812 21,812 21,812 
F statistic          
R-squared 0.490 0.604  0.497 0.604  0.498 0.608  
Deviance   7391.243   1539.444   7202.789 
Deviance/df   0.329   0.325   0.331 
*** <0.01, ** <0.05, * <0.1 
† Reference group 	  
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Table C5. Mean predictive ratios by deciles of predicted outpatient cost 
 
Decile 1 Decile 2 Decile 3 Decile 4 Decile 5 Decile 6 Decile 7 Decile 8 Decile 9 Decile 10 
2SLS 
          
NP/MD v. MD -0.75 1.19 1.59 1.71 1.76 1.67 1.59 1.52 1.40 1.25 
NP/MD v. NP -0.72 1.25 1.53 1.69 1.67 1.65 1.53 1.46 1.31 1.33 
NP v. MD -0.67 1.19 1.61 1.69 1.70 1.70 1.55 1.54 1.39 1.34 
PA/MD v. MD -0.67 1.14 1.62 1.77 1.71 1.58 1.68 1.45 1.28 1.24 
PA/MD v. PA -0.30 1.36 1.58 1.70 1.83 1.58 1.27 1.50 1.19 1.56 
PA v. MD -0.86 1.08 1.61 1.68 1.78 1.75 1.62 1.50 1.34 1.23 
LOG 2SLS 
          
NP/MD v. MD 1.34 1.49 1.48 1.46 1.39 1.38 1.32 1.34 1.29 1.51 
NP/MD v. NP 1.39 1.52 1.54 1.40 1.42 1.35 1.33 1.22 1.29 1.59 
NP v. MD 1.28 1.47 1.49 1.45 1.36 1.36 1.29 1.38 1.34 1.51 
PA/MD v. MD 1.34 1.46 1.51 1.49 1.41 1.31 1.35 1.32 1.27 1.48 
PA/MD v. PA 1.28 1.55 1.54 1.46 1.53 1.33 1.21 1.27 1.32 1.84 
PA v. MD 1.29 1.43 1.52 1.52 1.40 1.38 1.40 1.30 1.32 1.53 
GLM 
          
NP/MD v. MD 1.38 1.53 1.50 1.46 1.41 1.34 1.34 1.34 1.29 1.52 
NP/MD v. NP 1.42 1.61 1.51 1.41 1.39 1.31 1.27 1.27 1.25 1.61 
NP v. MD 1.33 1.51 1.49 1.44 1.38 1.39 1.28 1.38 1.33 1.54 
PA/MD v. MD 1.38 1.48 1.52 1.47 1.36 1.36 1.28 1.30 1.23 1.51 
PA/MD v. PA 1.30 1.58 1.55 1.38 1.54 1.30 1.15 1.21 1.26 1.93 
PA v. MD 1.33 1.44 1.50 1.47 1.41 1.38 1.37 1.29 1.30 1.52 
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Table C6. Mean absolute prediction error by deciles of predicted outpatient cost 
 
Decile 1 Decile 2 Decile 3 Decile 4 Decile 5 Decile 6 Decile 7 Decile 8 Decile 9 Decile 10 
2SLS 
          
NP/MD v. MD 2,087 924 1,321 1,775 2,244 2,495 2,834 3,579 4,677 6,234 
NP/MD v. NP 2,093 1,076 1,221 1,708 2,259 2,601 2,950 3,829 4,984 6,675 
NP v. MD 1,930 893 1,373 1,676 2,125 2,479 2,835 3,630 4,527 5,708 
PA/MD v. MD 1,970 899 1,265 1,849 2,391 2,536 3,055 3,568 4,907 6,488 
PA/MD v. PA 1,794 897 1,202 1,545 2,175 2,754 3,005 3,405 5,254 6,496 
PA v. MD 2,118 1,007 1,218 1,714 2,215 2,493 2,930 3,685 4,384 5,926 
LOG 2SLS 
          
NP/MD v. MD 683 1,005 1,208 1,481 1,942 2,128 2,492 3,238 4,398 7,335 
NP/MD v. NP 778 1,061 1,184 1,408 1,979 2,203 2,867 3,402 4,810 7,732 
NP v. MD 597 983 1,279 1,452 1,764 2,081 2,548 3,314 4,229 6,807 
PA/MD v. MD 640 986 1,222 1,644 1,973 2,239 2,660 3,439 4,838 7,311 
PA/MD v. PA 752 1,025 1,258 1,338 1,790 2,391 3,233 3,384 4,579 7,455 
PA v. MD 640 998 1,255 1,486 1,862 2,062 2,619 3,397 4,176 7,174 
GLM 
          
NP/MD v. MD 690 1,016 1,228 1,473 1,910 2,127 2,523 3,127 4,512 7,392 
NP/MD v. NP 727 1,117 1,203 1,403 1,957 2,190 2,838 3,469 4,738 7,864 
NP v. MD 598 983 1,315 1,457 1,749 2,042 2,522 3,332 4,327 6,906 
PA/MD v. MD 639 1,007 1,114 1,625 1,899 2,241 2,649 3,452 4,795 7,463 
PA/MD v. PA 723 962 1,155 1,337 1,781 2,556 2,700 3,498 4,536 7,846 
PA v. MD 628 986 1,220 1,502 1,856 2,143 2,437 3,388 4,142 7,157 
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Table C7. Root mean square error by deciles of predicted outpatient cost 
 
Decile 1 Decile 2 Decile 3 Decile 4 Decile 5 Decile 6 Decile 7 Decile 8 Decile 9 Decile 10 
2SLS 
          
NP/MD v. MD 2,637 1,430 1,846 2,308 3,239 3,307 3,622 4,839 6,294 8,067 
NP/MD v. NP 2,756 1,727 1,496 2,196 2,969 3,692 4,007 5,108 6,548 8,462 
NP v. MD 2,384 1,354 2,351 2,297 2,832 3,354 3,743 4,901 5,962 7,435 
PA/MD v. MD 2,383 1,364 1,720 2,345 3,435 3,292 4,142 4,920 6,554 8,278 
PA/MD v. PA 2,230 1,220 1,456 1,766 2,929 3,664 4,134 4,397 6,724 8,237 
PA v. MD 2,590 1,831 1,730 2,370 3,046 3,091 4,057 5,174 6,031 7,705 
LOG 2SLS 
          
NP/MD v. MD 1,017 1,496 1,760 2,166 3,187 3,090 3,585 4,627 6,100 9,845 
NP/MD v. NP 1,524 1,483 1,490 1,909 2,818 3,597 4,357 4,617 6,626 9,527 
NP v. MD 825 1,477 2,429 2,272 2,655 3,171 3,897 4,678 5,667 8,874 
PA/MD v. MD 873 1,359 1,809 2,359 3,247 3,452 3,771 4,977 6,537 9,536 
PA/MD v. PA 1,076 1,292 1,509 1,823 2,612 3,144 4,914 4,328 5,737 9,446 
PA v. MD 973 1,690 1,912 2,200 3,016 2,926 3,948 5,108 5,726 9,567 
GLM 
          
NP/MD v. MD 1,013 1,474 1,773 2,151 3,122 3,180 3,539 4,488 6,229 9,885 
NP/MD v. NP 1,278 1,658 1,536 1,966 2,849 3,566 4,349 4,733 6,517 9,786 
NP v. MD 813 1,418 2,470 2,247 2,622 3,126 3,754 4,689 5,821 9,076 
PA/MD v. MD 836 1,523 1,451 2,467 3,018 3,293 3,943 5,164 6,508 9,826 
PA/MD v. PA 1,009 1,237 1,384 1,595 2,726 3,788 3,999 4,581 5,972 9,586 
PA v. MD 941 1,603 1,935 2,267 3,009 3,278 3,640 5,078 5,812 9,524 
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Table C8. Full logistic regression results to estimate the probability of positive inpatient cost 
 (1) (2) (3) (4) (5) (6) 
 NP/MD v. 
MD 
NP/MD v. 
NP 
NP v. 
MD 
PA/MD v. 
MD 
PA/MD v. 
PA 
PA v. 
MD 
 OR/se OR/se OR/se OR/se OR/se OR/se 
Prescribing model 0.743 1.420 0.631 1.153 0.700 0.949 
 (0.340) (0.894) (0.205) (0.784) (0.525) (0.548) 
Age (centered at 
65) 1.010*** 1.008** 1.011*** 1.009*** 1.018*** 1.009*** 
 (0.003) (0.004) (0.002) (0.003) (0.006) (0.003) 
Female 0.713*** 0.576*** 0.729*** 0.750** 0.844 0.743** 
 (0.065) (0.097) (0.072) (0.088) (0.205) (0.087) 
Race_Black 0.939 0.972 0.976 0.958 0.968 0.987 
 (0.057) (0.089) (0.067) (0.074) (0.128) (0.082) 
Race_Hispanic 1.111 0.900 1.050 1.122 1.223 1.214 
 (0.124) (0.120) (0.121) (0.161) (0.270) (0.164) 
Race_Other 1.073 1.105 0.932 1.248 1.137 1.273 
 (0.128) (0.212) (0.121) (0.213) (0.342) (0.205) 
Race_unknown 0.664*** 0.480*** 0.740** 0.903 1.031 0.823 
 (0.085) (0.096) (0.092) (0.105) (0.217) (0.101) 
Unmarried 1.104*** 1.078 1.088** 1.117** 1.194* 1.123*** 
 (0.042) (0.063) (0.043) (0.055) (0.125) (0.049) 
10K<=Income<=30
K 1.064 1.162 1.055 0.938 0.782* 0.934 
 (0.063) (0.108) (0.066) (0.075) (0.101) (0.079) 
Income>30K 1.042 1.162 1.054 0.979 0.875 0.957 
 (0.055) (0.106) (0.063) (0.072) (0.119) (0.078) 
Income unknown 0.861** 1.023 0.900 0.781*** 0.854 0.820** 
 (0.063) (0.128) (0.068) (0.071) (0.153) (0.077) 
Priority status 1 0.523*** 0.557*** 0.571*** 0.551*** 0.657*** 0.531*** 
 (0.029) (0.057) (0.033) (0.043) (0.088) (0.036) 
Priority status 2 0.754*** 0.726*** 0.743*** 0.741*** 0.475*** 0.692*** 
 (0.052) (0.083) (0.053) (0.065) (0.089) (0.059) 
Priority status 3 0.755*** 0.874 0.771*** 0.740*** 0.998 0.737*** 
 (0.042) (0.088) (0.048) (0.055) (0.174) (0.056) 
Priority status 4 1.077 1.255 0.943 1.044 1.373 0.919 
 (0.113) (0.208) (0.106) (0.122) (0.361) (0.117) 
Priority status 6 0.953 0.956 0.927 0.971 0.835 0.892 
 (0.087) (0.139) (0.096) (0.113) (0.199) (0.116) 
Priority status 7 0.909 0.813 0.897 0.765** 0.646 0.761** 
 (0.091) (0.159) (0.094) (0.092) (0.176) (0.092) 
Priority status 8 1.038 1.205 1.034 0.986 0.951 0.955 
 (0.072) (0.162) (0.077) (0.101) (0.183) (0.097) 
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Priority status 9 1.952* 2.331** 2.373*** 1.221 0.921 1.140 
 (0.674) (0.945) (0.773) (0.441) (0.648) (0.424) 
Medicare 
beneficiary 0.896** 0.850** 0.857*** 0.930 0.787** 0.899* 
 (0.043) (0.070) (0.042) (0.052) (0.087) (0.052) 
log(OP visits) 5.517*** 5.690*** 5.538*** 5.387*** 5.655*** 5.646*** 
 (0.282) (0.494) (0.239) (0.306) (0.703) (0.317) 
Insulin use 3.325*** 2.855*** 3.401*** 3.028*** 3.306*** 3.024*** 
 (0.276) (0.266) (0.288) (0.282) (0.563) (0.289) 
log(Nosos) 1.636*** 1.569*** 1.591*** 1.577*** 1.605*** 1.532*** 
 (0.059) (0.085) (0.060) (0.077) (0.130) (0.082) 
Constant 0.000*** 0.000*** 0.000*** 0.000*** 0.000*** 0.000*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) (0.000)        
N 36037 12965 34890 22466 4758 21812 
LROC 0.8518 0.8550 0.8507 0.8468 0.8561 0.8475 
*** <0.01 ** <0.05 * <0.1 
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Figure C1. Mean predictive ratio by deciles of predicted outpatient cost 
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Figure C2. Mean absolute prediction error by deciles of predicted outpatient cost. 
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Figure C3. Root mean square error by deciles of predicted outpatient cost.
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APPENDIX D 
Definitions of Priority Groups 
 
Priority Group 1 
•Veterans with service-connected disabilities rated by VA as 50% or more disabling. 
•Veterans determined by VA to be unemployable due to service-connected conditions. 
•Veterans who have been awarded the Medal of Honor (MOH). 
 
Priority Group 2 
•Veterans with service-connected disabilities rated by VA as 30% or 40% disabling. 
 
Priority Group 3 
•Veterans who are former Prisoners of War (POWs). 
•Veterans who have been awarded a Purple Heart medal. 
•Veterans whose discharge was for a disability that was incurred or aggravated in the line 
of duty. 
•Veterans with service-connected disabilities rated by VA as 10% or 20% disabling. 
•Veterans who have been awarded special eligibility classification under Title 38, U.S.C., 
§ 1151, "benefits for individuals disabled by treatment or vocational rehabilitation." 
 
Priority Group 4 
•Veterans who receive aid and attendance or housebound benefits from VA. 
•Veterans who have been determined by VA to be catastrophically disabled. 
 
Priority Group 5 
•Veterans with a nonservice-connected or non-compensable service-connected disability 
and Veterans rated by VA as 0% disabled and who have an annual income below the 
VA’s geographically-adjusted income limit (based on your resident ZIP code). 
•Veterans receiving VA pension benefits. 
•Veterans eligible for Medicaid programs. 
 
Priority Group 6 
•Veterans with a compensable 0% service-connected disability. 
•Veterans exposed to ionizing radiation during atmospheric testing or during the 
occupation of Hiroshima and Nagasaki. 
•Project 112/SHAD participants. 
•Veterans of the Mexican border period or of World War I 
•Veterans who served in the Republic of Vietnam between January 9, 1962, and May 7, 
1975. 
•Veterans of the Persian Gulf War who served between August 2, 1990, and November 
11, 1998. 
•Veterans who served on active duty at Camp Lejeune for at least 30 days between 
August 1, 1953, and December 31, 1987. 
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•Currently enrolled Veterans and new enrollees who served in a theater of combat 
operations after November 11, 1998, and those who were discharged from active duty on 
or after January 28, 2003, are eligible for the enhanced benefits for five years post 
discharge 
 
Note: At the end of this enhanced enrollment priority group placement time period, 
Veterans will be assigned to the highest PG for which their status at that time qualifies. 
 
Priority Group 7 
•Veterans with gross household income below the geographically-adjusted VA income 
limit for their resident location and who agree to pay copayments. 
 
Priority Group 8 
•Veterans with gross household incomes above the VA income limits and the 
geographically- adjusted income limits for their resident location, and who agree to pay 
copayments. 
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